stock_BIIB r_up	purposes:1 general:1 proceeds:1 sell:1 use:1 said:1 working:1 which:1 capital:2 net:1 include:1 plans:1 may:1 company:1 undisclosed:1 expenditures:1 possible:1 filed:1 debt:2 acquisitions:1 sale:1 securities:2 amount:1 repayment:1 time:2 corporate:1
stock_BIIB r_down	significant:1 almost:1 issued:1 site:1 dose:1 warning:1 's:1 its:1 partners:1 trending:1 $:2 six:1 shares:2 companies:1 2:1 safety:1 new:1 has:1 multiple:2 after:1 problems:1 early:1 said:1 liver:2 letter:2 8:1 news:1 posted:1 injury:1 --:1 warned:1 eased:1 sclerosis:2 days:1 drug:2 while:1 afternoon:1 were:1 following:1 downward:1 first:1
stock_BIIB r_up	via:1 managers:1 deal:2 people:1 being:1 issued:1 doctors:2 disease:1 second:1 warning:4 multiple-sclerosis:2 multiple:1 its:1 market:1 information:1 trending:1 $:8 lead:1 two:1 1:2 their:1 participants:1 parts:1 safety:1 slide:2 new:2 injury:2 's:2 offering:1 partners:1 familiar:2 company:1 possibility:2 priced:1 joint:1 two-part:1 liver:2 letter:1 syndicate:1 news:1 downward:1 posted:1 billion:2 has:1 launch:1 --:3 warned:2 notes:1 sclerosis:1 according:2 drug:3 patients:2 afternoon:1 were:1 following:1 serious:2 senior:1 treated:1 taking:1 launched:1
stock_BIIB r_up	sell:1 fourth-quarter:1 posted:1 said:1 abandoned:1 loss:1 company:1 revenue:1 narrower:1 job:1 lower:1 260:1 itself:1 another:1 cuts:1 has:1 announced:1 plans:1
stock_BIIB r_up	biotech:1 smaller:1 buying:1 into:1 ``:1 '':1 strategy:1 its:2 giant:1 said:1 lead:1 preserve:1 spirit:1 development:1 take:1 units:1 developers:1 approach:1 therapies:1 more:1 wants:1 them:1 federation:1 form:1 cheaper:1 biologic:1 than:1 structure:1 faster:1 assets:1 developing:1 --:1 companies:1 drug:2 believes:1 entrepreneurial:1 those:1 massive:1 biotechnology:1 hands-off:1 corporate:1 order:1
stock_BIIB r_down	week:1 sagging:1 grapples:1 hoping:1 cancer:1 into:1 move:1 drug:2 slowdown:1 price:1 company:1 growth:1 lucrative:1 key:1 prescription:1 approval:1 gets:1 boost:1 its:2 market:1 stock:1
stock_BIIB r_up	there:1 evolving:1 high:1 added:1 need:1 's:1 occur:1 information:2 rapidly:1 review:1 warnings:1 patients:3 should:1 treatment:1 has:1 treat:1 product:2 used:1 multiple:1 whose:1 may:1 update:1 warn:1 liver:3 despite:1 injury:3 --:1 sclerosis:1 disease:2 reports:1 severe:1 activity:1 treated:1
stock_BIIB r_up	restore:1 broader:1 nerve:1 see:1 economic:2 motor:1 larger-cap:1 further:1 protein:2 market:1 gains:1 use:1 said:2 nervous:1 system:1 shares:1 biotech:1 potential:1 development:1 treatment:1 which:1 scientists:2 injury:1 price:1 virtually:1 function:1 rise:1 diseases:1 company:1 under:1 strong:1 sensory:1 gain:2 along:1 stocks:3 data:2 treating:1 has:1 license:1 developing:1 many:1 university:1 exclusive:1 can:1 positive:2 long-term:1 studies:2
stock_BIIB r_up	saying:1 over:1 share:1 drug:1 its:1 market:1 out:1 federal:1 support:1 insufficient:1 alleged:1 viability:1 their:1 potential:1 safety:1 has:1 case:1 multiple:1 dismissed:1 company:1 published:1 allegations:1 were:1 part:1 shareholder:1 biotechnology:1 judge:1 article:1 lawsuit:1 thrown:1 claims:1 regarding:1 fraud:1 --:1 sclerosis:1 against:2 securities:1 2005:1 opinion:1 plaintiffs:1
stock_BIIB r_up	down:1 product:1 developers:1 door:1 than:1 get:2 --:1 rather:1 drug:1 easier:1 break:1 their:1 lucrative:1 foot:1 trying:1 find:1 market:1 more:1
stock_BIIB r_down	smaller:1 orphan:1 down:1 wider:1 patient:1 find:1 market:2 concern:1 targeting:1 eventual:1 rather:1 its:1 their:2 pursuing:1 new:1 developers:1 conditions:1 easier:1 more:1 product:1 door:1 increased:1 get:3 drugs:1 approvals:1 scrutiny:1 break:1 applications:1 suffering:1 lucrative:1 groups:1 foot:1 article:1 trying:1 than:1 has:1 rare:1 --:1 companies:1 drug:2 while:1 published:1
stock_BIIB r_down	biotech:1 elect:1 people:1 fall:1 related:1 itself:1 's:2 its:1 sell:1 said:1 investor:2 three:1 fight:1 late:1 failed:1 activist:1 board:1 sued:1 run:1 seeking:1 billionaire:1 company:1 documents:1 proxy:1 filed:1 last:1 trying:1 lawsuit:1 advance:1 attempt:1 --:1 against:1
stock_BIIB r_up	comment:1 adjusted:1 cancer:4 revenue:1 cents:2 polled:1 share:2 sales:4 expectations:1 see:1 drug:1 82:1 its:5 information:1 giant:2 missed:1 bottom:1 profit:4 rose:1 due:3 mark:1 drugs:2 post:5 earnings:5 which:1 income:1 expected:3 net:1 boost:3 company:1 therapies:1 stock:2 first-quarter:3 increased:1 beat:1 price:1 reporting:1 but:2 reported:1 line:1 strong:2 12:6 largely:3 --:2 average:1 reports:3 flagship:1 below:1 expecting:2 76:1 biotechnology:2 higher:4 options:1 came:1 projections:1
stock_BIIB r_down	ended:1 including:1 per:1 its:5 previous:1 giant:2 $:4 rose:3 had:1 expectations:1 late:1 do:1 increased:1 beat:1 amp:2 --:2 did:1 quarter:2 weighs:1 some:1 projections:1 year:2 's:10 84:1 flagship:2 missed:2 bottom:1 profit:1 shares:1 net:4 boost:1 therapies:1 after:1 million:4 reported:3 downgrade:1 article:1 arthritis:1 items:1 31:1 climbed:1 drug:5 analysts:3 published:1 options:1 first:1 cancer:5 revenue:1 66:1 due:1 mark:1 passed:1 expected:1 company:2 but:3 line:1 analyst:1 those:1 posted:1 12:12 target:1 up:1 n't:1 below:1 were:1 acquisition:1 cents:5 share:4 sales:6 vs:1 compared:1 other:1 earnings:3 which:1 income:4 stock:1 first-quarter:3 earlier:1 74:3 weigh:2 largely:1 charges:1 well:1 costs:1 time:1 biotechnology:1 came:1
stock_BIIB r_up	oncology:2 medication:1 show:3 caused:1 over:1 primary:1 tested:1 disease:1 brain:1 multiple-sclerosis:1 efficacy:1 have:1 multiple:7 its:1 market:1 large:1 fails:2 said:3 end:1 tracked:1 companies:2 no:1 analyze:1 there:1 severe:1 been:1 their:1 clinical:2 safety:1 treatment:1 which:1 certain:2 most:1 has:1 type:2 's:1 form:1 infection:1 results:1 early:1 reported:1 slow:2 key:3 meet:1 phase:1 using:1 cases:1 weeks:1 relaunch:1 treating:2 endpoint:1 rare:1 failed:3 effective:2 course:1 --:1 could:1 sclerosis:7 according:2 drug:7 n't:4 trial:5 patients:1 continue:1 2006:1 2005:1 did:2 pulled:1 study:3 late-stage:2
stock_BIIB r_up	rocket:1 global:1 outlook:1 years:2 agricultural:1 still:2 its:2 before:1 treatment:3 has:1 gains:1 rebound:1 increases:1 using:1 drugmaker:1 progressive:1 --:2 companies:4 benefit:1 rockets:2 reassures:1 lifted:1 significantly:1 trading:1 multiple:2 index:1 said:3 lead:3 since:1 shares:5 safety:1 new:1 patient:1 reported:1 regulatory:1 news:1 healthy:1 study:1 drug:3 surge:2 drugmakers:2 major:1 two:1 multiple-sclerosis:1 approval:1 market:2 utilization:1 top:1 three:1 their:2 more:1 ``:1 company:3 gain:2 cases:1 than:1 showed:2 patients:4 headache:1 biotech:1 medication:1 investors:1 sclerosis:2 '':1 file:1 rally:2 foreign:1 end:2 no:1 migraine:1 indexes:1 higher:3 's:2 plans:1 after:2 helping:1 stocks:3 data:1 approved:1 exposure:1 considered:1 stronger:2 edge:2 2006:1 '09:2 overseas:2 2009:1 oral:1
stock_BIIB r_down	all:1 own:1 help:1 findings:1 show:1 nominated:3 system:1 brought:1 likely:1 election:1 removal:1 its:2 shunning:1 marking:1 said:2 additional:1 immune:1 addition:1 beginning:1 patients:1 fight:1 also:1 board:2 evaluate:1 nominees:1 company:4 slate:1 plasma:1 body:1 evolve:1 ``:1 's:3 exchange:2 may:1 billionaire:1 re-election:1 removing:1 director:1 proxy:1 investor:1 response:1 improve:1 '':1 central:1 accelerates:1 circulation:1 --:1 forth:1 study:1 method:1 large:1 directors:2 continue:1 nervous:1 options:1 blood:2
stock_BIIB r_down	investor:1 marking:1 own:1 beginning:1 billionaire:1 slate:1 likely:1 nominated:1 fight:1 brought:1 directors:1 board:1 nominees:1 forth:1 its:2 shunning:1 proxy:1
stock_BIIB r_down	cents:1 share:2 focus:2 trade:2 active:2 see:2 session:2 first-quarter:1 whose:2 $:1 shares:2 forecast:1 earnings:2 expected:3 's:2 71:1 report:1 post:1 second-quarter:1 fiscal:1 1.06:1 --:2 companies:2 according:2 analysts:2
stock_BIIB r_down	operations:1 over:1 results:1 actions:1 trade:1 ended:1 session:1 shares:1 year-earlier:1 its:12 24:4 whose:1 group:1 $:10 23:6 rose:1 workers:1 quarterly:1 disrupt:1 versus:1 his:1 advances:1 income:3 possible:1 report:1 investor:1 54c:2 59:1 132:1 --:1 warned:1 companies:1 54:2 earned:1 raised:2 quarter:2 thanks:2 week:1 38c:2 estimates:1 see:1 growth:2 projections:1 exceeded:1 's:5 contests:1 special:1 said:3 profit:7 broad:1 projected:1 comments:2 forecast:1 activist:1 nominees:1 net:3 boost:1 million:6 business:1 attention:1 reported:2 proxy:2 active:1 strong:2 first-quarter:4 declining:2 helping:1 38:2 items:2 could:1 double-digit:2 according:1 drug:1 products:1 outlook:1 revenue:2 rising:2 array:1 shareholders:1 management:1 would:1 three:1 fight:1 biggest:2 firm:2 ``:1 drugs:4 company:5 hurt:1 expected:1 lowered:1 filed:1 prices:1 analyst:1 posted:1 helped:1 target:2 up:2 flagship:1 can:1 31:1 biotech:2 climbed:1 costly:1 prompting:1 cents:6 year:2 share:5 sales:8 fellow:1 '':1 full-year:2 reports:1 83:1 information:1 compared:1 also:1 other:1 3.25:1 earnings:3 billionaire:1 performance:1 stock:1 gaining:2 multiple:2 boosted:1 earlier:2 director:1 stocks:2 grow:2 multiple-sclerosis:1 sclerosis:2 jumped:4 reiterated:1 biotechnology:1 2008:4
stock_BIIB r_down	revenue:3 narrower:3 period:3 helped:3 year:4 multiple:3 narrowed:3 total:3 its:6 ground:3 said:3 $:12 rose:3 detail:1 comments:1 performance:3 net:6 's:3 million:12 first-quarter:6 company:2 continues:3 operating:3 gain:3 press:1 93:3 176:3 posted:3 ago:4 loss:6 improved:3 --:3 sclerosis:3 drug:3 while:3 briefing:1
stock_BIIB r_up	roundup:1 saying:1 surprises:2 companies:1 reports:1 quarters:1 advisories:2 earnings:1 future:1 corporate:1 latest:1
stock_BIIB r_down	six:1 autoimmune:1 help:1 show:1 estimates:1 primary:1 month:1 not:2 second:1 systemic:1 another:1 also:1 its:3 said:4 goal:1 their:2 effort:1 marketed:1 comments:1 makers:1 failed:3 other:1 treatment:1 effectiveness:1 stock:1 count:1 's:2 see:1 400,000:1 any:1 could:1 seventh:1 jointly:1 did:2 reported:1 every:1 updates:1 prices:1 using:1 beginning:1 analyst:1 people:1 secondary:1 treating:1 physician:1 lupus:4 endpoint:1 battling:1 --:1 study:3 disease:1 drug:4 n't:2 trial:2 meet:3 endpoints:1 ailments:1 vary:1 late-stage:1
stock_BIIB r_down	sell:1 treating:1 lupus:3 off:1 failed:1 cancer:1 their:1 trials:1 efficiency:1 after:1 companies:1 see:1 drug:3 failure:2 slide:2 clinical:1 shares:3 popular:1 announce:1 its:1 test:1
stock_BIIB r_down	regain:1 everyone:1 investors:1 predict:1 over:1 charities:1 cash:1 done:1 signs:1 seem:1 appetite:1 shareholders:1 raise:1 shares:1 their:3 equity:2 markets:2 until:1 more:1 development:1 alternative:1 sharing:1 kinds:1 risk:1 get:1 far:1 slump:1 but:1 labs:1 fund:1 tapping:1 they:1 not:1 convinced:1 interests:1 always:1 --:1 approach:1 companies:1 sale:1 drug:1 deals:1 these:1 while:1 relied:1 long-term:1 biotechnology:1 revenues:1 approve:1 once:1
stock_BIIB r_up	sales:1 expect:1 's:1 rose:1 charge:1 does:1 treatment:1 income:1 net:1 first-quarter:1 company:1 reflecting:1 multiple:1 --:1 57:3 sclerosis:1 35:1 n't:1 pace:1 continue:1 acquisition:1 fell:1
stock_BIIB r_down	seeing:1 proposed:1 focus:2 trade:1 see:1 session:2 trading:1 sell:1 whose:2 shareholders:1 said:1 three:1 shares:2 late:1 reject:1 biggest:2 include:1 meeting:1 slate:1 sent:1 gaining:2 his:1 's:7 upcoming:1 company:3 material:1 hurt:1 director:1 expected:1 shareholder:1 proxy:2 letter:1 active:2 stocks:2 declining:2 has:1 --:1 annual:1 companies:1 drive:1 value:1 19:1 materials:1 agenda:1 efforts:1 nominees:1 urging:1 charged:1
stock_BIIB r_up	10:2 ``:1 's:1 lost:1 contest:1 investor:1 shareholders:1 faith:1 writing:1 '':1 directors:1 proxy:1 letter:1 unseat:1 has:1 officially:1 launched:1 board:2
stock_BIIB r_up	's:4 reported:1 holdings:1 eliminated:1 fund:1 hedge:1 investor:1 its:1
stock_BIIB r_down	saying:1 adjusted:1 financial:1 revenue:1 sclerosis:1 share:1 expects:1 quarters:1 rate:1 growth:2 through:1 drug:1 have:1 newest:1 its:2 said:1 20:1 surprises:2 per:1 forecast:1 also:1 advisories:2 earnings:2 2010:2 multiple:1 around:1 company:1 reiterated:1 compound:1 using:1 100,000:1 roundup:1 15:1 annual:2 companies:1 reports:1 patients:1 future:1 2007:1 long-term:1 corporate:1 latest:1
stock_BIIB r_up	sell:1 documents:1 's:2 last:1 failed:1 --:1 related:1 access:1 favor:1 itself:1 fall:1 attempt:2 ruled:1
stock_BIIB r_up	biotech:1 because:1 process:2 doomed:1 ``:2 up:1 '':2 not:1 participate:1 vote:2 impossible:1 bidders:1 its:1 if:1 again:1 shareholders:3 handled:1 bullish:1 support:1 three:1 traders:1 activist:1 asking:1 way:1 late:1 slate:1 board:1 them:1 his:3 's:1 company:2 after:1 took:1 roadblocks:1 letter:1 filed:1 put:1 investor:3 made:1 auction:1 positions:1 sale:2 urged:1 directors:3 2007:1 nominations:1 difficult:1 asked:1 wrote:1
stock_BIIB r_up	named:1 said:1 vice:1 previously:1 international:1 medical:1 executive:1 head:1 global:1 chief:1 operating:1 officer:1 president:1 served:1 company:1
stock_BIIB r_down	number:1 its:2 said:2 based:1 $:4 restricted:1 shares:2 units:1 new:1 price:1 stock:2 buy:1 company:1 award:3 270,000:4 receive:1 according:1 filing:1 common:2 each:1 biotechnology:1 closing:1 options:1
stock_BIIB r_down	firm:1 ...:2 named:2 45:1 old:1 effective:1 succeeds:1 --:1 executive:1 52:1 director:2 managing:1 chief:1 chairman:1 vice:1 immediately:1 years:1
stock_BIIB r_up	claim:1 30:1 statements:2 show:4 process:5 distributed:1 despite:1 memo:1 sales:2 '':2 seats:1 battle:1 's:4 its:4 little:2 documents:4 contest:1 continued:1 had:4 comments:1 failed:1 disclosed:2 statement:1 designing:2 input:2 alleges:1 public:1 board:5 ``:2 his:1 recently:2 very:2 company:5 number:1 released:2 said:1 gain:1 fall:1 investor:1 made:3 last:1 --:1 alleging:1 sale:3 authorized:2 filing:1 proxy:1
stock_BIIB r_down	elected:2 vote:2 controlled:2 fifth:1 if:2 shareholders:7 said:2 group:2 research:2 asking:1 board:1 billionaire:2 nominees:5 ethos:2 meeting:2 development:2 's:3 funds:8 slate:2 reject:1 component:2 director:4 letter:2 investor:2 central:2 19:2 annual:2 according:2 urged:2 filing:2
stock_BIIB r_down	advisory:1 major:1 because:1 says:1 process:1 move:1 setback:1 two:1 elected:1 advising:2 seats:1 vote:2 information:1 failed:1 began:1 get:1 three:1 comments:1 their:2 candidates:1 board:2 which:1 firms:2 company:1 firm:1 his:3 's:4 seeking:1 billionaire:2 slate:2 proxy:2 fall:1 last:1 attempt:1 --:2 could:1 clients:2 sale:1 against:2 directors:1 urging:1 gain:1
stock_BIIB r_down	advisory:1 's:2 service:1 less:1 win:1 company:2 seats:1 board:1 services:1 likely:1 activist:2 shareholder:1 proxy:2 making:1 battle:2 biotechnology:2 has:1 investor:2 its:1 he:1
stock_BIIB r_down	giant:1 said:1 methods:1 covering:1 patent:1 producing:1 over:1 products:1 basic:1 biotechnology:1 settled:1 dispute:1
stock_BIIB r_up	advisory:1 '':1 vote:1 pleased:1 shareholders:1 said:2 support:1 three:1 should:1 recommend:1 nominees:1 progress:1 disrupt:1 company:3 ``:1 his:1 's:3 slate:1 let:1 proxy:1 instead:1 companies:1 n't:1 directors:1 voting:1 filing:1
stock_BIIB r_up	operations:1 available:1 all:1 official:1 elect:1 investors:2 give:2 process:1 tally:1 preliminary:1 results:1 down:2 against:1 have:1 vote:3 voted:1 attract:1 its:5 shareholders:5 said:3 based:1 just:1 working:1 speed:1 writes:1 it’s:1 seems:1 two:1 fight:2 favor:1 much:3 board:4 nominees:4 new:1 you:1 meeting:1 slate:3 either:1 company’s:1 independent:1 handing:2 his:1 's:3 get:1 very:1 billionaire:2 company:4 pushing:1 warp:1 drug:1 management:1 proxy:4 suitor:1 smile:2 activist:2 approved:1 thank:1 count:1 four:1 weeks:1 won:1 rival:1 annual:1 sale:1 fine:1 maker:1 n't:2 directors:2 convince:1 does:2 defeat:2 following:1 over:1 dispute:1 order:1
stock_BIIB r_down	extended:1 factors:1 patent:1 drug:1 other:1 boost:1 maker:1
stock_BIIB r_down	's:2
stock_BIIB r_up	sector:1 lowers:1 investors:1 among:1 results:1 setback:2 dose:1 rate:1 session:1 multiple-sclerosis:1 reducing:1 its:1 ground:1 tumbled:1 relapse:1 lead:2 pace:1 bearish:1 shares:2 rivals:1 treatment:1 patients:1 higher:1 's:2 broadly:1 reported:1 finds:1 stocks:2 gained:1 lower:3 effective:1 study:1 no:1 drug:4 loses:1 trial:1 slide:2 fresh:1 more:1 maker:1
stock_BIIB r_up	sector:1 disclosure:1 since:1 financial:1 investors:1 caused:1 into:1 health-care:1 share:1 $:2 rest:1 hopes:1 see:1 oil:2 names:1 headlines:1 trust:1 hate:1 investment:1 14:1 out:1 index:1 ones:1 renewed:1 20:1 deal:1 breaking:1 fears:1 day:1 been:1 lately:1 their:1 winners:1 disclosed:1 above:1 spike:1 before:1 has:1 over:1 sent:2 stock:1 back:1 plunge:1 's:3 tried:1 than:1 offer:1 funds:1 but:1 regulatory:1 early:1 market:1 fell:2 they:2 prices:1 news:1 buyout:1 stocks:1 second-quarter:1 recent:1 received:1 15:1 real-estate:1 sectors:1 level:1 --:1 invest:1 drop:1 companies:1 up:1 against:1 've:1 n't:1 more:1 points:1 losers:1 shares:1 had:1 balance:1 traded:1 filing:1
stock_BIIB r_down	oil:2 covered:1 cancer:1 climbs:2 dips:2 healthcare:1 dollar:2 system:1 drug:1 leads:1 news:1 rally:2 stocks:3 its:1 vaccine:1 upward:1
stock_BIIB r_down	growth:1 cancer:1 profit:3 rose:1 double-digit:1 sales:1 reports:2 its:2 late:1 reported:1 part:1 5:3 thanks:1 treatments:1 boost:2 second-quarter:3
stock_BIIB r_up	raised:1 4.6:1 's:1 rose:1 company:1 double-digit:1 sales:1 outlook:1 helped:1 also:1 full-year:1 growth:1 income:1 biotechnology:1 net:1 its:1
stock_BIIB r_up	them:1 risk:1 cancer:1 chances:1 could:1 rejecting:1 successful:1 patients:1 treatment:1 sharply:1 found:1 study:1 kidney:1 improve:1
stock_BIIB r_up	biotech:2 already:1 have:1 developed:1 over:1 focus:2 highly:1 own:1 including:1 another:1 high-profile:1 market:1 partners:1 busy:1 $:2 44:2 two:1 company:1 does:1 earnings:1 surprise:1 boost:1 remaining:1 nice:1 scheduled:1 independent:1 buy:1 's:3 plans:1 relationship:1 get:1 successful:1 bid:3 took:1 but:1 number:1 early:1 gain:1 ownership:1 report:1 news:1 stocks:3 day:1 drugmaker:1 billion:2 stokes:2 full:1 --:4 decades:1 companies:1 n't:1 risks:1 biotechnology:1 stock:1 delicate:1
stock_BIIB r_up	saying:1 being:1 quarters:1 its:5 poorly:1 $:2 surprises:2 second-quarter:3 advisories:2 treatment:1 get:1 rise:2 early:1 years:1 investor:1 day:3 drugmaker:1 --:1 54:1 companies:2 activity:1 second:3 year:1 's:4 said:1 since:1 seller:1 won:1 safety:1 net:3 million:2 acquisition-related:1 reported:1 proxy:1 latest:1 activist:1 news:1 strong:6 roundup:1 last:1 drug:1 trial:1 month:1 rose:1 outlook:2 two:1 multiple-sclerosis:1 buoyed:2 hammered:3 fight:1 their:1 clinical:1 more:1 drugs:3 company:1 91:1 than:1 posted:2 11:4 recall:1 patients:1 future:1 following:1 performed:1 investors:1 cents:4 share:3 sales:5 reports:2 partner:1 compared:1 2nd-quarter:2 also:1 earnings:5 which:1 income:3 higher:1 used:1 multiple:3 boosted:3 earlier:1 react:1 70:2 cardiac:1 overseas:1 relaunch:1 largely:1 amid:1 sclerosis:3 costs:1 2008:4 cholesterol:1 corporate:1 once:1
stock_BIIB r_up	biotech:1 raised:1 because:1 investors:1 warns:1 estimates:1 past:1 surrounding:1 still:1 its:2 cancer:1 marketed:1 seems:1 only:1 treatment:1 which:1 has:1 more:1 product:1 's:2 but:1 pressure:1 cultural:1 link:1 such:1 than:1 icon:1 tangible:1 --:1 uncertainty:1 cloudy:1 future:1 long-term:1 become:1
stock_BIIB r_up	bullish:3 favors:2 volatility:1 approach:1 lift:1 lows:1 risk/reward:2 view:2 markets:3 recent:1
stock_BIIB r_down	unemployment:2 four-year:1 domestic:1 focus:4 trade:4 brain:5 session:2 signs:1 patient:2 its:5 based:1 whose:2 but:1 $:3 rose:1 had:1 symptoms:1 setting:2 treatment:3 announce:1 gains:2 rise:2 fluid:1 nearly:3 they:1 not:2 bit:2 day:1 maintaining:1 loss:3 progressive:1 lost:2 ended:1 --:5 companies:2 52:1 predicted:2 downward:1 stock:4 disorder:2 week:1 findings:1 consistent:1 tempered:2 see:2 diagnosis:3 multiple:5 said:2 since:1 shares:5 safety:2 7:1 evaluation:1 jobs:4 commercial:1 agencies:1 following:1 imaging:1 key:3 active:2 news:1 declining:2 received:1 volatile:1 rare:1 many:2 31:1 30:1 drug:6 keep:1 afternoon:1 traded:2 relevant:1 economists:2 period:1 two:3 down:1 regulatory:1 multiple-sclerosis:1 drove:1 market:1 industrials:1 pharmaceuticals:2 leading:1 spiral:1 been:1 their:1 clinical:2 expected:2 more:2 firm:1 plunge:2 company:2 60:3 biggest:2 known:1 cases:2 highest:1 detection:1 made:1 target:1 showed:1 plunged:3 rate:2 patients:1 were:3 report:2 treated:1 biotech:2 high:1 have:1 slumped:1 partner:1 linked:3 confirmed:2 deadly:1 concerns:2 potentially:4 higher:4 gaining:2 oil:1 's:5 users:2 though:2 after:7 upon:1 fell:3 infection:3 stocks:7 data:1 billion:3 lower:2 15.5:3 futures:4 sclerosis:5 points:1 2004:1 weigh:2 downswing:1
stock_BIIB r_up	sector:2 sell:1 hold:1 upgrade:3 's:2 gains:2 analysts:1 amid:2 after:1 drug:2 hard-hit:1 remain:1 shares:3 gain:1 broad:2 territory:1 climb:2 stocks:1 stock:1 positive:1 firmly:1
stock_BIIB r_up	6:1 prompt:1 slipped:1 purchases:1 well:1 results:1 funds:1 general:1 discussions:1 proxy:1 plunge:1 value:1 have:1 ready:1 controlled:1 fight:1 seek:1 action:1 issues:1 said:1 business:1 candidate:1 suggest:1 stake:2 shares:2 its:1 clinical:1 tumbles:2 inch:2 he:1 fibrosis:1 his:5 's:1 advantage:1 may:1 boosted:1 company:2 after:1 early:1 released:1 shareholder:1 activist:1 billionaire:1 boosting:1 regulatory:1 relating:1 stocks:3 investor:2 discuss:1 recent:1 lower:2 lost:1 reported:1 concerns:1 taking:1 drop:1 plunged:1 sale:1 drug:1 n't:1 trial:1 continue:1 mixed:1 biotechnology:1 efforts:1 late-stage:1 filing:1 cystic:1
stock_BIIB r_up	brain:2 reports:1 have:2 said:1 end:1 two:3 been:2 symptoms:1 attack:1 more:1 only:1 multiple:1 infection:2 cases:2 than:1 those:1 received:1 12:1 rare:2 progressive:1 --:3 similar:1 taking:1 months:1 sclerosis:1 drug:1 regulator:1 patients:3 evaluating:1 2008:1 treated:2
stock_BIIB r_up	pharmaceutical:1 territory:2 sectors:1 positive:2 into:2 move:2 session:1 trading:1 gain:1 biotechnology:1 action:1 during:1 stocks:3 midday:1 relatively:1
stock_BIIB r_up	sector:1 slow:1 being:1 month:1 rebound:3 continues:2 negative:1 shares:1 trade:1 their:1 continue:1 battered:1 mixed:3 news:1 stocks:3 after:1 earlier:1
stock_BIIB r_up	while:1 working:1 amend:1 taking:1 after:1 two:1 drug:1 label:1 brain:1 patients:1 multiple-sclerosis:1 serious:1 got:1 disorder:1
stock_BIIB r_down	pull:2 territory:1 reverse:1 spending:1 positive:1 into:1 after:1 back:2 drug:2 negative:1 turf:1 stocks:3 morning:1 discuss:2 diabetes:2
stock_BIIB r_up	comment:1 early-stage:1 they:2 cancer:3 painkiller:1 being:1 sclerosis:2 health-care:1 powerful:1 early:1 unveiled:2 partner:2 array:1 throughout:1 makers:1 concern:1 information:1 said:2 20:1 agency:1 system:1 anti-cancer:1 its:2 adverse:1 potential:3 safety:1 details:1 listing:1 policy:1 new:2 has:1 type:1 events:1 therapies:1 treatment:2 started:2 's:2 wide:1 drugs:3 possible:1 includes:1 warn:1 test:1 part:1 therapy:2 effects:1 background:1 report:2 multiple:3 analyst:1 drugmaker:2 professionals:1 have:2 --:3 study:2 clinical:2 list:2 myeloma:1 drug:2 responded:1 n't:1 trial:3 patients:3 without:1 context:1 activity:1 investigating:2 other:1 side:1 blood:1
stock_BIIB r_up	case:1 said:1 patient:1 reported:1 deadly:1 taking:1 blockbuster:1 infection:1 one:1 brain:1 regulators:1 been:1 's:1 has:1 drug:1
stock_BIIB r_up	information:1 patient:1 amended:1 --:1 arthritis:1 infection:1 label:1 brain:1 disclosed:1 have:1 rare:1 include:1 rheumatoid:1 died:1 first:1
stock_BIIB r_up	week:1 territory:1 lead:2 spending:1 after:1 negative:1 deep:1 better:1 drug-stock:2 part:1 broader:1 rallies:1 rally:2 stocks:1 roll:1 market:1
stock_BIIB r_up	advisory:1 updated:1 multiple-sclerosis:1 been:1 have:1 further:1 information:2 upgrade:1 lead:2 marketed:1 shares:1 increase:1 recommended:1 medicine:1 include:1 awareness:1 higher:2 body:1 product:2 recommends:1 's:3 risk:2 drugs:1 after:1 update:1 said:1 gain:1 climbing:1 stocks:3 multiple:1 analyst:1 has:1 progressive:2 --:1 sclerosis:1 drug:3 regulator:1 patients:1 treated:1
stock_BIIB r_up	sector:1 load:1 own:3 financial:1 dire:1 just:1 hard:1 50:1 '':2 zero:1 because:1 have:1 says:1 any:1 even:1 mutual:1 biggest:2 investors:2 no:1 rundown:1 fast:1 their:1 track:1 varies:1 attractive:1 which:1 answer:1 gaining:2 do:1 ``:3 move:1 's:4 way:1 may:1 funds:3 downs:1 specialty:1 quite:1 fund:1 designed:1 they:1 bit:1 stocks:5 analyst:1 declining:2 --:1 many:2 up:1 daily:1 n't:1 banking:1 yields:1 broad-based:1 ups:1
stock_BIIB r_down	sector:2 load:1 own:3 financial:1 dire:1 just:1 over:1 hard:1 hurting:1 50:1 '':2 zero:1 because:1 been:1 have:2 year:1 says:1 any:1 financials:2 even:1 index:1 mutual:1 investors:2 no:1 managers:1 fast:1 their:1 track:1 varies:1 attractive:1 which:1 worst-performing:1 answer:1 do:1 ``:3 's:1 way:1 big:1 may:1 funds:3 downs:1 specialty:1 quite:1 fund:1 designed:1 they:1 bit:1 stocks:2 analyst:1 past:1 --:1 many:3 up:1 n't:1 banking:1 yields:1 broad-based:1 ups:1 bet:1
stock_BIIB r_down	comment:1 saying:1 unsolicited:3 sea:1 deal:4 share:1 searching:3 one:1 6.5:3 signed:3 have:2 throughout:2 open:1 its:2 out:1 try:1 use:1 drama:3 $:7 would:1 had:3 two:3 1:1 pearl:1 other:1 superior:3 statement:1 crack:1 details:1 include:1 recasts:1 more:1 outbid:1 's:3 offer:4 may:1 bid:3 acquire:4 but:1 effects:1 new:1 prices:1 ending:3 effort:1 analyst:1 raise:1 billion:4 has:1 third:1 lost:2 --:3 months:3 62:1 drug:1 n't:1 biotechnology:1 stock:1 maker:1
stock_BIIB r_down	sector:2 major:1 reverse:1 some:1 sales:1 competition:1 quarters:1 high:1 n't:1 growth:1 trading:2 wo:1 turn:2 seek:1 find:1 pharmaceutical:1 said:1 bullish:1 may:1 generic:1 patients:1 been:1 crisis:1 note:1 their:1 much:1 dominated:1 expected:1 write-offs:1 has:1 development:1 after:1 pipelines:1 shelter:1 weakness:1 negative:1 weak:1 delayed:2 leukemia:1 takeover:1 related:1 they:1 prices:1 news:1 post:1 stocks:3 beginning:1 day:1 recent:1 session:1 territory:1 unlike:1 third:1 course:1 solid:1 companies:3 drug:1 face:1 large:1 credit:1 benefit:2 continue:1 products:1 afternoon:2 promising:1 biotechnology:1 ending:1 quarter:1 its:1 south:2
stock_BIIB r_down	development:1 use:1 endpoint:1 's:2 14:1 prompting:1 did:1 company:1 arthritis:2 discontinue:1 primary:1 drug:2 disease:1 n't:1 trial:1 treat:1 meet:1 weeks:1 improvement:1 rheumatoid:2 its:1
stock_BIIB r_down	seeing:1 oncology:1 cancer:1 revenue:1 sales:1 6.7:1 growth:1 trading:1 year:1 82:1 led:1 3.6:1 forecast:1 investment:1 down:1 really:1 information:1 '':2 said:1 20:1 $:2 trials:1 third-quarter:1 comments:1 strategy:1 their:2 high:1 earnings:1 jumped:1 outlook:1 previous:1 low:1 status:1 ``:2 's:3 drugs:1 company:1 after-hours:1 giant:1 biotech:1 despite:1 end:1 strong:1 analyst:1 narrowing:1 jump:1 quarter:1 17:3 --:1 accelerating:1 solid:1 products:1 rose:1 latest:1 its:4 better-than-expected:1
stock_BIIB r_down	cancer:1 revenue:1 sales:2 three:1 jump:1 led:1 its:2 said:1 profit:1 rose:2 top:1 third-quarter:1 earnings:1 quarterly:1 's:4 gains:1 drugs:2 company:1 strong:1 posted:1 6.7:2 17:3 --:1 double-digit:1 biotechnology:1 better-than-expected:1
stock_BIIB r_up	adding:1 hurdles:1 's:1 propose:1 revised:1 shareholders:1 nominate:1 directors:1 wake:1 proxy:1 bylaws:1 year:1 battle:1 resolutions:1 corporate:1 its:1
stock_BIIB r_down	issued:1 outlook:1 trade:1 brain:1 session:1 controversial:1 its:5 issues:2 whose:1 $:2 rose:1 has:1 gains:1 rise:2 focus:2 background:1 report:2 58:1 --:1 companies:1 stock:1 better-than-expected:1 financial:1 see:1 growth:3 year:1 multiple:2 out:4 trending:1 lead:2 profit:1 shares:1 forecast:1 net:3 cause:1 earlier:1 million:2 acquisition-related:1 reported:3 active:1 strong:7 rare:1 eke:1 drug:1 infection:1 south:2 raised:1 previously:1 manage:1 third-quarter:4 multiple-sclerosis:2 rolls:3 market:1 due:1 expected:1 firm:1 head:2 posting:1 drugs:4 company:1 but:2 98:1 wake:1 reiterates:1 cases:1 posted:2 flagship:1 biotech:1 cents:4 sclerosis:2 share:2 sales:4 helped:2 reports:1 compared:1 41:1 earnings:6 income:3 performance:1 higher:1 product:1 's:2 quote:1 after:1 73:5 two:1 70:1 stocks:3 recent:1 lower:1 largely:1 well:1 costs:1 2005:1 biotechnology:1 2008:1 pulled:1
stock_BIIB r_down	gaining:2 whose:1 's:2 seeing:1 companies:1 shares:1 trade:1 active:1 session:1 biggest:2 stocks:2 declining:2
stock_BIIB r_up	1.1:1 revenue:3 move:1 narrower:1 results:1 comfortable:1 '':1 multiple-sclerosis:1 53:2 controversial:1 said:1 group:1 $:1 remains:1 due:1 quarterly:2 net:1 drugmaker:1 2011:3 higher:1 ``:1 narrows:2 's:2 rises:2 company:1 helped:1 debt:1 he:1 billion:1 loss:3 third-quarter:1 ahead:1 --:1 posts:1 cash:1 drug:2 growing:1 position:1
stock_BIIB r_up	broader:1 less:1 within:1 alongside:1 share:1 insulated:1 medical-technology:1 economic:1 dropped:1 another:1 year:1 throughout:1 market:1 impact:1 pouring:1 hide:1 additional:1 swoon:1 comments:1 indexes:2 health:1 details:1 care:1 economy:1 updated:1 health-care:1 declined:1 than:1 pharmaceutical:1 big:1 safe:1 water:1 prices:1 heads:1 stocks:1 analyst:1 areas:1 tracking:1 viewed:1 industry:1 companies:1 economically:1 place:1 have:1 more:1 notion:1 south:1
stock_BIIB r_down	comment:1 rocket:2 developed:1 move:1 share:1 soon:1 rally:3 years:1 brain:1 growth:1 trading:1 broader:3 partner:1 patient:1 market:3 companies:1 since:1 three:1 shares:1 than:1 late:1 their:1 concerns:1 rates:1 disclosed:1 interest:1 damage:1 has:1 price:1 sent:1 more:1 lowest:1 multiple:1 company:1 driver:1 infection:1 warms:1 updates:1 key:1 hopes:1 news:1 stocks:3 analyst:1 relaunch:1 lower:1 rare:1 third:1 level:1 --:1 could:1 sclerosis:1 drug:1 2006:1 after-hours:1 further:2
stock_BIIB r_down	developed:1 years:2 brain:3 session:1 bank:1 late:1 board:1 has:1 sent:1 around:1 nearly:1 world:1 multiple:2 day:2 advanced:1 progressive:1 level:1 --:1 companies:1 after-hours:1 two:1 because:1 growth:1 trading:1 close:2 said:1 since:1 shares:2 medicine:1 patient:3 sixth:1 commercial:1 agencies:1 key:1 regulatory:1 article:1 prospects:1 rare:2 taking:1 months:1 drug:2 published:1 action:1 relevant:1 one:1 multiple-sclerosis:1 another:1 news:1 market:1 cheered:1 support:1 three:1 their:1 disclosed:1 lowest:1 drugs:1 took:1 infection:2 central:1 than:1 case:2 18:1 straight:3 economies:1 more:1 treated:1 could:2 investors:1 further:1 partner:1 linked:1 confirmed:1 deadly:2 damage:1 concerns:2 earnings:1 higher:2 's:1 after:1 driver:1 marking:1 but:1 such:1 relaunch:1 ago:1 off:1 third:4 sclerosis:2 disease:1 2006:1
stock_BIIB r_up	sector:1 one:1 report:1 rate:1 trading:1 broader:1 rally:3 led:3 market:2 incorrect:1 cut:1 date:3 late:1 gave:1 product:1 's:5 climbs:1 after:1 put:1 stocks:3 day:1 launch:3 30:1 drug:1 afternoon:1 2004:1
stock_BIIB r_up	advance:1 upgrade:3 climbs:2 shares:1 edge:3 following:1 stocks:3 analyst:1 higher:3
stock_BIIB r_up	firm:1 off:1 infringement:1 over:1 arthritis:1 alleged:1 drug:2 facing:1 production:1 products:1 affiliates:1 rheumatoid:1 other:1 patents:1
stock_BIIB r_up	selected:1 pharmaceutical:1 money:1 into:1 move:1 some:1 billions:1 patent:1 down:1 patents:1 medical-device:1 table:1 still:1 its:1 before:1 whose:1 giant:1 believe:1 funding:1 $:2 would:1 prove:1 federal:1 implosion:1 shares:1 2:1 listed:2 issued:1 expected:1 survive:1 you:1 if:1 order:1 thrive:1 more:3 week:2 do:1 's:2 emergency:1 dirt:1 share:1 government:1 after:2 cheaper:1 mention:1 putting:1 they:1 biotechnology:1 not:1 last:1 stocks:1 than:2 earn:1 has:1 wise:1 especially:1 released:1 --:1 clear:1 companies:3 calling:1 banking:1 near:1 can:1 smoke:1 were:1 following:1 let:1 approvals:1 could:1 road:1
stock_BIIB r_down	ratings:1 raised:1 's:1 drugs:1 amid:1 arthritis:1 well:1 credit:1 growth:1 multiple-sclerosis:1 treatment:1 which:1 rheumatoid:1 its:2
stock_BIIB r_up	physicians:1 deemed:1 multiple:1 22:1 level:1 --:1 caused:1 sold:1 sclerosis:1 according:1 drug:1 early:1 brain:1 infection:1 rare:1 controversial:1 filed:1 suspected:1 cases:1 through:1 reports:1
stock_BIIB r_down	comment:2 promising:1 statements:2 significantly:1 toward:1 number:2 '':2 experienced:1 opportunities:1 fewer:1 's:5 research:1 sufficient:1 its:5 late:1 shown:2 said:7 based:2 generally:1 submit:2 analyst:2 better:2 been:1 treatment:4 which:2 new:1 stage:1 pill:2 resources:1 more:2 development:1 activities:2 ``:2 earlier:2 multiple:2 plans:2 company:1 end:2 commercial:2 free:2 several:1 job:2 involving:1 ensure:1 background:1 regulatory:2 approval:2 line:2 product:2 than:3 those:2 drugmaker:4 directed:1 pipeline:2 has:1 showed:1 most:1 --:4 positions:2 study:2 work:2 sclerosis:2 up:2 drug:5 options:1 investment:2 patients:1 cutting:2 offices:2 refining:2 were:1 injectable:1 closing:2 2009:2 treated:1 taking:1 experimental:2 assessing:1
stock_BIIB r_down	comment:2 relevant:1 being:3 companies:2 potent:1 two:2 '':1 brain:3 26:1 multiple-sclerosis:1 have:3 news:1 's:3 withdrawn:1 market:1 marking:1 said:4 temporary:2 due:1 same:1 fourth:1 medicine:1 include:1 issue:1 stock:1 ago:2 ``:1 added:1 patient:5 which:1 found:3 company:1 earlier:1 seventh:1 agencies:1 infection:3 regulatory:1 release:1 background:1 fresh:1 prices:1 such:1 years:2 multiple:3 case:3 received:1 rare:2 progressive:2 reported:1 taking:1 months:1 sclerosis:3 drug:4 were:1 ban:2 serious:1 led:2 treated:3 filing:1
stock_BIIB r_up	comment:1 because:1 followed:1 deal:1 years:1 set:1 including:1 drug-industry:2 its:1 said:1 1982:1 lead:2 patent:1 make:1 since:1 charge:2 longtime:2 under:1 probably:2 has:1 sixth:1 company:2 acquire:2 consolidation:2 pressure:1 protection:1 coming:1 such:2 analyst:3 industry:3 lose:1 according:2 drug:1 large:2 products:1 cholesterol:1 biotechnology:2 top:1
stock_BIIB r_down	comment:2 significantly:2 cancer:2 less:2 previously:4 share:1 brain:2 slowed:2 patient:2 alone:2 information:1 confirmed:1 said:4 based:4 additional:1 damage:4 approved:2 late:1 being:2 disclosed:2 new:2 has:2 's:4 combined:2 multiple:2 arthritis:2 infection:2 standard:6 reported:1 suffering:2 compared:2 blood:2 prices:1 adds:1 details:1 analyst:2 died:2 case:1 received:4 rare:2 showed:4 progressive:1 joint:4 --:4 rheumatoid:2 study:2 sclerosis:2 drug:8 n't:2 patients:6 were:2 treated:4
stock_BIIB r_up	disclosure:1 purchases:1 share:1 site:1 brain:1 multiple-sclerosis:1 return:1 sells:1 any:1 weekly:1 shareholders:1 said:1 make:2 its:1 does:1 which:1 dividends:1 new:1 has:1 leader:1 resources:1 buybacks:1 's:1 plans:1 big:1 company:1 infection:1 if:1 but:1 significant:1 using:1 post:1 cases:1 acquisitions:1 rare:1 --:1 cash:1 drug:2 n't:1 patients:1 through:1 2009:2 maker:1
stock_BIIB r_up	disclosure:2 often:1 consistent:1 move:2 site:1 brain:1 multiple-sclerosis:1 article:1 sells:1 any:1 weekly:1 conference:1 effort:1 decision:1 its:1 disclosed:1 which:1 policy:1 new:1 fatal:1 more:1 plans:1 infection:1 using:1 post:1 cases:1 condition:1 rare:1 --:1 drug:1 patients:1 published:1
stock_BIIB r_up	fourth-quarter:1 lines:1 some:1 unhedged:2 separating:1 if:2 bottom:1 bite:1 able:1 their:1 winners:1 role:1 take:1 which:1 big:1 out:1 earnings:2 play:1 's:1 dollar:3 pressure:2 hedge:1 exposure:1 could:3 companies:2 surge:1 losers:1 risks:2 were:1 overseas:1 left:2
stock_BIIB r_up	sector:1 biotech:1 major:1 smaller:1 revenue:1 being:1 harder:1 some:1 heels:1 article:1 talks:1 targets:1 raise:1 crisis:1 needed:1 potential:1 new:1 turmoil:1 's:2 seeking:1 drugs:1 near-term:1 possible:1 eyed:1 such:1 vaccine:1 purchase:1 companies:1 cash:1 drug:1 credit:1 published:1 makes:1 maker:2 acquisition:3
stock_BIIB r_up	comment:2 over:1 results:2 ninth:1 through:2 its:9 fifth:1 slow:2 securing:1 merger:6 investor:2 troubles:1 has:3 fourth:3 seeking:4 updates:1 continued:2 drugmaker:3 --:3 quarter:2 some:3 surrounding:1 growth:2 result:2 multiple:6 11th:1 investment:2 minority:2 said:7 funding:3 lead:4 review:9 comments:2 research:1 safety:2 new:5 boost:3 15th:1 infrastructure:1 business:1 commercial:1 sold:2 seventh:1 reported:2 key:1 come:1 faced:2 pipeline:4 working:1 could:6 drug:9 maker:1 block:1 criticism:2 alliance:2 had:2 strategic:7 done:1 aimed:1 additional:1 puts:1 there:1 strategy:2 much:1 expected:2 launching:3 drugs:3 funds:1 company:5 prices:1 true:1 analyst:3 17:1 patients:1 can:1 promising:1 following:3 toward:1 launched:1 accelerate:1 would:1 sale:6 13th:1 itself:1 rally:1 finance:1 goal:1 damage:1 concerns:2 details:3 which:4 stock:2 poor:2 's:4 plans:2 price:1 starting:1 sclerosis:6 disease:1 so:1 experimental:2 rallies:2 dream:1
stock_BIIB r_down	prospect:1 repair:1 some:1 system:1 itself:1 done:1 victims:1 seek:1 occur:1 slow:1 goal:1 working:1 true:1 there:1 damage:2 research:1 current:1 also:1 only:1 other:1 conditions:1 therapies:1 body:1 multiple:1 may:1 literally:1 published:1 stop:1 aid:1 article:1 come:1 condition:1 would:1 developing:1 --:1 could:1 sclerosis:1 disease:2 drug:1 thought:1 attacks:1 patients:1 nervous:1 promising:1 situation:1 toward:1 dream:1
stock_BIIB r_up	comment:2 fourth-quarter:2 outlook:2 cancer:2 biotech:2 share:2 sales:2 disappointing:2 economic:1 economy:1 year:2 further:2 throughout:2 its:2 uncertainties:3 giant:2 said:2 number:2 $:6 profit:2 47:6 make:2 there:2 expectations:2 per-share:2 forecast:2 current:1 noting:2 details:2 between:2 gave:2 product:1 's:2 business:2 drugs:2 earnings:6 company:1 faces:1 but:2 expects:2 reflecting:1 key:1 strong:2 analyst:1 developments:1 ``:2 2009:3 --:2 uncertainty:1 large:2 below:2 '09:4 rose:2 difficult:3
stock_BIIB r_down	biotech:1 because:1 brain:1 suspected:1 partner:1 its:1 market:1 weekly:1 no:1 there:1 2005:1 new:1 multiple:1 users:1 sold:1 published:1 update:1 infection:1 reported:1 link:1 article:1 cases:1 beginning:1 rare:1 progressive:1 --:1 18:1 months:1 sclerosis:1 drug:1 were:1 pulled:1
stock_BIIB r_up	repair:1 multiple:1 sentiment:3 developing:1 nervous:1 sclerosis:1 damage:1 drug:1 system:1 suggests:3 likely:3 done:1 downside:3 further:3 might:1
stock_BIIB r_down	s:2 $:2 8217:2
stock_BIIB r_up	giant:1 's:1 $:2 takeover:1 rival:1 some:1 only:1 but:1 deal:1 say:1 hailed:1 solve:1 planned:1 long-term:1 68:2 problems:1 partially:1 drug:1 its:1 analysts:1
stock_BIIB r_up	sector:2 purchases:1 through:1 68:1 pharmaceutical:1 $:1 battles:1 deal-making:1 start:1 more:1 expiring:1 ball:1 's:1 consolidation:1 takeover:1 rolling:1 billion:1 could:1 companies:1 drug:1 traditional:1 either:1 threat:1 biotechnology:1 toward:1 patents:1
stock_BIIB r_up	v.:2
stock_BIIB r_up	acquisitions:1 picture:1 emerging:1 's:2 lead:1 huge:1 sit:1 companies:1 clearer:1 drug:1 which:2 pursuing:1 follow:1 major:1 sidelines:1 might:2
stock_BIIB r_down	saying:1 focus:2 nominated:1 quarters:1 four:1 session:2 through:1 battle:1 whose:1 rose:3 had:1 late:1 advisories:2 4:2 take:1 hit:1 income:1 they:1 dearly:1 trade:1 years:1 investor:1 --:1 drop:1 companies:3 higher:1 people:1 hard:1 estimates:1 see:1 actively:1 trading:1 year:1 multiple:1 2.7:6 even:1 provided:1 said:1 shares:1 health:1 net:2 knowing:1 were:1 quite:1 proxy:1 consolation:1 active:1 strong:1 care:1 resumed:1 nonfarm:1 last:1 climbed:1 reports:1 34:1 figures:3 surprises:2 fourth-quarter:1 outlook:1 market:1 fight:1 expected:1 gained:1 500:1 board:1 roundup:1 drugs:1 funds:2 company:1 hurt:1 payrolls:1 showed:1 nominate:1 edged:1 up:1 until:1 n't:1 future:1 can:1 invest:1 spotlight:2 1.5:1 1.6:1 losses:1 1.3:1 penny:1 sales:2 slowing:1 helped:1 full-year:1 rekindling:1 mutual:1 topped:1 also:1 other:1 earnings:2 largest:1 stock:1 's:6 after:1 most:1 stocks:1 types:1 amid:1 futures:1 sclerosis:1 lasted:1 directors:1 '09:2 corporate:1 latest:1
stock_BIIB r_down	over:2 results:2 yet:1 industries:1 hopeful:1 than:1 better:1 weeks:1 has:1 versus:3 hit:1 around:1 overall:1 they:1 dearly:1 --:4 companies:1 activity:1 hard:1 year:2 said:5 decision:1 patients:3 shares:1 its:2 health:1 downturn:1 knowing:1 patient:1 free:1 quite:1 although:1 article:1 improve:2 last:1 many:1 taking:3 losses:1 drug:4 suggests:2 published:1 placebo:3 options:1 comment:1 consolation:1 strategic:1 multiple-sclerosis:2 uncertainties:1 way:1 forward:1 care:2 final:1 speaking:1 more:1 manufacturers:1 funds:3 company:1 but:1 hurt:1 known:1 hold:1 true:1 analyst:1 population:1 10:3 made:1 n't:2 remain:1 can:1 were:2 ready:1 hospitals:1 relatively:1 mutual:1 generally:1 detail:1 other:2 take:1 several:1 product:2 's:4 most:1 types:1 invest:1 disease:1 analysis:2 '09:2 time:2 biotechnology:1 2009:1 review:1
stock_BIIB r_down	comment:1 fourth-quarter:5 all:3 interest:1 financial:1 revenue:4 year:2 tax:5 $:7 one-off:1 helped:5 itself:1 per:2 cuts:2 's:2 aggressive:2 swung:5 open:2 its:6 option:1 strategic:1 basic:1 said:4 adds:1 raise:2 million:5 also:3 profit:6 way:1 review:2 stake:3 detail:2 comments:1 while:1 chief:1 treatment:1 remain:3 under:1 net:8 before:1 cost-cutting:1 deferred:1 ``:2 selling:2 multiple:4 minority:4 sale:2 10:1 share:2 company:1 after:1 but:6 results:1 made:1 preference:2 loss:2 one:1 weeks:1 raising:1 he:2 ago:2 '':2 posted:1 has:1 assets:1 ahead:1 --:5 income:1 prefers:2 sclerosis:4 cash:3 drug:6 maker:2 perhaps:1 benefit:4 cost:2 officer:1 recommendations:1 quarter:1 options:3 added:2
stock_BIIB r_up	biotech:1 product:1 may:2 lead:1 candidate:1 --:1 pipeline:1 tiny:1 leave:1 failure:1 partner:1 end:1 hole:1 late-stage:1 its:2 road:1 recent:1
stock_BIIB r_up	s:2 8217:2
stock_BIIB r_up	'':2 amp:2 ``:2
stock_BIIB r_up	s:2 8217:2
stock_BIIB r_up	prospect:1 development:1 tough:1 proposed:1 expensive:1 may:1 generic:1 long:1 their:1 new:1 week:1 's:1 drugs:1 outlined:1 but:1 biologic:1 inevitable:1 last:1 versions:1 budget:1 faces:1 road:1
stock_BIIB r_down	streak:1 's:1 winning:1 fund:1 broke:1 2008:2 hedge:1 market:1
stock_BIIB r_down	ratio:1 longer:1 no:1 positive:1 57:2 says:1 risk/reward:1
stock_BIIB r_up	smaller:1 help:1 into:1 drive:1 questions:1 begun:1 speed:1 its:1 landscape:1 fates:1 said:1 would:1 stake:1 makers:1 increase:1 fuel:1 development:1 company:1 consolidation:1 raising:1 plants:1 industry:1 companies:1 up:1 drug:1 turn:1 have:1 biofuels:1
stock_BIIB r_up	biotech:1 right:1 's:1 ability:1 --:1 demonstrates:1 price:1 tag:1 assets:1 leverage:1 downtrodden:1 buyer:1 especially:1 otherwise:1 market:1 higher:1
stock_BIIB r_down	biotech:2 right:1 prompt:1 deal:1 health-care:1 tag:1 seen:1 its:1 market:1 if:1 even:1 remaking:1 leverage:1 remains:1 demonstrates:1 time:1 higher:1 's:1 ability:1 hefty:1 price:1 published:1 additional:1 buyer:1 article:1 valuation:1 especially:1 acquisitions:1 assets:1 --:1 industry:1 face:1 large:1 itself:1 downtrodden:1 changes:1 otherwise:1
stock_BIIB r_up	mainly:1 elderly:1 years:1 brain:1 schizophrenia:1 thinks:1 if:1 asthma:1 would:1 area:1 research:2 fatal:1 treatment:1 dozens:1 more:1 's:5 diseases:1 drugs:1 strikes:1 most:1 important:1 condition:1 he:1 advance:1 land:1 acquiring:1 target:1 ahead:1 --:2 many:1 proud:1 disease:1 range:1 yields:1 efforts:1 experimental:1
stock_BIIB r_down	mainly:2 elderly:2 years:2 brain:2 schizophrenia:2 thinks:2 if:2 asthma:2 would:2 area:2 research:4 fatal:2 treatment:2 dozens:2 more:2 's:10 diseases:2 drugs:2 strikes:2 most:2 important:2 article:1 condition:2 he:2 advance:2 land:2 acquiring:2 target:2 ahead:2 --:4 many:2 proud:2 disease:2 range:2 yields:2 published:1 efforts:2 experimental:2
stock_BIIB r_down	profile:1 risk:1 investors:1 --:1 big:1 up:1 been:1 next:1 jointly:1 step:1 defense:1 multiple-sclerosis:1 treatment:1 controversial:1 ramping:1 sells:1 has:1 presentation:1 its:1 take:1
stock_BIIB r_up	gainers:3 favorites:1 cancer:1 orders:1 into:1 move:1 player:1 broader:1 news:1 multiple:1 its:1 market:1 significantly:1 highlighting:1 lead:2 research:1 also:1 other:1 expected:1 durable-goods:1 seeks:1 higher:1 's:2 reacts:1 but:1 significant:1 such:1 than:1 positively:1 areas:1 treating:1 standout:1 --:1 sclerosis:1 disease:1 remain:1 efforts:1 came:1
stock_BIIB r_up	gaining:2 among:1 moves:1 's:3 lead:2 biotech:2 north:2 notable:1 shares:2 front:1 market:1 pack:1 those:1 were:1 biggest:2 making:1 advance:1 stocks:3 declining:2 stock:1
stock_BIIB r_down	earlier:1 's:2 earned:1 --:1 annual:2 company:1 less:1 according:1 drug:1 than:1 published:1 bonus:1 year:1 report:1 2008:3 57:1 after:1 he:1
stock_BIIB r_down	investors:1 warning:1 shocked:1 another:1 first-quarter:1 its:1 opposes:1 contest:1 shares:1 much:1 low:1 nominees:1 setting:1 board:1 kicked:1 's:1 earnings:1 after:1 fell:1 activist:2 investor:2 off:1 17:1 --:1 drug:1 maker:1 three-year:1 high-growth:1 filing:1 proxy:1
stock_BIIB r_up	kicked:1 off:1 billionaire:1 filing:1 board:1 fight:1 second:1 activist:1 proxy:1 nominees:1 's:1 investor:1 its:2 opposed:1
stock_BIIB r_up	biotech:1 would:2 just:1 deal:1 bankruptcies:1 fit:1 number:1 years:1 through:1 looks:1 financier:1 year:1 premium:1 total:1 attract:1 its:1 market:1 hit:1 pharmaceutical:1 said:1 $:2 5.6:1 rose:1 stake:1 least:1 much:2 5:1 boom:1 8:1 euro:2 might:1 company:1 firm:1 billion:2 such:1 used:1 's:2 minority:1 offer:1 month:1 bid:1 million:1 most:1 takeover:1 five:1 plan:1 prescription:1 15:2 highest:1 chatter:1 he:1 acquisitions:3 value:1 last:2 like:1 world:1 level:1 seek:1 cap:1 companies:1 according:1 35:1 34:1 range:1 since:1 2004:1 11:1 position:1 maker:1 nearly:1
stock_BIIB r_up	psoriasis:1 rare:1 often:1 withdrawing:1 after:1 drug:1 linked:1 brain:1 but:1 voluntarily:1 fatal:1 disorder:1 its:1 market:1
stock_BIIB r_down	re:2 8217:2
stock_BIIB r_down	demanding:1 down:1 step:1 board:1 letter:1 sent:1 he:1
stock_BIIB r_up	whose:1 's:1 companies:1 focus:2 shares:1 trade:1 active:1 see:1 session:1 expected:1
stock_BIIB r_down	sales:1 helped:1 trading:1 broader:1 first-quarter:1 yet:1 market:1 strong:1 profit:1 its:1 earnings:3 higher:1 's:2 weak:1 treatments:1 slides:2 wake:1 sharply:1 stocks:3 posted:1 advance:1 trades:1 up:1 reports:1 afternoon:1 multiple-sclerosis:1 climb:2 slightly:1 better-than-expected:1
stock_BIIB r_up	adviser:1 shareholders:1 's:4 influential:1 largest:1 fight:1 backed:1 likely:1 board:1 seats:1 vote:1 comes:1 proxy:1
stock_BIIB r_down	cancer:1 over:1 period:1 brain:1 reports:1 ground:1 use:1 shares:1 should:1 shorter:1 take:1 taken:1 fatal:1 company:1 soar:1 breaks:1 link:1 gain:1 stoke:2 stocks:3 whether:1 light:1 could:1 disease:1 drug:3 patients:1 usually:1 speculation:1 discussing:1
stock_BIIB r_up	sector:1 1.5:1 slid:1 recess:1 into:1 two:1 down:1 actively:1 trading:1 dropped:1 seats:1 rally:2 whose:1 said:1 negative:1 shares:1 1:2 won:1 board:1 which:1 territory:1 meeting:1 roll:1 500:1 slips:1 bulk:1 following:1 stocks:3 investor:1 he:1 lost:1 annual:1 companies:1 drug:2 called:1 while:1 session:1 were:1 mixed:2 maker:1
stock_BIIB r_down	seat:4 another:1 vote:1 close:2 still:1 said:2 least:2 1:2 won:2 call:2 board:2 has:1 too:2 's:1 slate:1 but:1 shareholder:2 activist:1 preliminary:1 one:3 count:1 according:1
stock_BIIB r_down	pointing:1 nominated:1 trade:1 session:2 seats:2 its:1 whose:1 based:1 $:3 rose:3 add:1 activist:2 candidates:1 board:2 billionaire:1 investor:2 day:1 --:1 companies:2 50:1 extinguishment:1 stock:1 back:2 elections:1 surrounding:1 second:1 actively:1 targets:1 said:2 federal:1 assistance:1 shares:1 tend:1 won:2 available:1 jumps:1 takeover:1 100:1 strong:1 change:1 both:1 many:1 climbed:1 days:1 into:1 profit:1 another:1 68:1 confidence:1 debt:1 few:1 two:2 start:1 interest:1 basic:1 expected:1 500:1 billion:1 company:1 criteria:1 finished:1 gain:1 sharply:1 prices:1 95:1 second-quarter:1 13:1 economies:1 appealing:1 meet:1 biotech:1 investors:1 range-bound:1 expenses:1 inspector:1 equities:1 make:1 toehold:1 higher:1 week:1 independent:1 's:4 after:1 paid:1 driven:1 push:1 71:2 preliminary:1 stocks:2 data:1 fiscal:1 lower:1 largely:1 futures:4 commodities:2 giving:1 points:3 banks:1 biotechnology:1 latest:1
stock_BIIB r_down	shareholders:1 management:1 amid:1 challenge:1 easier:1 moving:1 new:1 law:1 makes:1 its:1 manufacturer:1
stock_BIIB r_up	partial:1 deal:1 cease:1 contract:1 another:1 pharma:1 there:1 three:1 arbitrator:1 under:1 sparking:1 ruled:1 development:1 terms:1 business:1 report:1 projects:1 recent:1 mega:1 hunt:1 drug:1 must:1 victory:1 newspaper:1 speculation:1 works:1
stock_BIIB r_down	being:1 developed:1 discovered:2 91:1 session:4 7.8:1 its:3 whose:4 $:1 rose:2 had:2 has:1 early:1 fall:1 report:1 progressive:1 lost:1 brain:3 --:1 companies:4 slide:3 after-hours:1 925:1 energy:1 jump:1 actively:4 trading:4 multiple:1 87:1 since:1 shares:6 closed:1 red:2 patient:1 sold:1 reported:1 downgrade:1 article:1 beginning:1 gained:4 rare:1 climbed:1 drug:3 infection:1 published:1 traded:4 slipped:1 point:1 into:2 one:1 62:1 multiple-sclerosis:2 another:2 news:3 drove:1 market:1 8.3:1 positive:1 two:1 been:2 6:1 500:4 led:1 but:1 link:1 prices:1 suspected:1 analyst:1 case:2 3.6:1 12:1 18:1 up:1 were:1 10th:3 slid:1 months:1 0.5:1 sales:1 dropped:1 tumbled:1 5.8:2 1:1 fourth:1 higher:4 added:3 's:6 after:1 update:2 falls:2 fell:2 eight:1 user:2 such:1 stocks:8 lower:1 off:1 sclerosis:1 disease:2 points:10 2005:1 pulled:1
stock_BIIB r_down	saying:1 relevant:1 disclosure:1 brain:1 trading:1 's:7 moves:1 its:1 no:1 rose:1 there:1 selloff:1 benefit:1 shares:1 clinical:1 patient:1 treatment:1 biggest:2 include:1 gaining:2 multiple:1 company:2 sparked:1 infection:1 biotech:1 medicine:1 fell:1 significant:1 stocks:2 declining:2 multiple-sclerosis:1 taking:1 sclerosis:1 trial:1 patients:1 making:1 discontinued:1
stock_BIIB r_up	exclusive:1 less:2 issued:1 move:1 outlook:2 session:3 gauge:2 shares:4 signs:2 its:1 traders:2 21:2 zone:2 rose:5 improvement:2 attractive:2 include:1 kick:2 therapy:1 tanks:2 advanced:1 --:3 companies:3 did:2 higher:4 6.2:1 significantly:1 deal:2 see:2 actively:3 trading:4 's:6 said:2 while:1 comments:1 forecast:1 spokesman:1 outside:1 announced:2 whose:3 agreement:3 takeover:2 key:2 news:1 100:1 manufacturing:2 beginning:1 declining:2 gained:3 quarter:2 license:1 climbed:3 analysts:2 mixed:3 traded:3 liked:1 revenue:1 previously:1 multiple-sclerosis:1 licensing:2 reached:1 would:1 come:1 expected:1 500:4 company:2 but:1 biggest:2 target:2 showed:2 polls:2 below:1 were:1 similar:2 0.9:1 1.1:3 1.2:1 1.3:1 watched:2 if:2 develop:1 make:2 1:3 fourth:1 9:1 stock:2 gaining:2 added:1 edged:1 collaboration:3 after:2 fell:2 stocks:8 euro:2 off:2 third:2 futures:4 points:3 biotechnology:2 2009:1 44:1
stock_BIIB r_down	1.5:2 futures:1 help:1 investors:1 higher:2 reduce:1 encouraging:1 helped:1 economic:2 trading:3 reports:1 year:1 after-hours:1 next:1 its:2 string:1 11:1 medications:1 end:1 $:6 profit:1 rose:2 make:2 stocks:2 investment:2 1:3 also:1 points:3 session:1 4:1 closed:2 400:1 deal:1 gains:1 net:1 pretax:1 500:1 gives:1 actively:1 gained:1 enable:1 's:5 plans:1 exchange:1 million:1 commercial:1 modest:1 kicking:1 reason:1 said:1 billion-plus:2 70:1 gold:2 debt:1 data:1 day:1 celebrate:1 drugmaker:1 billion:3 13:2 quarter:2 off:1 whose:1 third:2 rights:1 --:2 invest:2 57:1 climbed:1 companies:2 disease:1 drug:2 41:2 lift:1 shares:1 rallies:2 first:1 maker:2 experimental:1 small-caps:1
stock_BIIB r_up	because:1 brain:1 suspected:1 multiple:1 market:1 weekly:1 no:1 new:1 sold:1 's:2 users:1 company:1 update:1 infection:1 reported:1 link:1 article:1 cases:1 rare:1 progressive:1 --:1 18:1 months:1 sclerosis:1 drug:1 published:1 pulled:1
stock_BIIB r_down	sector:1 biotech:1 investors:1 trend:1 some:1 expenses:1 second:1 growth:1 signs:1 hit:1 makers:1 expensive:1 may:1 spending:1 expectations:1 pressures:1 earnings:2 expected:1 struggling:1 economy:1 controlled:1 drugs:1 report:1 last:1 look:1 solid:1 many:1 vulnerability:1 companies:1 drive:1 drug:1 large:1 more:1 continue:1 meet:1 quarter:2 consumer:1 order:1
stock_BIIB r_up	autoimmune:1 hoping:1 focus:2 doubters:1 trade:1 see:1 session:1 seen:1 whose:1 discloses:1 army:1 shares:1 clinical:1 expected:1 surprise:1 has:1 decades:1 's:1 therapy:1 new:1 active:1 data:1 treating:1 lupus:1 --:2 companies:1 disease:1 drug:1 n't:1 experimental:1 late-stage:1
stock_BIIB r_up	aided:1 help:1 pointing:1 over:3 results:4 years:1 leads:2 bring:1 session:3 its:5 weekly:1 impact:1 whose:2 $:2 22:1 23:1 rose:5 revenue:1 had:2 expectations:2 outlook:1 improvement:1 add:1 potential:1 pre-market:1 4:1 under:1 usage:2 8:2 0.5:1 uptake:2 loan:1 3.8:1 details:1 pact:1 increased:2 very:1 advances:1 early:2 nearly:1 despite:4 continued:2 volatility:1 stability:1 regarding:1 cases:2 --:3 companies:2 accelerating:2 morning:1 continue:1 worries:1 multiple-sclerosis:1 higher:4 view:2 deal:2 hard:1 some:1 product:1 rally:1 see:1 actively:1 trading:1 110:1 3.1:1 substantially:2 multiple:5 2.1:1 2.5:1 said:4 bottom:1 profit:7 since:2 while:2 shares:2 increase:1 safety:2 newly:1 previous:1 told:1 available:1 we:1 led:2 pharmaceutical:2 component:1 million:1 notable:1 reported:3 management:1 others:1 100:3 strong:4 appears:1 declining:2 roundup:1 quarter:2 last:1 cheered:1 31:3 losses:1 36:2 reports:2 a.m.:1 analysts:1 published:1 action:1 slightly:1 maker:1 comment:1 among:1 major:1 slipped:1 point:2 partnering:1 into:2 smashing:1 three:1 down:2 weaker:1 rising:1 licensing:1 clinical:1 open:1 market:1 bankruptcy:1 decline:1 story:1 industrials:1 jobless:3 positive:1 due:1 been:1 their:2 2:1 disappointed:1 biggest:3 upbeat:1 meeting:1 500:3 more:2 firm:1 rallied:1 ``:7 north:2 releases:1 share:1 company:6 corrected:1 but:1 hurt:1 expected:1 part:1 brain:2 gain:1 prices:1 line:1 general:1 investment-banking:1 second-quarter:4 those:1 11:1 10:1 kind:1 16:1 markets:1 up:1 signed:1 greatly:1 below:1 were:4 following:1 making:1 taking:2 launched:1 dropped:2 stronger-than-forecast:1 1.5:1 carves:2 annual:1 tap:1 1.2:1 ...:1 handset:1 partnership:1 turned:2 sales:2 0.7:1 0.6:1 '':6 drug:11 have:2 further:1 partner:2 moves:1 blockbuster:2 detail:1 1:1 run:1 concerns:2 patient:3 earnings:5 9:1 you:1 stock:5 gaining:3 topping:1 's:23 though:1 boosted:1 price:2 after:4 fell:7 experiences:1 stocks:8 data:1 payment:5 recent:3 billion:1 lower:2 futures:10 sclerosis:5 disease:2 points:12 claims:3 latest:1
stock_BIIB r_down	roundup:1 saying:1 's:1 --:1 surprises:2 future:1 companies:2 reports:2 surge:1 helped:1 solid:1 advisories:2 trading:1 earnings:2 closed:1 latest:1 quarters:1 out:1 slightly:1 corporate:1 higher:1
stock_BIIB r_up	biotech:2 '':1 arrangements:1 have:1 rally:2 data:1 its:2 boosts:2 index:1 positive:1 shares:1 largest:1 gets:1 boost:1 soar:1 ``:1 's:4 rekindles:1 huge:1 component:1 benchmark:3 takeover:1 relating:1 multiple:1 lupus:1 markets:1 sclerosis:1 drug:2 place:1 biotechnology:1 speculation:1
stock_BIIB r_up	comment:1 biotech:1 medication:1 says:1 help:1 deal:2 revenue:3 '09:2 over:1 narrower:3 4.6:3 increased:3 strategic:1 second:3 cost:3 multiple-sclerosis:2 another:1 year:3 partner:1 narrowed:7 cut:1 its:5 if:1 profitable:3 said:4 $:12 million:6 influence:1 stake:1 diluted:3 add:1 per:3 arrangement:1 only:1 future:1 basic:3 net:4 has:1 's:4 grows:2 gives:1 arises:1 multiple:3 finance:1 loss:12 share:3 company:2 rise:1 but:1 reported:3 reflecting:1 significant:1 demand:3 technologies:1 strong:1 opportunity:1 second-quarter:1 takeover:1 ago:3 purchase:1 2009:3 prescription:1 target:3 third:1 --:4 performances:1 30:1 sclerosis:3 50:1 drug:6 while:3 cutting:3 due:3 shrinks:2 quarter:3
stock_BIIB r_down	rights:1 's:1 give:1 18:1 could:1 stake:1 sclerosis:1 drug:1 half:1 multiple:1 company:1
stock_BIIB r_up	control:1 early:1 edged:1 company:1 after:1 questioned:1 controls:2 practices:1 defends:2 report:1 while:1 fell:1 shares:1 mixed:2 's:1 stocks:3 quality:3 higher:1
stock_BIIB r_down	control:1 deal:1 certain:1 against:1 reached:1 throughout:1 information:1 breached:1 additional:1 their:1 treatment:1 suit:1 manufacturer:1 's:2 announced:2 take:1 development:1 full:1 multiple:1 seeking:1 marketing:1 collaboration:1 agreement:1 affiliates:1 transaction:1 filed:1 prices:1 comply:1 recent:1 has:1 --:2 alleging:1 sclerosis:1 drug:1 aspects:1 recently:1 relief:1 stock:1
stock_BIIB r_up	multiple:1 federal:1 marketing:1 over:1 intervene:1 sclerosis:1 its:1 medicine:1 judge:1 partner:1 asked:1 dispute:1
stock_BIIB r_up	among:1 autoimmune:2 illnesses:1 sclerosis:1 over:1 hearing:1 manager:1 portfolio:1 federal:1 children:1 sell:1 these:1 tackling:1 investing:1 their:1 rates:1 treatment:1 between:1 has:1 dispute:1 scheduled:1 multiple:1 diseases:1 collaboration:1 rise:1 agreement:1 judge:1 --:1 31:3 companies:1 suggests:1 continue:1 problem:1
stock_BIIB r_down	regarding:1 court:2 --:1 31:3 sclerosis:1 agreement:2 hearing:1 federal:1 whether:1 treatment:1 focus:1 's:1 ending:1 should:1 multiple:1 collaboration:1 block:1
stock_BIIB r_up	regarding:1 court:2 --:1 31:3 sclerosis:1 agreement:2 hearing:1 federal:1 whether:1 treatment:1 focus:1 's:1 ending:1 should:1 multiple:1 collaboration:1 block:1
stock_BIIB r_down	comment:1 benefited:1 producer:1 almost:2 lack:1 period:1 6.7:1 known:1 second:3 through:1 natural-gas:1 portfolio:2 total:1 its:2 fifth:2 filings:2 information:2 moves:1 $:3 million:1 no:2 holdings:2 activism:1 run:1 shares:1 spokesman:1 being:2 only:2 17.1:1 exit:2 market:1 previously:1 billionaire:1 increasing:1 1.57:1 his:3 's:3 amended:1 sixth:1 sold:1 rise:1 overall:1 reported:2 significant:2 regulatory:2 change:2 billion:3 10th:1 fund:1 --:2 30:2 according:2 value:1 filing:1 quarter:3 changes:2 investments:3 first:1
stock_BIIB r_down	biotech:1 because:1 limited:2 copies:1 topic:1 cost:1 have:1 close:1 struggles:1 market:2 their:3 generic:1 defend:1 biosimilars:1 able:1 complex:1 traction:1 may:2 hot:1 version:1 which:1 more:1 drugs:4 possible:1 but:1 biologic:2 effects:1 they:1 turf:1 exact:1 gained:1 reveal:1 --:1 hint:1 n't:2 savings:1 threat:1 worries:1 lucrative:1
stock_BIIB r_up	n't:1 said:1 cancer:1 developing:1 wo:1 company:1 results:1 drug:1 targets:1 disappointing:1 reported:1 full-year:1 meet:1 biotechnology:1 studies:1 its:1 experimental:1
stock_BIIB r_down	comment:1 over:2 hearing:2 multiple-sclerosis:1 multiple:1 court:2 prepare:2 federal:2 treatment:2 collaboration:2 more:2 updated:1 's:2 price:1 agreement:2 delayed:2 allowing:2 key:2 declining:1 10:6 --:2 sclerosis:1 until:2 time:2 dispute:2 stock:1
stock_BIIB r_down	says:1 led:1 spending:1 companies:1 new:1 growth:1 '09:1 half:1 report:1 during:1 first:1
stock_BIIB r_down	biotech:1 also:1 generic:1 wins:3 loses:3 drugs:1 finally:1 allowed:1 known:1 market:1 if:1
stock_BIIB r_up	key:1 biotech:1 version:1 deal:2 previously:1 endless:1 coming:2 moved:1 soon:1 hearing:1 '':1 judge:3 second:1 multiple-sclerosis:1 multiple:1 exclusivity:1 moves:1 its:3 market:2 if:1 sell:2 medications:2 end:1 federal:3 p.m.:2 also:1 finally:1 breaches:2 treatment:2 which:1 forward:1 details:1 ruled:2 correct:1 more:1 scheduled:1 ``:1 's:3 plans:1 collaboration:3 published:1 agreement:1 remedy:1 biologic:2 recent:2 breach:1 date:1 come:1 nine-year:2 10:1 regarding:1 has:4 versions:2 --:2 follows:1 could:1 sclerosis:1 days:1 biologics:1 morning:1 headline:1 allow:1 error:1 industry:1 generic:1
stock_BIIB r_up	all:2 help:2 unemployment:1 unsolicited:4 illustrated:1 ended:1 attempts:3 session:3 including:1 still:1 its:5 developer:3 industries:1 whose:2 terms:1 $:13 rose:4 had:1 should:3 add:1 going:1 treatment:4 recommend:1 under:1 has:3 might:4 happened:2 modestly:2 evening:1 premium:1 increased:2 analysts:2 bid:1 nearly:1 fall:1 report:1 multiple:4 day:1 ruled:3 several:1 like:1 bring:1 --:6 large-caps:1 companies:2 winter:2 lose:2 through:1 went:2 stock:6 out:3 week:2 shunned:3 smaller:3 deal:7 declines:1 back:3 3.7:1 rate:1 actively:2 trading:2 umbrella:1 await:1 subject:1 resurgence:2 recently:1 federal:3 shares:4 enough:1 does:1 health:2 beating:2 public:3 red:1 available:1 breaches:3 earlier:5 led:1 team:1 million:5 agreement:1 takeover:1 although:1 losing:1 100:1 finishing:1 contraction:1 choppy:1 service:1 mulled:1 30:1 pandemic:2 drug:3 became:1 figures:2 swine:2 faces:1 action:1 traded:2 first:2 major:1 tone:1 key:2 win:2 baskets:1 active:1 set:2 64:1 determine:2 market:3 decline:1 log:2 would:1 2:1 6:1 expected:1 9.5:1 9.7:1 500:3 more:1 firm:1 pare:1 buy:3 offer:4 offered:1 acquire:1 but:1 broke:2 prices:2 90:1 payrolls:2 those:2 nine-year:3 autumn:1 account:1 made:1 jobs:3 look:2 rights:1 amend:1 18:1 flu:4 up:1 n't:4 near:1 were:4 biotech:2 buying:1 judge:3 slowing:1 according:2 collaboration:3 experience:1 partner:2 gains:3 sell:5 indexes:1 pay:1 claiming:3 41:1 traders:2 points:9 5:1 details:1 which:5 if:1 company:5 higher:8 development:2 added:3 's:6 highs:1 after:8 reach:3 sold:1 authorities:2 climbing:1 stocks:9 data:3 recent:3 task:1 futures:6 sclerosis:4 2001:1 11.5:1 latest:1
stock_BIIB r_up	unsolicited:1 years:1 not:3 session:4 through:1 shares:4 its:6 developer:1 24:1 whose:4 giant:1 $:8 rose:3 29:1 actually:1 8:1 has:1 do:1 goes:1 than:1 bid:3 cheaper:1 background:1 buyer:1 slogan:2 buyout:3 --:2 56:1 companies:4 calling:4 collect:1 after-hours:1 higher:1 shunned:3 says:1 often:1 deal:1 'inadequate:2 up:1 past:1 actively:4 trading:4 targets:2 best:3 out:1 missed:1 entertainment:1 jumped:1 comments:1 research:2 current:2 7:1 new:1 electronics:1 365:1 ability:1 sixth:1 million:8 notable:1 380:1 approaches:3 takeover:3 declining:2 gained:5 hostile:1 could:2 climbed:4 turn:1 options:1 spirit:1 comment:1 among:1 initial:1 extra:1 into:1 rising:1 throughout:1 market:1 shareholders:3 sheet:1 additional:1 would:2 rejects:3 holdings:1 there:1 creativity:1 their:1 interest:3 6:2 biggest:2 500:4 ``:8 offer:6 company:2 but:1 prices:2 analyst:1 10:1 15:1 look:1 19:1 cash:2 n't:1 nine:1 were:1 making:1 balance:1 seven:1 30:1 inadequate:3 wsj.com:1 '':8 overheard:1 owes:1 partner:1 moves:1 if:2 again:3 ideas:1 40:1 reality:2 note:1 forgo:1 earnings:2 fourth:1 9:2 stock:3 gaining:3 's:13 information:1 bonus:1 paid:1 forecasts:2 stocks:7 payment:1 fiscal:1 considered:1 points:12
stock_BIIB r_down	shunned:1 interest:1 rocket:2 inadequate:1 executive:1 results:1 '':2 not:1 high-level:1 its:1 best:1 again:1 shareholders:1 investors:1 fourth:1 shares:4 treatment:1 statement:1 stock:1 ``:2 million:1 's:2 soar:1 offer:1 await:1 seventh:1 approaches:1 takeover:1 wake:1 key:1 prices:1 closing:1 drugmaker:1 --:1 leaves:2 drop:1 departure:1 calling:1 obesity:1 higher:2 studies:1 $:1
stock_BIIB r_down	assessing:1 risk:1 medical:1 treatments:1 benefit:1 can:1 challenging:1
stock_BIIB r_down	stock:4 1.5:2 major:1 eliminating:1 deal:5 biotech:1 judge:1 consistent:1 partnership:2 reduce:1 prospect:2 breached:1 trade:2 brain:3 say:1 multiple-sclerosis:3 have:2 ruled:1 its:3 market:1 risk:1 sell:1 said:1 group:1 investors:1 weakened:1 remains:1 media:1 since:1 anniversary:2 investment:1 one-year:2 concerns:2 treatment:1 collapse:1 between:2 breach:1 bankruptcy:1 price:4 more:3 over:1 users:2 seeking:3 sold:1 after:1 infection:3 focus:2 part:1 eve:2 negotiating:1 separate:1 fall:2 report:1 such:1 cases:3 updating:1 $:2 billion:2 lower:3 rare:2 --:2 amid:1 taking:1 futures:4 according:1 drug:3 war:2 weaken:1 patients:1 stopped:1 planned:1 worries:2 situation:1 fixed:1 first:1
stock_BIIB r_up	1.5:1 one-year:1 slipped:1 partnership:2 sales:1 trade:1 115:1 multiple-sclerosis:2 optimistic:1 eliminating:1 7.8:1 throughout:1 2.7:1 its:3 declined:1 bankruptcy:1 sell:2 cut:1 deal:3 data:1 fix:1 fears:1 anniversary:1 inflation:1 speech:1 earnings:1 closed:1 fixed:1 details:1 moderate:1 war:1 500:1 stock:1 edged:1 gains:1 million:1 forecasts:1 early:1 drug:1 fell:1 background:1 breach:2 previous:1 100:1 stocks:1 come:1 additional:1 billion:1 lower:1 has:1 17:1 --:1 wholesale:1 futures:3 well:1 value:1 $:2 more:1 points:3 replaced:1 said:1 treatment:2 speculation:1 retail:1 dip:1 order:1 likes:1
stock_BIIB r_down	help:1 rituxan:1 results:2 brain:1 identify:1 its:6 group:2 $:1 rose:1 treatment:1 include:1 updated:1 good:2 early:1 suffering:2 lymphoma:3 continued:1 advanced:1 --:3 did:1 rheumatoid:2 related:1 laboratory:1 said:4 jumped:2 marketed:2 shares:2 safety:1 new:3 receiving:1 officially:1 sold:1 announced:2 arthritis:2 recently:1 jumps:2 alone:1 pharma:1 advance:2 rare:1 launch:2 study:1 drug:4 trial:2 carrier:2 helps:1 late-stage:2 cancer:3 unit:3 their:1 genetic:1 chemotherapy:1 's:4 screening:2 lived:1 company:3 infection:1 known:1 than:1 those:1 has:4 showed:3 edged:1 up:1 n't:1 patients:4 launched:3 biotech:4 illness:1 moved:2 information:2 carriers:1 test:3 worsening:1 fibrosis:2 higher:2 product:1 used:1 multiple:1 after:3 stocks:4 longer:1 sclerosis:1 disease:1 together:1 maker:1 without:1 cystic:2
stock_BIIB r_up	shareholders:1 smaller:1 bid:1 $:2 offer:2 merger:1 company:2 million:2 urged:1 discuss:1 takeover:1 rejected:2 directly:1 tender:2 taking:1 has:1 its:2 launched:2
stock_BIIB r_down	biotech:1 raised:1 appeals:1 help:1 investors:1 extra:1 suddenly:1 text:1 executive:1 some:1 around:1 dose:1 '':1 overheard:1 accounts:1 thanks:1 committee:1 rally:1 find:1 if:1 given:1 speaking:1 court:1 $:3 shares:1 stake:1 seems:1 legal:1 its:2 only:1 way:1 under:1 before:1 8:1 out:2 meeting:1 announced:1 bought:1 sort:1 ``:1 's:2 7:2 abysmal:1 share:1 offered:1 fund:1 courage:1 wsj.com:1 they:1 not:1 group:1 elite:1 why:1 15:1 --:1 could:1 cash:1 morning:1 contrary:1 ruling:1 have:1 trading:1 traded:1
stock_BIIB r_up	biotech:1 said:1 ingredients:1 provide:1 trials:1 secured:1 detail:1 clinical:1 markets:1 development:1 used:1 's:1 drugs:1 company:2 agreement:1 long-term:1 background:1 manufacturing:1 --:1 required:1 contract:1 products:1 small:1 called:1 once:1
stock_BIIB r_up	related:3 disease:2 multiple-sclerosis:3 battered:1 year:2 disclosures:4 its:1 market:1 subject:1 information:3 said:3 rumors:1 shares:1 traders:1 's:4 seeking:3 takeover:1 buyout:1 chatter:1 received:3 made:1 last:2 companies:1 batch:1 drug:7 options:1 maker:2 subpoena:3 responded:1 experimental:2 latest:1
stock_BIIB r_down	executive:1 years:4 known:4 go:4 its:9 $:4 than:4 treatment:1 has:4 pill:2 seeking:1 possible:3 early:3 background:2 taking:4 projects:4 drugmaker:7 name:4 --:4 companies:1 '10:6 related:1 likely:4 trading:1 year:5 multiple:5 said:6 adds:1 shares:1 new:4 regulatory:1 news:1 beginning:1 generate:4 received:1 last:1 launch:3 flare:4 industry:1 annual:4 drug:9 trial:1 maker:1 experimental:6 first:1 comment:1 seeing:4 revenue:4 one:8 multiple-sclerosis:1 approval:1 two:4 least:1 next:3 clinical:1 treat:1 way:4 more:8 hopes:4 trying:1 analyst:2 showed:4 up:4 patients:4 three:1 were:4 study:4 battered:1 pushes:1 sclerosis:5 performed:1 disclosures:2 information:1 end:1 generic:4 detail:1 1:4 also:4 potential:4 details:1 9:1 stock:2 development:4 's:6 price:1 most:4 important:4 paving:4 competitor:1 billion:4 well:1 disease:5 without:4 subpoena:1 2008:1 oral:5 filing:1
stock_BIIB r_down	already:1 best:1 inadequate:1 '':2 prices:1 parties:1 tender:2 throughout:1 its:1 inquiries:1 developer:1 information:1 shareholders:3 $:2 holdings:2 had:1 comments:1 their:2 disclosed:1 interest:1 new:1 has:1 bid:1 told:2 ``:2 's:4 offer:2 company:2 million:2 takeover:2 background:1 not:3 recent:1 received:1 third:1 --:1 stock:1 called:1
stock_BIIB r_down	undervalued:1 25:2 says:1 $:2
stock_BIIB r_up	biotech:1 says:1 stocks:1 group:1 candidate:1 dive:1 rise:1 shares:1 its:1 halting:1 clinical:1 drug:1 rally:2 plunges:2 study:1 after:1
stock_BIIB r_down	control:1 biotech:1 months:1 revenue:1 expenses:1 ended:1 growth:1 makers:1 takes:1 three:1 earnings:1 expected:1 economy:1 hit:1 report:1 many:1 30:1 companies:1 drug:1 large:1 while:1 continue:1
stock_BIIB r_up	's:3 investors:1 agency:1 been:1 concerns:1 so:1 shocked:1 have:1 staff:1
stock_BIIB r_down	comment:1 heavy:1 all:1 among:1 raised:1 up:1 trading:2 dropped:1 questions:1 multiple:2 its:2 panel:4 confidence:2 documents:1 $:2 rose:2 support:2 sending:1 question:1 shares:2 than:1 favor:1 voted:1 which:1 got:1 increasing:2 's:5 company:1 stock:2 recently:1 premarket:1 strongly:1 received:1 price:1 after:2 but:1 volume:1 others:1 approval:2 day:1 recent:1 halted:1 include:1 last:1 40:1 --:2 53:1 sclerosis:2 21:1 drug:5 after-hours:1 briefing:1 effectiveness:1 more:1 maker:1
stock_BIIB r_down	deal:1 focus:2 trade:1 see:1 session:1 tender:1 its:1 whose:1 $:1 no:1 two:1 shares:2 interest:1 expected:1 has:1 extended:1 's:2 offer:1 million:1 nearly:1 despite:1 active:1 16:3 months:1 companies:1
stock_BIIB r_up	1.5:2 135:2 bleeding:1 well:1 6.7:1 move:1 injections:1 50:1 helped:2 see:1 frequency:1 likes:2 another:2 protein:1 its:2 earlier:1 busy:2 spending:2 rose:6 there:2 treatment:2 should:2 their:1 earnings:4 which:1 test:1 new:1 if:1 type:1 500:6 stock:2 week:6 11.5:1 added:2 's:3 said:1 protection:1 reporting:2 lift:2 blood:2 they:1 kicks:2 last:2 100:2 after:1 clot:1 12:1 off:2 hemophilia:1 ahead:1 slow:1 study:1 futures:6 ramp:2 up:2 reports:2 points:6 testing:1 components:2 47:1 disorder:1 reduces:1 6.2:1
stock_BIIB r_down	sector:2 saying:1 producer:1 focus:2 quarters:1 brain:2 session:1 bucking:1 thanks:1 broader:2 90:1 talks:2 follow:2 forecast:1 its:10 6.9:1 ground:1 whose:2 $:4 rose:5 28:1 expectations:2 advisories:2 smaller-than-expected:1 disclosed:2 usage:2 gave:1 updated:1 risk:2 rise:2 cutting:3 every:1 they:1 report:1 trade:1 day:1 --:5 drop:1 companies:5 loser:1 morning:1 trimmed:2 lose:1 higher:2 better-than-expected:1 unexpected:1 billion:2 trend:1 cuts:2 back:1 up:1 see:1 cost:5 trading:3 year:1 's:8 2.6:1 2.5:1 index:2 mid-:1 actively:2 profit:6 jumped:2 shares:4 label:2 increase:1 future:1 closed:2 pared:1 falling:3 announced:1 cost-cutting:1 core:2 sold:2 key:2 backed:1 strong:3 5.38:1 declining:1 roundup:1 buck:1 cautious:1 rare:2 starts:1 according:1 drug:6 34:14 monthly:1 gainer:1 surprises:2 view:2 slightly:2 comment:2 outlook:4 projection:3 revenue:7 down:1 active:1 maintained:1 multiple-sclerosis:1 throughout:2 telecommunications:2 market:2 decline:2 '':4 additional:2 addition:2 housing:1 third-quarter:5 their:1 dropping:1 biggest:2 black:1 markets:1 500:2 more:2 digits:4 ``:4 buy:1 drugs:2 company:12 but:4 expected:1 lowered:3 longer-term:2 analyst:2 those:1 11:1 high:4 12:1 permits:1 amend:2 single:4 project:1 while:1 growth:7 were:2 following:1 biotech:5 sales:4 helped:2 full-year:2 against:1 increased:2 information:3 strength:2 prior:2 mid:1 topped:2 1:4 also:1 earnings:7 gains:1 stock:4 gaining:1 multiple:3 plans:1 though:1 price:3 earlier:1 driver:2 reflect:2 fell:1 infection:2 stocks:5 building:1 lower:5 off:1 amid:2 futures:1 sclerosis:3 reports:2 points:4 biotechnology:2 2008:1 2009:2 corporate:1 came:1 latest:1
stock_BIIB r_down	raised:3 deal:4 outlook:3 expenses:1 helped:3 full-year:2 multiple-sclerosis:1 swung:4 its:10 said:4 profit:4 reduction:1 net:4 higher:1 multiple:3 sales:4 restructuring:4 operating:1 lifted:1 lower:1 quarter:3 third:3 --:3 sclerosis:3 drug:8 costs:1 2009:1 maker:4
stock_BIIB r_down	among:1 woes:2 biotech:1 previously:1 sclerosis:2 brain:1 say:1 session:2 reviewing:1 multiple:2 review:1 bearish:1 citing:1 much:1 safety:1 disclosed:1 biggest:2 has:1 sold:1 higher:1 gaining:2 's:2 mostly:1 get:1 started:1 bid:1 infection:1 most:1 regulators:1 they:1 fall:2 active:1 stocks:3 than:1 declining:2 panel:1 treating:1 lower:1 rare:1 companies:1 rate:1 drug:5 were:1
stock_BIIB r_up	comment:1 among:1 raised:1 controversial:2 disclosure:1 previously:2 infections:1 number:1 detail:1 brain:3 rate:1 actively:2 trading:3 dropped:1 questions:1 80:1 its:2 whose:2 adds:1 rose:1 review:2 point:1 severe:1 shares:2 analyst:1 1:1 citing:2 much:2 slipping:1 new:1 falling:1 has:3 company:1 500:2 stock:2 disclose:1 's:7 reaction:1 started:2 price:2 disclosed:2 infection:2 2:1 fresh:1 sold:2 20:1 cases:1 stocks:2 than:2 declining:1 panel:2 session:2 10:1 lower:1 rare:2 lost:1 16:1 --:3 taking:1 companies:2 drug:3 patients:1 points:5 policies:1 were:2 mixed:1 multiple-sclerosis:1 higher:2
stock_BIIB r_up	respond:1 controversial:3 session:1 previously:3 infections:2 number:2 lower:1 brain:3 rate:1 actively:2 trading:3 dropped:1 have:1 throughout:1 118:1 comments:1 whose:2 adds:1 much:3 review:3 marketed:1 patients:1 shares:2 than:3 failed:1 citing:3 other:1 treatment:1 details:1 falling:2 has:3 price:1 500:2 higher:3 's:6 started:3 sold:3 after:1 leukemia:1 infection:1 hours:1 109:1 disclosed:3 stocks:2 beginning:1 approved:1 declining:2 panel:3 11:2 13:1 rare:3 14:1 third:1 --:3 companies:2 drug:3 slipping:2 points:6 therapies:1 were:1 stock:1
stock_BIIB r_down	respond:1 marketed:1 leukemia:1 failed:1 patients:1 other:1 treatment:1 have:1 approved:1 therapies:1
stock_BIIB r_down	rare:1 deaths:1 --:1 taking:1 since:1 sclerosis:1 patients:1 infection:1 its:1 four:1 reported:1 regulators:1 2006:1 brain:1 4:2 multiple:1 '06:2 sold:1 relaunch:1
stock_BIIB r_up	sees:1 20:1 current:1 levels:1 upside:1 nearly:1 's:2
stock_BIIB r_up	number:3 ninth:1 brain:3 planning:2 experts:1 should:1 pharmaceutical:1 regulate:1 additional:1 everything:1 media:1 consortium:3 comments:2 research:3 their:3 details:1 fourth:1 has:3 tell:1 form:2 drugs:3 forming:1 ads:1 infection:3 specialists:1 gurus:1 rare:3 --:4 taking:3 patients:3 advertising:1 social:1
stock_BIIB r_up	all:1 certain:1 ca:1 share:1 number:2 brain:3 experts:1 expect:1 specialists:1 's:1 makers:2 information:1 confirmed:2 develop:1 ads:1 jumped:2 agency:1 sites:1 other:1 safety:1 treatment:2 way:2 new:2 told:1 multiple:2 risk:1 sold:2 after:2 problems:1 infection:3 reported:2 regulators:2 understand:1 article:1 cases:4 data:1 why:1 present:1 recent:2 rare:3 --:3 try:1 study:1 months:2 sclerosis:2 drug:3 n't:1 patients:3 advertising:1 published:1 example:1 latest:1
stock_BIIB r_down	previously:1 owned:1 elected:1 selling:1 investment:2 filings:1 sell:1 jumped:1 stake:1 traders:1 interest:1 new:3 he:1 reporting:1 firm:1 his:2 's:1 which:1 normal:1 company:1 after:1 reported:2 regulatory:2 article:1 continued:1 investor:2 level:1 --:2 30:3 companies:1 according:1 drug:1 options:1 twice:1 while:1 published:1 biotechnology:1 filing:1 stakes:2
stock_BIIB r_up	biotech:2 stalling:1 six:1 letters:1 1.3:2 executive:2 share:1 product:1 one:1 past:1 including:1 seats:1 return:2 its:3 shareholders:2 said:1 spending:2 pattern:1 activism:1 stake:2 two:1 comments:1 won:1 board:4 which:1 marks:1 has:1 company:2 sent:3 inaction:1 development:1 ``:2 move:1 's:3 less:1 billionaire:1 price:1 after:2 fund:3 management:1 shareholder:1 letter:2 hedge:2 than:1 '':2 --:2 18:1 months:1 cash:2 record:1 compensation:2 owns:2 fresh:1 urging:2
stock_BIIB r_up	major:2 investors:2 being:2 years:2 drug:4 hit:2 its:2 market:2 shares:2 more:2 company’s:2 fuels:2 's:3 company:2 pushing:2 eight:2 highest:2 than:2 lupus:4 level:2 value:2 banking:2 experimental:2
stock_BIIB r_up	investors:1 high:1 done:1 partner:1 unsure:1 its:2 deal:1 positive:1 get:1 enough:1 company:1 ocrelizumab:1 development:1 's:1 offer:1 boosted:1 bid:1 multiple:1 but:1 reported:1 takeover:1 phase:1 data:1 21:1 attempt:1 hostile:1 --:2 sclerosis:1 whether:1 patients:1 analysts:1 antibody:1
stock_BIIB r_up	biotech:2 named:1 its:2 addition:1 activist:2 board:2 struggling:1 has:1 more:2 firm:1 independent:2 's:1 after:2 director:2 fund:2 hedge:2 beginning:2 pressure:2 --:1 signal:2 push:2 changes:2 could:2 comes:1
stock_BIIB r_up	focus:2 trade:1 session:5 7.4:1 talks:2 issues:1 whose:5 $:3 rose:5 should:1 other:1 board:2 premarket:1 8:1 increased:2 bid:1 after-hour:1 early:1 background:1 fall:1 continued:1 --:1 companies:6 calling:1 7.1:1 cooperation:1 suitors:1 see:1 actively:4 trading:4 entering:1 tender:1 81:1 said:1 opened:1 shares:8 forecast:3 7:1 between:1 420:2 2.9:1 million:2 possibility:1 active:1 gained:2 reaction:1 invited:1 climbed:2 stressed:1 mixed:1 climb:3 traded:3 comment:1 raised:2 into:1 66:1 69:1 throughout:1 there:1 interest:1 expected:1 500:2 ``:1 offer:2 company:2 rejected:2 6.4:1 analyst:1 11:1 13:1 grew:1 word:1 14:1 up:3 n't:1 while:1 acquisition:2 larger:1 investors:1 inadequate:2 moved:2 '':1 financial:1 potential:2 details:1 higher:3 's:13 though:1 after:1 falls:2 action:1 75:1 but:1 stocks:7 points:12
stock_BIIB r_up	results:2 its:3 previous:1 whose:1 but:1 $:1 candidate:1 rose:1 late:1 board:1 has:1 presentation:1 2010:1 bid:1 day:1 represents:1 lost:1 55:1 companies:1 --:2 continue:1 become:1 rheumatoid:2 related:1 actively:1 trading:1 year:1 best:1 said:6 shares:1 3:1 420:1 arthritis:2 million:1 met:2 step:1 gained:1 study:1 drug:3 trial:2 mixed:1 maker:1 late-stage:1 raised:1 primary:2 down:1 unit:2 pharmaceutical:1 positive:1 submit:1 their:1 2:1 analyze:1 meeting:1 final:1 500:1 treatment:1 firm:1 ``:1 upcoming:1 offer:2 company:1 rejected:1 endpoint:2 showed:1 patients:1 were:1 acquisition:1 inadequate:1 '':1 partner:1 again:1 end:1 efficacy:1 1:1 chairman:2 ocrelizumab:2 's:4 after:1 plan:1 stocks:1 data:1 response:1 medical:1 together:1 points:3 biotechnology:1
stock_BIIB r_up	replace:1 '':1 battle:1 shares:1 tender:1 its:1 if:1 shareholders:1 said:1 $:1 would:1 their:1 least:1 majority:1 board:1 420:1 ``:1 's:1 million:1 prepared:1 most:1 proxy:1 effort:1 launch:1 time:1 acquisition:1 first:1
stock_BIIB r_up	'':1 actively:1 trading:1 poison:1 its:2 24:1 whose:1 shareholders:1 5.3:1 $:1 rose:1 two:1 shares:1 increase:1 their:1 points:3 biggest:1 420:1 pill:1 500:1 higher:1 11:1 ``:1 's:1 increased:1 bid:1 million:1 allowing:1 ward:1 stocks:1 provision:1 gained:1 off:1 amid:1 companies:1 without:1 session:1 acquisition:1 efforts:1 traded:1 triggering:1 stakes:1
stock_BIIB r_down	walking:1 one:2 trading:1 want:1 tender:1 happen:1 saw:1 its:2 after:1 whose:1 shareholders:1 said:1 $:1 would:1 their:1 away:2 had:1 shares:1 1:1 majority:1 does:1 biggest:2 got:1 bid:1 stock:1 gaining:2 acquire:1 's:3 offer:1 couple:1 million:1 walk:1 420:1 active:1 stocks:2 effort:1 declining:2 like:1 going:1 last:1 look:1 did:1 deals:1 companies:1 've:1 n't:2 without:1 plus:1 were:1 holders:1 support:2
stock_BIIB r_up	comment:2 biotech:2 old:2 broader:1 dayside:1 give:2 51:2 retire:2 some:2 focus:2 trade:3 global:1 known:2 see:1 session:1 trading:1 controversial:2 multiple:2 throughout:1 its:2 fifth:1 concern:2 announcement:2 shareholders:2 stocks:2 trajectory:2 tip:1 detail:1 shares:1 late:2 lower:1 activist:2 treatment:2 strong:2 expected:1 has:4 sold:2 executive:2 's:3 gains:3 track:1 funds:1 company:3 after:1 treatments:2 back:2 pressure:2 market:2 background:1 active:1 president:2 years:2 data:1 those:1 successor:2 faced:2 search:2 manufacturing:1 --:2 sclerosis:2 drug:2 round:1 chief:2 growth:2 comes:2 after-hours:1 push:1 easing:1 maker:2 launched:2
stock_BIIB r_down	money:1 retire:3 trade:1 manager:3 session:1 shares:3 broader:1 positions:1 its:1 whose:1 $:1 rose:2 it’s:1 8:1 has:1 pending:1 executive:1 joint:1 they:1 retreat:1 successor:2 turns:1 companies:1 bad:1 after-hours:1 economy:1 dip:2 globe:1 searching:1 likely:1 actively:1 trading:2 year:2 's:8 said:3 lead:2 jumped:1 contributed:1 comments:1 new:1 across:1 business:1 -2:2 news:2 100:1 manufacturing:1 advance:1 39:1 ahead:1 according:1 drug:1 maker:1 1.5:1 rising:1 market:2 surveys:1 two:2 start:1 stock:2 way:1 expected:1 500:2 slips:2 form:1 company:1 search:1 13:1 16:2 car:1 matter:1 venture:1 stages:1 launched:1 biotech:2 156:1 sales:1 his:1 slip:1 home:1 develop:1 which:1 higher:1 gaining:1 added:1 edged:1 plans:1 after:1 update:2 jumping:1 president:1 stocks:6 data:1 rallied:1 effective:1 futures:3 picks:2 chief:1 points:6 tech:2 biotechnology:1 1.25:1
stock_BIIB r_down	biotech:3 force:1 deal:1 leads:2 bring:1 drug:1 hammer:1 positive:1 out:1 merger:1 rose:1 two:1 shares:1 candidates:1 bosses:1 higher:3 them:1 's:1 combination:1 includes:1 early:1 therapy:1 new:1 stocks:3 --:2 study:1 together:1 time:1
stock_BIIB r_down	climbed:1 says:1 cancer:1 sales:1 facilities:1 controversial:1 's:2 sells:1 blockbuster:2 its:3 said:2 $:3 there:1 28:3 yet:1 1:1 treatment:4 which:1 entered:1 has:1 status:1 billion:1 multiple:3 reaching:1 infection:1 number:1 using:1 cases:1 manufacturing:1 prostate:1 approved:1 building:1 territory:1 rare:1 brain:1 --:1 30:3 sclerosis:3 drug:1 patients:2 were:1 2009:3
stock_BIIB r_up	biotech:1 investors:1 doing:2 executive:2 back:2 feet:2 brain:1 his:2 plagued:1 year:2 multiple:1 sells:1 open:2 its:3 were:1 conference:2 provided:1 believe:1 recovery:1 remains:2 there:1 28:3 patients:1 comments:1 should:2 outside:2 does:2 rare:1 which:1 interview:1 input:2 might:1 difficult:2 someone:2 's:2 plans:2 though:2 company:2 after:2 problems:1 update:1 new:1 else:2 job:2 leadership:1 focused:2 infection:1 coming:2 article:2 cases:1 manufacturing:1 come:1 he:4 necessary:1 full:1 getting:2 --:3 many:1 sclerosis:1 think:2 n't:2 chief:2 treatment:1 said:1 published:2 health-care:1 2009:2 spend:2
stock_BIIB r_down	10:1 within:1 overhaul:2 pushes:2 highs:1 health-care:1 companies:1 52-week:1 91:1 stocks:2 500:1 higher:2
stock_BIIB r_down	biotech:1 all:1 uncertainty:1 associated:1 broader:3 fourth-quarter:1 health-care:1 removed:1 teams:1 around:1 risk:1 early:2 brain:1 say:1 growth:1 projections:1 have:1 further:1 's:2 aggressive:1 conservative:1 makers:1 market:3 increased:1 said:2 group:1 reform:1 provide:1 review:1 there:2 administration:1 encourage:1 been:1 should:2 few:1 report:1 quick:1 earnings:1 which:1 medicine:1 suspension:1 cardiovascular:1 markets:1 events:1 recommends:1 multiple:1 plans:1 may:1 marketing:1 sold:1 incentives:1 infection:1 slides:1 push:1 weight-loss:1 strong:1 new:1 regulatory:1 news:1 cases:1 stocks:2 analyst:1 tighter:1 panel:1 roundup:1 restrictions:1 cautious:1 rare:1 --:2 might:1 31:3 drop:2 sclerosis:1 according:1 drug:2 2010:1 large:1 patients:1 so:1 banks:1 management:1 guidance:1 research:1
stock_BIIB r_down	faster:1 walk:1 n't:2 patients:1 helps:1 minority:1
stock_BIIB r_up	revolutionary:1 repairing:1 begin:1 multiple:1 --:1 sclerosis:1 testing:1 some:1 damage:1 drug:1 step:1 done:1 take:1 human:1 hopes:1 has:1 experimental:1
stock_BIIB r_down	biotech:2 slate:1 year:1 nominated:2 years:2 past:1 held:2 second:1 deadline:1 notify:1 seats:1 battle:2 rekindling:2 given:1 additional:1 three:1 winning:1 multi-year:1 intends:1 activist:2 exuberance:1 details:1 way:1 seemed:1 meeting:2 until:2 board:3 his:2 's:4 plans:1 big:1 company:4 night:1 possible:1 two:2 stocks:1 beginning:1 multiyear:1 minute:2 ago:1 has:3 last:3 succeeded:1 anything:1 --:2 nominate:3 age:1 annual:2 days:1 directors:5 were:1 usually:2 biotechnology:1 youthful:1
stock_BIIB r_up	among:1 old:1 leaders:1 soon:1 years:1 likely:1 65:1 year:1 mandatory:1 pharmaceutical:1 retirement:1 there:1 age:1 2011:1 announced:1 more:1 his:1 's:1 reaching:1 could:1 continues:1 replacement:1 change:1 recent:1 industry:1 drug:2 turn:1 turnover:1 changes:1 maker:2 generational:1
stock_BIIB r_up	comment:1 letter:2 number:2 brain:3 planning:1 controversial:1 's:2 risk:2 use:1 said:3 adds:1 lead:1 increase:2 clinical:1 treatment:2 medicine:2 has:1 sold:1 stock:1 multiple:2 greater:2 company:1 earlier:1 confirmed:1 infection:3 background:1 doctors:2 prices:1 taking:1 cases:1 rare:3 progressive:1 getting:2 --:3 could:1 sclerosis:2 disease:1 trial:1 patients:1 infusions:2 fresh:1 stages:1 31:1 first:1
stock_BIIB r_down	sector:1 activists:1 's:1 like:1 increasingly:1 --:1 industry:1 under:1 companies:1 sign:1 traditional:1 maturity:1 microscope:1 shareholder:1 act:1 want:1 coming:1 businesses:1 more:1
stock_BIIB r_up	fourth-quarter:3 over:1 executive:1 focus:4 setback:1 trade:1 bright:1 session:1 controversial:2 its:9 whose:3 $:3 rose:6 treatment:1 suffered:1 has:2 heart-failure:1 2010:6 rescue:1 broadly:1 rise:2 early:1 lymphoma:1 multiple:2 above:1 --:2 companies:4 continue:1 steps:1 either:1 works:1 back:1 bounce:1 jump:1 see:1 actively:2 trading:2 diving:1 said:2 lead:2 bottom:1 profit:4 since:1 below:1 shares:4 forecast:3 3:1 does:1 closed:1 new:3 net:1 core:1 assist:1 recently:1 25:2 sold:1 million:1 continuing:1 franchise:1 strong:1 gained:2 search:1 recovering:1 reports:2 products:1 analysts:1 efforts:1 traded:2 experimental:1 first:1 among:1 outlook:1 benefited:1 revenue:2 down:1 active:1 beneficiaries:1 multiple-sclerosis:2 raises:2 another:1 industrials:1 support:1 recruiting:1 mark:1 process:1 stock:1 expected:2 500:2 helps:1 firm:1 company:2 pipeline:1 sales:5 gain:1 hopes:1 line:1 15:1 believes:1 n't:3 while:1 growth:4 making:1 more:2 1.4:1 biotech:1 1.6:1 almost:2 1.9:1 metals:1 continued:3 10,000:1 drug:6 strength:1 48:7 40:1 also:1 concerns:1 earnings:4 offered:1 higher:5 development:1 added:2 's:7 after:2 forecasts:1 hired:1 such:1 stocks:5 data:1 rallied:1 futures:1 sclerosis:2 chief:1 points:3 time:1 biotechnology:1 oral:1
stock_BIIB r_up	saying:1 expects:4 years:4 session:1 year-earlier:1 before:4 whose:1 $:4 surprises:2 had:3 advisories:2 2010:8 hit:3 background:1 quarters:1 loss:4 --:7 companies:2 large:4 benefit:5 after-hours:1 quarter:4 because:3 actively:1 trading:1 year:4 's:2 investment:1 said:5 profit:5 shares:1 deficit:1 closed:1 net:6 offsets:1 million:4 restructuring:1 109:1 operating:4 post:1 debt:3 gained:1 reports:1 rose:1 maker:4 first:4 period:1 strategic:1 chronic:1 rising:3 writedown:1 due:3 500:1 more:1 roundup:2 booked:4 but:4 gain:1 than:1 posted:1 refinancing:3 future:1 revenues:3 150:1 associated:1 1.3:1 tax:5 drug:5 swung:4 compared:1 detail:2 costs:7 earnings:2 fourth:4 income:4 several:4 higher:1 added:1 pain:1 earlier:4 stocks:1 lower:3 transaction:1 charges:1 points:2 time:4 2009:6 corporate:1 latest:1
stock_BIIB r_down	move:1 one:2 high:1 dropped:1 another:1 its:5 market:1 information:1 lead:2 lifeline:2 potential:1 which:2 evaluation:1 gives:1 product:1 's:2 form:2 after:1 reach:2 pressure:2 chance:1 blood:1 key:2 data:1 eighth:1 expand:2 treating:2 received:2 pipeline:2 drug:1 products:2 following:1
stock_BIIB r_up	rare:1 --:1 sclerosis:1 number:1 35:3 four:1 brain:1 patients:1 infection:1 disclosed:1 which:1 multiple:1 cases:2 total:1 bringing:1 sells:1 more:1
stock_BIIB r_down	sector:1 biotech:1 often:1 move:1 four:1 pushed:1 his:1 including:1 marking:1 management:1 activist:1 board:1 has:1 himself:1 's:1 plans:1 he:1 --:1 nominate:1 companies:1 sale:1 directors:1 latest:1
stock_BIIB r_down	biotech:1 caused:1 1.8:1 '':1 attempts:1 himself:1 including:1 recover:1 its:2 market:1 setbacks:1 decline:1 confirmed:1 said:1 holdings:1 fix:1 stake:1 4.8:1 shares:1 activist:1 board:1 fourth:1 products:1 more:1 ``:1 his:2 's:1 plans:2 influence:1 company:2 million:1 broken:1 tripled:1 regulatory:1 during:1 manufacturing:1 valuation:1 than:1 he:1 four:1 attempt:1 --:1 nominate:1 directors:1 substantial:1 ongoing:1 shortage:1 quarter:1 top:1 comes:1
stock_BIIB r_up	billion:2 biotech:2 buy:1 bid:1 plans:1 launch:1 acquire:1 drugmaker:1 move:1 bids:2 research:1 conglomerate:1 fueled:1 hostile:1 3.5:1 7.5:1 stoke:2 stocks:3 roll:1 $:2
stock_BIIB r_up	treating:1 use:1 used:1 's:6 combination:1 cancer:1 --:1 arthritis:1 patients:1 drug:1 standard:1 recommended:1 treatment:1 disease:1 rheumatoid:1
stock_BIIB r_up	because:2 help:1 deal:1 due:1 companies:1 agreed:1 moved:1 focus:2 one:1 session:3 curb:1 another:1 further:2 rally:1 present:1 soon:1 its:2 market:3 out:1 sell:1 pharmaceutical:2 little:1 said:3 end:2 candidate:3 area:1 deaths:1 detail:1 shares:3 their:1 recommended:1 program:4 safety:2 treatment:2 adds:1 which:1 suspend:1 suspension:1 previous:1 patients:1 momentum:1 stock:1 led:1 independent:1 arthritis:4 's:4 gains:1 divisions:1 company:2 after:2 back:1 several:1 modest:1 cutting:2 they:1 risks:1 hopes:1 using:2 cases:1 squeeze:1 concerns:2 developments:1 partner:1 loss:2 prospects:1 potential:3 benefits:1 blockbuster:1 --:3 could:1 futures:1 infections:1 drug:6 suspended:2 serious:1 upside:1 ocrelizumab:3 were:1 small:2 found:1 choppy:2 rheumatoid:4 spotlight:1 experimental:2
stock_BIIB r_up	focus:2 trade:1 60:1 see:1 session:1 whose:1 takes:1 shares:3 late:2 expected:1 more:1 nod:1 agreement:1 active:1 buyout:1 than:1 panel:1 light:2 trades:2 companies:1 up:2 while:1 receives:1 soar:1
stock_BIIB r_up	deal:1 focus:2 7.2:1 actively:3 trading:3 sight:1 partner:1 2.6:1 whose:3 $:1 rose:3 top:1 had:1 shares:3 forecast:2 3:2 points:9 7:1 722:1 500:3 higher:1 development:1 product:1 added:4 which:1 million:1 pipeline:1 bulk:1 fell:2 stocks:3 11:1 13:2 18:1 rebuffed:1 companies:3 up:1 morning:1 overtures:1 session:3 stories:1 were:3 mixed:2 its:1
stock_BIIB r_up	0.8:1 days:1 60:1 actively:1 trading:3 close:1 its:1 index:1 highest:1 lead:2 rose:4 since:1 shares:1 consecutive:1 500:1 shoot:1 2.95:1 added:1 's:4 whose:1 early:1 eight:1 stocks:3 session:1 both:1 30:1 companies:2 up:2 drug:2 2000:1 points:4 after-hours:1 north:2 2008:1
stock_BIIB r_down	fourth-quarter:1 cancer:1 revenue:2 cents:1 share:1 expects:1 expenses:1 115:1 widened:1 growth:1 113:1 hit:1 developer:1 said:1 $:5 candidate:1 bottom:1 began:1 six:1 2.38:1 shares:1 being:1 high:1 black:1 2010:1 momentum:1 higher:1 's:1 company:2 million:3 commercial:1 108:1 takeover:1 operating:1 eyed:1 offset:1 report:1 line:2 loss:1 all-time:1 solid:1 annual:1 --:1 diagnostics:1 biotechnology:1 speculation:1
stock_BIIB r_up	fair:1 '':1 including:1 its:1 market:1 said:1 stake:1 should:1 their:1 interest:1 largest:1 has:1 remaining:1 bought:1 ``:1 buy:1 's:1 option:1 shareholder:1 --:1 value:1 controlling:1
stock_BIIB r_down	seven:1 number:1 '':1 brain:1 multiple:1 sells:1 deal-making:1 open:1 yet:1 confidence:1 said:2 $:1 remains:1 42:3 integration:1 its:1 disclosed:1 which:1 total:1 more:2 ``:1 his:1 's:1 completed:1 giant:1 infection:1 takeover:1 using:1 cases:2 bringing:1 he:1 billion:1 pipeline:1 rare:1 last:1 --:2 sclerosis:1 drug:1 large:1 patients:1
stock_BIIB r_down	over:1 years:1 brain:1 adding:1 group:1 $:1 investor:1 should:1 disclosed:1 diseases:1 early:1 every:1 using:1 bringing:1 day:1 areas:1 --:1 medicines:1 large:1 slide:2 become:1 large-cap:1 ten:1 growth:1 year:1 's:3 said:2 lead:1 research:1 new:1 blockbusters:1 news:1 strong:1 generate:1 rare:1 launch:1 dollars:1 drug:1 published:1 long-term:1 among:1 already:1 secure:1 cancer:1 revenue:1 number:1 clout:1 one:1 article:1 total:1 deal:2 system:1 next:1 few:1 more:3 firm:2 ``:1 buy:1 drugs:1 company:1 infection:1 central:1 cases:2 than:1 10:2 last:1 up:3 patients:1 nervous:1 gives:1 could:1 seven:1 diverse:1 sells:1 generic:1 42:3 5:1 which:1 gaining:1 multiple:1 plans:1 may:1 such:1 stocks:1 billion:2 sclerosis:1 position:1
stock_BIIB r_up	system:1 already:1 secure:1 ten:1 revenue:2 over:2 clout:2 years:2 diverse:1 year:2 next:2 research:1 drugs:2 adding:2 said:3 group:2 cancer:1 dollars:2 detail:1 than:2 few:2 strong:1 new:2 day:1 more:4 firm:3 ``:1 's:4 diseases:1 may:2 company:1 blockbusters:2 every:2 position:1 such:1 one:2 investor:1 generate:2 areas:1 billion:2 10:1 central:1 launch:2 should:1 medicines:2 large:1 growth:1 nervous:1 long-term:1 become:2 gives:1 could:2
stock_BIIB r_up	operations:1 help:1 agreed:1 move:1 nominated:3 comments:1 still:1 agrees:1 adding:3 cut:2 appointed:1 board:8 has:3 split:1 executive:1 appointment:1 get:1 billionaire:1 slate:4 designated:1 now:1 investor:2 --:8 drop:1 right:1 deal:2 thinks:1 even:1 said:2 concessions:2 reaching:1 shares:1 its:5 current:1 favor:1 activist:4 between:1 nominees:1 new:2 ends:1 exchange:2 continuing:1 agreement:4 appointments:4 proxy:1 members:3 change:1 reaction:1 search:1 annual:1 moving:1 makes:1 comment:1 into:1 one:2 smaller:1 another:1 vote:1 reached:3 throughout:1 would:1 whom:3 two:5 fight:1 needed:1 meeting:1 more:2 direction:1 upcoming:1 company:5 analyst:1 he:1 include:1 bellwether:1 while:1 dispute:1 biotech:2 his:2 sense:1 sit:1 chief:1 member:1 details:1 which:1 interview:2 's:6 may:1 after:1 shareholder:2 third:1 well:1 directors:2 biotechnology:2 order:1
stock_BIIB r_down	closes:2 nudging:1 index:1 rose:1 benchmark:3 its:1 high:3 fourth:1 close:1 lifetime:3 closing:1 stocks:1 day:1 stock:2
stock_BIIB r_down	comment:1 biotech:2 developing:1 cancer:2 appeared:1 issued:1 over:1 related:1 '':1 infringes:1 been:1 partner:1 recently:1 throughout:1 unit:1 story:1 said:1 court:1 patent:2 same:1 p.m.:1 version:2 details:1 firms:1 has:1 sold:1 treatment:2 ``:1 sued:1 's:3 sixth:1 company:1 earlier:1 corrected:1 filed:1 lawsuit:1 covering:1 --:2 follows:1 alleging:1 a.m.:1 error:1 claims:1 view:1 published:1
stock_BIIB r_down	comment:1 biotech:1 because:2 false:2 up:1 companies:2 influence:1 promotional:2 '':2 brain:2 substantial:1 hurdle:1 against:1 seats:1 's:4 fifth:1 law:1 information:1 said:2 additional:1 rivals:1 their:1 activist:1 treat:1 interest:1 passed:1 conflict:1 board:1 ``:2 his:1 multiple:3 risk:2 sitting:1 may:1 sold:1 formed:1 infection:2 running:1 involving:2 jointly:1 webcast:1 fellow:1 potential:1 boards:1 --:3 sclerosis:3 disease:1 drug:2 face:1 directors:1 misleading:2 push:1 serious:2 starting:1 gain:1
stock_BIIB r_down	key:1 biotech:1 tough:1 leaders:1 presidents:1 0.3:1 four-year:1 number:1 intellectual:1 weighed:1 satellites:1 agreed:1 individual:1 trading:1 signed:1 year:1 agricultural:1 next:1 makers:1 issues:1 if:1 move:1 push:1 reform:1 stronger:1 make:1 two:1 research:1 seats:1 continue:1 agreements:1 cooperation:1 expected:2 international:1 weaken:1 's:2 easier:1 board:1 week:1 begin:1 oil:1 first-quarter:1 benefiting:1 price:1 reporting:1 weak:1 activist:1 results:1 director:1 drug:1 increases:1 fell:2 plan:1 year-over-year:1 prices:1 immediately:1 investor:1 improve:1 organizations:1 last:1 products:1 rights:1 --:3 should:1 could:1 work:1 companies:2 space:1 together:1 face:1 large:1 weather:1 period:1 many:1 action:1 comparisons:1 property:1 head:1 promised:1
stock_BIIB r_down	11:2 rare:1 brain:1 46:3 sclerosis:1 number:1 infection:1 four:1 --:1 patients:1 disclosed:1 which:1 6:3 multiple:1 cases:2 total:1 bringing:1 sells:1 more:1
stock_BIIB r_up	listed:1 despite:1 share:1 detail:1 assess:3 chronic:1 value:3 separating:4 its:5 previous:1 impact:3 whose:1 giant:1 said:8 pharma:1 decision:3 two:4 comments:1 other:1 treatment:1 statement:3 expected:3 main:4 price:1 treat:1 exploring:4 ``:3 's:4 creating:4 business:5 separate:4 drugs:1 marketing:1 company:4 leukemia:2 possibility:4 treatments:1 shareholder:3 designed:1 background:1 coming:3 opportunity:3 approved:1 '':3 has:2 publicly:1 --:4 months:3 companies:5 disease:1 drug:4 patients:1 exploration:3 more:1 maker:4
stock_BIIB r_down	soar:1 biotech:1 slower:1 revenue:1 caused:2 opting:1 powerful:1 sales:7 expectations:2 disappointing:2 charges:3 growth:4 projections:1 controversial:1 link:1 multiple:3 throughout:1 its:4 take:1 while:1 missed:1 serious:1 bottom:1 partly:1 rose:1 treatment:1 label:1 below:1 details:2 benefit:1 new:1 has:2 's:6 company:1 earnings:3 first-quarter:4 increased:1 overall:1 sold:2 rise:1 results:1 infection:1 number:1 break:1 reported:1 fell:3 therapy:2 effects:1 background:2 despite:1 franchise:1 line:1 strong:1 continued:3 grow:1 11:10 short:1 rare:2 brain:1 --:2 taking:1 drop:1 sclerosis:3 drug:5 profit:1 patients:2 costs:1 analysts:2 were:2 biotechnology:1 quarter:1 changes:1 side:1 dropped:1
stock_BIIB r_down	being:1 caused:1 underlying:1 including:1 its:6 overhaul:1 $:2 rose:1 28:1 analyst:3 has:3 powerful:1 therapy:1 effects:1 2:1 multiple:3 loss:7 --:5 drop:1 taxes:1 quarter:2 repaired:3 side:1 some:1 growth:1 projections:1 year:6 first-quarter:6 said:1 missed:1 profit:5 forecast:5 current:4 net:6 announced:2 arrival:1 core:3 full:5 business:3 million:2 reported:3 operating:5 debt:1 change:2 reaction:1 rare:1 dollars:1 reports:1 stand:3 maker:3 first:1 comment:2 own:3 revenue:1 narrower:5 period:1 feet:2 narrowed:1 sheet:3 two:3 been:2 their:3 much:3 company:1 but:1 than:1 posted:1 11:3 divisions:3 crossroads:1 can:3 were:2 balance:3 history:1 investors:3 health-care:1 share:1 sales:1 reassuring:3 disappointing:1 drug:4 blockbuster:1 detail:1 same:1 earnings:1 which:1 income:1 difficult:1 product:1 's:7 plans:2 price:1 after:2 helped:1 transformational:2 ago:1 charges:1 sclerosis:3
stock_BIIB r_up	comment:1 biotech:2 1.6:1 because:2 background:1 point:1 115:2 session:1 trading:2 throughout:1 fine:2 its:4 declined:2 whose:2 manufacturing:4 $:2 rose:2 facility:2 detail:1 shares:2 1:1 points:4 4:1 closed:1 expected:1 8:1 has:2 price:1 500:2 stock:1 million:2 first-quarter:2 continue:2 shortages:2 going:2 company:3 after-hours:1 problems:2 reported:2 fallout:2 regulatory:2 stocks:2 analyst:1 gained:1 loss:2 main:2 14:1 --:2 warned:2 climbed:1 companies:2 actively:2 were:1 mixed:2
stock_BIIB r_down	operations:1 selling:1 would:1 --:1 company:1 after:1 some:1 according:1 reviews:1 businesses:1 open:1 its:1 noncore:1
stock_BIIB r_up	pharmaceutical:1 improved:1 versions:1 drugs:1 big:1 becoming:1 developing:1 aim:1 industry:1 biotech:1 take:1 biotechnology:1 maker:1 latest:1
stock_BIIB r_up	his:1 revenue:1 '':1 growth:1 year:1 7.8:1 total:1 down:1 $:7 28:1 due:1 incentive:1 p.m.:1 version:1 income:1 net:1 ``:1 million:2 's:7 option:1 mostly:1 published:1 corrected:1 awards:1 plan:1 article:1 earlier:1 10.4:1 received:1 valued:1 --:1 follows:1 drop:1 cash:1 compensation:1 figures:1 11.3:1 were:1 2009:7
stock_BIIB r_down	drugs:1 's:1 help:1 cancer:1 --:1 similar:1 could:1 also:1 patients:1 offers:1 therapy:1 new:1 approval:1 developers:1 prostate:1 hope:1
stock_BIIB r_up	help:1 cancer:2 article:1 find:1 immune:1 data:1 since:1 had:1 system:1 been:1 approved:1 late:1 also:1 attack:1 offers:1 new:2 developers:1 therapies:1 more:1 's:1 get:1 drugs:1 but:1 therapy:1 approval:2 trying:1 prostate:1 class:1 --:1 could:1 work:1 disease:1 patients:1 2006:1 hope:1 published:1 similar:1 asked:1 stimulating:1 first:1
stock_BIIB r_up	his:1 filings:1 --:1 initial:1 31:1 stake:1 according:1 doubled:1 investment:1 reported:1 regulatory:1 investor:1 than:1 more:1
stock_BIIB r_down	profile:2 own:1 autoimmune:2 existing:1 together:2 unfavorable:2 partner:2 its:3 millions:2 said:4 detail:1 potential:2 safety:2 treat:3 ocrelizumab:2 shaving:2 development:3 's:6 risk:2 efficacy:2 arthritis:3 discontinue:3 treatments:1 hundreds:2 suffering:2 compared:1 designed:3 off:2 showed:2 --:2 dollars:2 disease:2 drug:5 analysis:2 patients:3 future:2 revenues:2 rheumatoid:3 experimental:3
stock_BIIB r_down	chemotherapy:1 evidence:1 significantly:2 cancer:5 certain:3 results:3 increased:2 myeloma:1 chronic:3 second:1 multiple:1 unit:2 transplant:1 information:2 cut:3 additional:2 their:1 provide:1 separate:1 progressing:1 two:1 looking:1 also:1 treatment:5 maintenance:3 new:3 before:1 rheumatoid:2 's:5 risk:3 returning:3 drugs:1 becoming:1 arthritis:2 leukemia:2 often:1 released:3 'd:1 uses:1 survived:1 half:3 lymphoma:5 approved:2 disease:3 showed:1 stem-cell:1 --:3 starting:1 study:5 according:3 drug:1 patients:5 without:1 time:2 fresh:1 studies:1
stock_BIIB r_down	chemotherapy:1 among:2 before:1 1.1:1 cancer:3 0.8:1 certain:1 crosshairs:1 according:1 actively:1 trading:1 investors:2 multiple:1 makers:1 risk:1 increased:2 conference:2 information:1 myeloma:1 lymphoma:1 additional:1 rose:1 separate:1 returning:1 shares:1 looking:1 also:1 treatment:1 maintenance:1 policy:1 new:1 transplant:1 500:1 higher:1 's:2 4,000:2 whose:1 time:1 results:1 released:4 cut:1 moving:2 key:2 half:1 stocks:1 beginning:1 than:2 gained:1 disease:1 showed:1 ahead:2 stem-cell:1 --:3 study:4 companies:2 1.2:1 drug:1 unveils:1 significantly:1 'd:1 patients:2 session:1 were:3 biotechnology:1 more:2 16th:1 researchers:1
stock_BIIB r_up	major:1 version:1 just:1 executive:1 three:1 buy:1 begun:1 need:1 reached:1 weaken:1 copycat:1 cancer:1 two:1 research:1 successful:1 activist:1 board:1 nominees:1 new:1 you:2 has:1 meeting:1 sold:1 week:1 do:1 himself:1 's:3 get:1 may:1 company:2 arthritis:1 shareholder:1 effort:1 milestones:1 16:1 --:2 might:1 according:1 drug:1 chief:1 testing:1 rheumatoid:1
stock_BIIB r_down	major:1 already:1 cancer:1 consent:1 three:1 60:1 drug:2 reached:1 its:2 market:1 weaken:1 decree:1 comparing:1 agency:1 had:1 two:2 approved:1 also:1 activist:1 board:1 nominees:1 biosimilar:1 meeting:1 treat:1 week:1 himself:1 kinds:1 get:1 may:1 company:2 arthritis:1 shareholder:1 article:1 along:1 effort:2 multiyear:1 projected:1 milestones:1 succeeded:1 16:1 --:1 largely:1 lines:1 disease:1 signed:1 trial:1 patients:1 published:1 rheumatoid:1
stock_BIIB r_up	``:6 said:4 's:4 business:2 --:2 price:2 share:2 pipeline:1 drug:4 pleased:2 '':6 fundamentals:2 made:2 but:2 progress:2 disconnect:2 he:4 maker:2 group:2 shows:2
stock_BIIB r_up	biotech:1 own:1 multiple:1 like:1 drugs:1 sclerosis:1 its:1 forms:1 beta:1 treatment:1 suing:1 makers:1
stock_BIIB r_up	comment:1 biotech:1 appeals:2 being:1 over:1 retire:1 long-running:1 years:1 '':2 held:1 fortunes:1 been:2 trading:1 comments:1 have:1 turning:1 after-hours:1 down:1 facing:1 said:3 patent:3 jumped:1 decision:2 since:1 due:1 shares:1 p.m.:1 process:1 version:1 upheld:1 disclosed:1 which:1 conduct:1 interview:1 correct:1 adopted:1 board:2 ``:2 after:1 's:4 around:1 company:4 published:1 step:1 management:1 shareholder:1 included:1 roller-coaster:1 succession:1 analyst:1 10:1 last:1 --:1 follows:1 discussed:1 drug:1 n't:1 2003:1 directors:1 statement:1 ruling:1 were:1 2012:4 maker:1 joining:1
stock_BIIB r_down	advisory:1 managed:1 show:2 retire:1 nominated:1 trade:1 four:1 held:1 before:1 27:2 rose:2 going:1 4:1 equity:1 2012:3 around:1 big:1 early:1 decide:1 report:2 years:2 --:2 small:2 wrote:1 jump:2 finish:1 calendar:1 employment:2 out:1 index:2 said:2 since:1 research:1 waiting:1 activist:1 issue:1 turning:1 release:2 focused:2 100:1 nonfarm:3 eke:1 drug:1 analysts:1 slightly:1 maker:1 one:2 vote:1 shareholders:1 positive:1 there:1 been:1 2:1 way:1 expected:2 markets:1 500:1 firm:1 ``:2 upcoming:2 company:1 but:1 payrolls:4 analyst:1 case:1 12:1 can:1 investors:2 dissident:1 '':2 fortunes:1 firmly:2 end:1 recommended:1 which:3 largest:2 gains:2 stock:2 week:1 added:1 's:3 yesterday:1 data:2 lower:1 off:1 futures:4 2003:1 directors:1 points:3 joining:1
stock_BIIB r_down	proposed:1 global:2 month:2 session:1 higher:1 issues:1 whose:1 26:1 22:1 rose:7 flash:2 2.8:1 4:1 volatile:2 hit:2 increased:1 they:2 during:2 did:2 warned:1 companies:1 weighing:1 worries:2 difficult:1 financial:1 see:2 actively:1 trading:1 expect:2 multiple:1 recession:2 said:3 below:2 shares:1 safety:1 7:2 between:1 earlier:1 recently:1 100:2 last:2 carried:1 drug:1 mixed:1 point:1 number:1 double-dip:2 market:2 industrials:2 would:1 positive:1 support:1 comments:1 negative:1 treat:1 upbeat:1 territory:1 markets:2 500:3 ``:3 slumping:2 but:2 lows:2 those:2 he:2 n't:2 while:2 growth:2 were:3 slid:1 1.7:1 0.2:1 moved:1 '':3 warning:1 against:1 crash:2 relatively:1 overcoming:1 1:1 stock:2 's:5 after:1 stocks:3 euro:2 lower:2 kept:2 effective:1 futures:2 sclerosis:1 jitters:1 points:8 position:1 drawing:1
stock_BIIB r_up	week:1 's:3 just:1 --:1 company:1 annual:1 agreement:1 ending:1 their:1 proxy:1 time:1 battle:1 reached:1 next:1 meeting:1
stock_BIIB r_down	stock:5 advisory:2 oral:1 6.7:1 ended:1 session:3 committee:1 7.9:1 before:2 25:1 26:1 third-biggest:2 rose:4 has:1 gains:1 nod:2 big:2 effects:1 report:1 multiple:3 day:2 --:4 drop:2 companies:3 after-hours:1 quarter:1 side:1 questions:1 hard:2 actively:3 trading:3 year:2 's:10 2.6:1 declined:1 even:2 still:1 giving:1 shares:4 52-week:2 3:1 previous:2 boost:1 whose:3 key:1 backed:1 approval:1 100:2 gained:1 39:1 22:1 ahead:1 taking:1 climbed:1 drug:3 mixed:2 retail:5 traded:2 first:1 reversing:2 slipped:2 point:1 surround:1 confidence:3 one-day:2 mark:2 low:2 500:7 treat:1 flat:1 but:1 gain:2 12:1 up:3 near:1 were:4 3.2:1 0.8:1 10000:2 toss:1 sales:5 dropped:1 rally:2 increased:1 tentative:1 4.8:1 traders:2 higher:2 2.95:2 edged:4 after:3 extending:2 said:1 climbing:2 stocks:5 rallied:2 off:1 wins:2 futures:9 sclerosis:3 reports:2 points:13 consumer:3
stock_BIIB r_up	rare:1 7:1 --:1 55:1 six:1 sclerosis:1 number:1 infection:1 brain:1 patients:1 disclosed:1 which:1 6:2 multiple:1 cases:2 total:1 bringing:1 sells:1 more:1
stock_BIIB r_up	reversing:1 cap:2 tap:2 4.9:1 over:2 retire:1 finished:2 outlook:2 competition:1 disease:1 '':1 brain:1 fortunes:1 economic:2 rising:1 year:1 multiple:1 100:2 4.6:1 rose:6 42:1 credited:1 43:1 below:2 version:1 potentially:1 earnings:2 fatal:1 correct:1 500:2 stock:2 ``:1 added:2 's:3 successful:2 estimates:2 published:1 but:2 industrial:2 flurry:2 7.5:1 unmoved:2 cases:1 stocks:2 data:2 day:2 production:2 euro:2 helped:2 grew:2 showed:2 largely:4 --:1 follows:1 futures:6 sclerosis:1 second:1 drug:2 auction:2 while:2 points:6 figures:2 faces:1 worries:2 maker:1 bond:2
stock_BIIB r_up	biotech:1 handful:1 matter:1 auction:1 familiar:1 early-stage:1 up:1 according:1 person:1 heavyweights:1 interest:1 such:1 drawn:1 sale:1 has:1 health-care:1
stock_BIIB r_down	off:1 selling:1 's:2
stock_BIIB r_down	named:1 smaller:1 away:1 executive:1 same:1 hiring:1 chief:1 role:1 drug:1 him:1 developer:1
stock_BIIB r_down	named:2 smaller:2 retired:2 shoes:2 into:2 executive:2 focus:2 month:2 challenges:2 hiring:2 developer:2 away:2 marketed:2 same:2 role:2 products:2 several:2 numerous:2 multiple:2 company:2 earlier:2 treatments:2 him:2 --:2 sclerosis:2 drug:2 chief:2 steps:2 faces:2
stock_BIIB r_up	comment:1 all:1 1.1:2 1.2:1 2.5:1 companies:2 move:3 slid:1 report:3 3.2:1 actively:2 trading:2 's:2 aggressive:1 moves:1 market:1 considering:2 whose:2 giant:1 rumors:2 pharma:1 rose:1 make:1 since:1 4.8:1 shares:3 points:3 declined:1 exceed:1 more:2 has:1 might:1 company:3 500:2 higher:3 gained:2 multiple:1 increased:1 acquiring:1 may:1 price:1 after:2 marking:1 20:2 fueled:1 takeover:3 preparing:2 sharply:1 prices:1 approval:1 major:2 stocks:2 surged:2 than:1 recent:1 billion:2 valued:1 off:1 lost:1 most:1 19:2 ever:1 30:1 sclerosis:1 according:1 drug:4 $:2 --:3 fell:1 sent:1 2004:1 were:1 biting:1 speculation:3 stock:1 slightly:1 maker:2 acquisition:1
stock_BIIB r_up	tough:1 investors:1 move:1 sales:1 reassuring:1 pressing:1 year:2 helm:1 facing:2 giant:1 pharma:1 decision:1 question:1 strategy:1 lauded:1 expected:1 issue:1 expiring:1 his:1 's:3 drugs:2 big:1 faces:1 but:1 most:1 half:1 active:1 he:1 ago:1 loss:1 target:1 --:1 large:1 whether:1 patents:1 time:1 make:1 acquisition:1
stock_BIIB r_up	biotech:1 health-care:1 reform:1 may:1 across:1 away:1 larger:1 focus:1 drug:1 second-quarter:1 large:1 pressures:1 earnings:1 have:1 coming:1 report:1 downward:1 price:1 makers:1
stock_BIIB r_down	sells:1 rare:1 58:1 --:1 sclerosis:1 three:1 infection:1 number:1 1:2 brain:1 3:2 2:1 disclosed:1 which:1 multiple:1 cases:2 total:1 bringing:1 patients:1 more:1
stock_BIIB r_up	development:1 setbacks:1 pipeline:1 end:1 biotech:1 --:1 company:1 move:1 drug:1 spate:1 's:6 experimental:1 latest:1
stock_BIIB r_up	saying:1 raised:1 sales:1 quarters:1 helped:1 reports:1 its:1 surprises:2 also:1 advisories:2 earnings:3 more:1 gains:1 company:1 estimate:1 than:1 roundup:1 companies:1 doubled:1 future:1 corporate:1 latest:1
stock_BIIB r_up	saying:3 ``:3 management:3 's:3 campaign:3 company:4 destroyed:3 up:3 value:3 years:3 '':3 activist:3 shareholder:6 board:3 have:3 shake:3 biotechnology:3 launching:3 recent:3
stock_BIIB r_up	results:4 brain:1 controversial:2 its:12 fifth:1 setbacks:1 $:1 rose:1 guidance:3 expectations:2 than:4 charge:1 treatment:1 quarterly:1 2010:3 earnings:8 updated:1 risk:1 showing:1 updates:1 enrollments:1 loss:1 --:4 companies:1 doubled:4 solid:3 estimates:1 prediction:1 growth:5 projections:3 second-quarter:5 exceeded:3 's:7 profit:1 legal:1 label:1 current:1 new:1 net:1 cost-cutting:1 core:3 full:1 patient:1 sold:1 reported:1 operating:1 key:2 franchise:3 estimate:1 strong:1 come:1 reaction:2 pipeline:1 rare:1 clarify:1 losses:1 drug:2 analysts:1 faces:1 slightly:1 maker:2 comment:2 raised:4 multiple-sclerosis:3 least:1 wider:1 throughout:1 market:1 due:1 per-share:3 pared:1 meeting:1 more:4 back:2 company:7 but:1 reiterated:1 top-line:1 construction:1 analyst:2 15:1 permits:1 amend:1 bellwether:1 below:1 were:1 biotech:3 trouncing:1 cents:1 year:1 share:3 sales:3 reports:1 string:1 tumbled:1 again:1 concerns:1 details:2 which:1 performance:1 gains:1 stock:3 multiple:3 plans:1 though:1 boosted:1 price:2 after:3 driver:1 treatments:1 fell:1 infection:1 buybacks:2 booked:1 short:1 third:1 futures:1 sclerosis:3 latest:1
stock_BIIB r_down	epilepsy:1 results:1 brain:1 session:1 controversial:1 its:4 24:1 whose:1 $:3 rose:1 guidance:1 expectations:1 second-quarter:3 treatment:1 has:2 worth:1 earnings:2 amended:1 government:1 background:1 loss:2 --:1 companies:1 doubled:1 settle:1 after-hours:1 set:1 deal:1 doing:1 back:1 actively:1 trading:1 projections:1 year:1 's:3 shares:1 label:1 investigation:1 deficit:1 closed:1 net:3 core:1 reporting:1 approached:1 marketing:1 million:3 reported:1 key:1 franchise:1 earlier:1 gained:1 rare:1 clarify:1 dollars:1 climbed:1 reports:1 maker:2 comment:2 raised:1 into:1 102:1 wider:1 per-share:1 much:1 500:1 more:2 company:6 infection:1 than:2 posted:1 solid:1 2010:1 below:1 growth:2 were:1 biotech:1 exceeded:1 share:2 sales:1 drug:2 triple:1 risk:1 aside:1 details:1 which:1 9:1 registered:1 higher:1 multiple:2 price:1 after:1 driver:1 stocks:1 buybacks:1 sclerosis:2 points:2
stock_BIIB r_up	pharma:1 's:3 like:1 deal:1 industry:1 company:1 top:1 up:2 one:1 deals:1 pair:1 overtures:1 stories:1 another:1 dealmaker:1 nothing:1 speculation:1 morning:1 casual:1 round:1 spice:1
stock_BIIB r_down	sector:1 biotech:1 major:1 investors:1 people:1 lifted:1 drug:1 have:1 find:1 market:1 out:1 rundown:1 gainers:1 sentiment:1 rivals:1 informal:1 been:1 whether:1 interested:1 interest:1 inherited:1 biggest:2 got:1 struggling:1 has:1 boost:1 public:1 stock:1 gaining:2 play:1 's:7 which:1 drugs:1 familiar:1 possible:1 includes:1 news:1 stocks:3 declining:2 also:1 scrambling:1 made:1 rare:1 disorders:1 --:1 approach:1 could:1 bankers:1 daily:1 matter:1 became:1 making:1 decliners:1 told:1 makes:1 maker:1 acquisition:2
stock_BIIB r_up	sending:1 full:1 multiple:1 higher:1 --:1 sclerosis:1 sales:1 shares:1 symptoms:1 reported:1 quarter:1 selling:1 6.3:1 treatment:1 trading:1 strong:1 its:2 midday:1 first:1
stock_BIIB r_down	correct:1 ``:1 's:1 follows:1 company:1 cash:2 p.m.:1 '':1 reported:1 version:1 investments:1 short-term:1
stock_BIIB r_down	stake:2 widened:2 second:2 through:2 fifth:1 additional:1 holdings:2 holds:2 regulatory:2 shares:2 activist:2 various:2 details:1 fourth:1 boosted:2 new:2 his:6 filings:2 funds:2 seventh:1 reported:2 known:2 investor:2 eighth:1 exposure:2 aggressively:2 --:2 according:2 quarter:2 corporate:2 investments:2
stock_BIIB r_up	rating:1 major:1 sales:1 makers:1 market:1 ratings:2 weakened:1 biosimilars:1 citing:1 race:1 potentially:1 expensive:1 which:1 take:1 fork:1 but:1 coverage:1 fall:2 regulatory:1 hold:1 valuation:1 analyst:2 uncertain:1 --:1 route:1 drug:1 face:1 initiate:1 nascent:1 enter:1 road:1
stock_BIIB r_down	background:1 agreed:2 global:1 ``:1 focus:1 held:2 attempts:1 session:1 controversial:1 go:1 its:5 fifth:1 whose:1 giant:1 1.10:1 rose:1 had:1 expectations:1 late:1 treatment:4 bypass:1 has:4 remaining:1 five-session:1 beat:1 bid:1 closely:2 --:1 follows:1 companies:1 past:1 rate:1 actively:1 trading:1 year:1 's:7 shares:1 version:1 7:1 sold:1 agreement:1 disappointments:1 reported:1 losing:1 100:1 strong:1 improve:1 reaction:1 pipeline:1 hostile:1 31:1 drug:2 3.5:1 published:1 mixed:1 maker:1 comes:1 comment:1 down:1 multiple-sclerosis:1 directly:1 bolster:1 shareholders:1 2:2 marginally:1 firm:1 mining:1 company:1 corrected:1 sharply:1 known:4 analyst:1 helped:1 decided:1 500:2 were:1 streak:1 sales:1 '':1 seen:1 develop:2 breaking:1 also:2 5:3 earnings:1 which:1 performance:1 several:1 stock:1 development:2 product:1 edged:1 after:2 treatments:1 fell:3 stocks:2 rallied:1 lower:1 futures:3 sclerosis:3 disease:3 points:6 experimental:3
stock_BIIB r_down	rare:1 --:1 continuing:1 taking:1 sclerosis:1 infection:1 brain:1 patients:1 concerns:1 drug:2 multiple:1 climb:1 future:1 's:1 sold:1 raising:1
stock_BIIB r_down	help:1 results:1 brain:1 determine:1 partner:1 decide:1 before:1 said:1 develop:1 support:1 been:1 human:1 investigational:1 take:1 test:1 's:1 announced:1 multiple:1 company:1 joint:1 virus:1 detect:1 they:1 data:1 antibodies:1 rare:1 have:1 --:2 plasma:1 could:1 sclerosis:1 disease:1 drug:1 whether:1 patients:1 venture:1 published:1 biotechnology:1 two-step:1
stock_BIIB r_up	lower:1 uncertain:1 fearing:1 investors:1 --:1 amid:1 companies:1 up:1 disappointing:1 safe-haven:1 economic:1 trading:1 closed:1 snapped:1 data:1 recovery:1
stock_BIIB r_down	certain:1 bright:1 multiple-sclerosis:1 gamut:1 span:1 $:1 expectations:1 rejecting:1 settle:1 shared:1 offer:1 may:1 price:1 but:1 takeover:1 not:1 those:1 billion:1 prospects:1 --:1 drug:1 n't:1 future:1 18.5:1 experimental:1
stock_BIIB r_down	firm:1 pharmaceutical:1 made:1 formally:1 $:1 offer:1 bid:2 rejects:3 share:1 takeover:2 saying:1 biotechnology:1 69:1 buyout:1 company:1 undervalues:1
stock_BIIB r_up	criticism:1 executive:1 positioned:1 defended:1 '':3 growth:1 against:1 its:1 shareholders:1 said:1 governance:1 has:1 firm:1 ``:3 's:2 company:1 management:1 --:1 well:1 drug:1 chief:1 maintain:1 corporate:1 maker:1
stock_BIIB r_up	firm:3 biotech:3 unusual:3 own:3 allegations:3 regulators:3 one:3 twist:3 reported:3 directors:3 potential:3 boardroom:3 insider-trading:3 has:3 its:3 spat:3
stock_BIIB r_up	point:2 streak:2 industrial:2 investors:2 yen:2 dollar:2 number:1 halting:2 currency:2 3.5:1 dropped:2 68:1 multiple:1 sells:1 total:1 cases:2 2.5:1 25:1 four-session:2 brain:1 bringing:1 rebounded:2 patients:1 winning:2 1:1 stock-market:2 production:2 disclosed:1 which:1 import:2 markets:2 500:2 more:1 edged:1 mostly:2 index:2 0.5:1 after:2 infection:1 fell:2 five:1 eyed:2 prices:2 rare:1 100:2 stocks:2 data:2 those:1 2:1 down:1 lower:4 off:1 ahead:2 ended:2 --:1 18:1 futures:2 sclerosis:1 against:2 while:4 points:4 were:3 latest:2
stock_BIIB r_up	own:1 findings:1 month:1 defending:1 have:1 its:1 shareholders:1 said:1 no:1 review:2 there:1 two:1 legal:1 their:1 breaches:1 board:1 wrongdoing:1 independent:1 's:1 after:1 resign:1 released:1 management:2 shareholder:1 letter:1 accepted:1 both:1 launch:1 --:1 wish:1 against:1 directors:1 governance:2 found:1 corporate:2 maker:1
stock_BIIB r_down	sector:1 1.4:1 sclerosis:1 soon:1 increased:1 actively:3 trading:3 against:1 multiple:1 stand:1 its:1 declined:2 out:1 24:1 whose:3 use:1 said:1 20:1 22:1 rose:1 fears:1 shares:6 41:1 points:9 closed:1 6:1 falling:1 2.4:1 type:1 today:1 common:1 's:3 7:1 drugs:1 but:1 most:1 fell:2 competition:1 fall:2 known:1 unmoved:1 stocks:3 approved:1 gained:1 lower:2 15:1 lost:3 could:1 companies:3 drug:1 facing:1 session:3 500:3 benchmarks:1 after-hours:1 mixed:1 traded:2 maker:1
stock_BIIB r_up	gaining:2 among:1 made:1 moves:1 notable:1 market:1 biggest:2 stocks:3 declining:2 stock:1
stock_BIIB r_up	big-ticket:1 end:1 pharma:1 deal:1 could:1 mark:1 future:1 through:1 goes:1
stock_BIIB r_up	among:1 said:1 multiple:1 $:1 most:1 drugs:1 wholesale:1 price:1 sclerosis:1 disease:1 drug:1 person:1 per:1 have:1 year:1 new:1 its:1 expensive:1 making:1
stock_BIIB r_up	significantly:1 into:1 reduce:1 '':1 brain:1 blockbuster:1 market:1 said:2 relapse:1 trials:1 make:1 reduction:1 mid-stage:1 medicine:2 type:1 ocrelizumab:2 shows:1 eventually:1 ``:1 multiple:3 significant:1 hopes:1 raising:1 showed:1 --:2 could:1 sclerosis:3 disease:1 drug:2 turn:1 patients:2 activity:1 study:1 experimental:2
stock_BIIB r_up	biotech:1 horizon:1 being:2 many:1 companies:1 eclipsed:1 large:1 their:1 numbers:1 significant:1 performance:1 quarterly:1 watched:1 corporate:1 developments:1
stock_BIIB r_down	rare:1 --:1 sclerosis:1 two:1 infection:1 number:1 1:1 brain:1 patients:1 disclosed:1 which:1 70:1 multiple:1 cases:2 total:1 bringing:1 sells:1 more:1
stock_BIIB r_up	drugs:1 's:1 amended:1 --:1 agreement:1 related:1 their:1 follow-up:1 have:1 unit:1
stock_BIIB r_up	comment:1 biotech:3 have:1 revenue:4 improving:1 share:2 results:7 expectations:4 weighed:4 repurchase:3 growth:7 multiple-sclerosis:7 dropped:4 another:1 exceeded:3 been:1 11th:1 its:6 per:2 again:3 '':1 per-share:1 8.5:11 topped:1 bolstered:1 rose:5 began:3 show:3 had:2 third-quarter:5 comments:2 while:3 increase:1 consistently:1 5:4 earnings:7 which:1 interview:1 details:1 multiple:1 boost:3 price:2 stock:5 core:4 updated:1 's:13 increased:1 though:1 boosted:3 company:10 said:1 driver:3 sells:1 sales:5 driven:1 most:1 fell:1 plan:3 key:3 treatment:3 franchise:4 solid:1 continued:4 recent:1 campus:1 down:2 revenues:1 beginning:1 ``:1 --:3 sclerosis:1 sale:1 drug:1 charges:5 below:3 analysts:1 were:6 biotechnology:1 efforts:3 quarter:2 slightly:3 projections:3
stock_BIIB r_up	comment:1 saying:2 adjusted:1 deal:1 revenue:2 tax:1 related:1 caffeinated:1 61:1 full-year:3 growth:2 third-quarter:3 swung:3 hospitals:1 its:6 drinks:1 even:2 confirmed:3 said:1 $:3 profit:2 jumped:2 away:1 rose:1 detail:1 forecast:1 charge:1 earnings:2 statement:1 under:1 net:3 before:1 cost-cutting:2 product:2 multiple:2 interest:1 though:2 fire:1 million:3 but:1 hurt:1 operating:2 continued:2 analyst:1 loss:3 kids:1 third:1 launch:3 --:2 sclerosis:2 drug:5 maker:3 turn:1 due:2 depreciation:1 quarter:3 guidance:2
stock_BIIB r_down	deals:1 right:1 says:2 sail:1 no:1 should:1 executive:1 day:1 n't:2 chief:1 ignore:1 call:1 officer:1 transformative:1 yes:1 boss:1 's:1 until:1 he:1
stock_BIIB r_up	operations:1 oncology:1 terminate:3 focus:1 facilities:3 through:1 cuts:4 its:11 cardiovascular:1 cut:3 $:1 merger:1 facility:1 than:1 details:3 around:4 results:1 sweeping:4 streamlines:1 --:3 joined:3 remove:1 consolidate:3 force:4 estimates:1 closures:1 year:1 close:3 review:3 comments:1 research:3 current:4 new:3 4.85:1 announced:1 focuses:4 business:3 seventh:1 restructuring:5 franchise:5 come:3 reaction:1 biologics:1 efforts:1 changes:3 comes:1 comment:2 revenue:1 spinning:1 multiple-sclerosis:2 been:1 throughout:2 additional:1 long:2 reduction:1 lot:1 's:2 more:1 drugs:4 company:15 analyst:1 13:6 15:1 target:1 developing:4 work:4 were:1 closing:1 have:1 cents:1 certain:6 share:1 drug:1 unveiled:4 earnings:1 which:2 stock:1 development:4 added:1 multiple:3 plans:1 boosted:1 price:1 after:3 treatments:4 includes:1 driven:1 plan:4 off:1 programs:3 sclerosis:3 2003:1 costs:4 starting:1 affirmed:1
stock_BIIB r_down	operations:1 ``:1 eye:1 would:1 offering:1 revamp:1 rebates:1 '':1 secret:1 tell:1 doctors:1 you:1 its:1
stock_BIIB r_up	75:1 rare:1 --:1 bringing:1 sclerosis:1 number:1 infection:1 brain:1 patients:1 2:1 five:1 disclosed:1 which:1 5:2 cases:2 total:1 multiple:1 sells:1 more:1
stock_BIIB r_up	biotech:1 cancer:1 guidelines:2 one:1 need:1 makers:1 conventional:1 said:1 adds:1 proceed:1 generic:2 develop:1 comments:1 complex:1 draft:1 way:1 which:1 firms:1 markets:1 more:1 's:1 copying:1 drugs:2 most:1 lucrative:1 paving:1 such:1 than:1 antibodies:1 clarify:1 --:1 industry:2 drug:3 regulator:1 compete:1 published:1 difficult:1 medicines:2
stock_BIIB r_up	full:1 fit:1 shortcuts:1 always:1 twists:1 some:1 but:1 keep:1 gifts:1 right:1 detours:1 turns:1 not:1 you:1 investments:1 road:1 can:1
stock_BIIB r_down	success:1 their:1 --:1 study:1 its:1 reported:1 multiple-sclerosis:1 late-stage:1 pill:1 first:1
stock_BIIB r_up	four:1 rare:1 --:1 sclerosis:1 disclosed:1 infection:1 number:1 1:2 brain:1 patients:1 2:1 4:2 which:1 multiple:1 cases:2 total:1 bringing:1 sells:1 79:1 more:1
stock_BIIB r_up	biotech:1 because:1 among:1 developed:1 number:3 one:1 four:1 brain:1 rate:1 growth:1 have:1 's:1 sells:1 total:1 if:1 death:1 additional:1 may:1 1:2 also:1 high:1 2:1 4:2 which:1 more:1 multiple:1 climbs:1 company:1 disclosed:1 infection:3 sales:1 reported:1 important:1 too:1 known:1 cases:3 now:1 bringing:1 analyst:1 79:1 reaction:1 rare:1 progressive:1 16:1 --:3 drop:1 sclerosis:1 drug:1 patients:2
stock_BIIB r_up	biotech:1 named:2 scientist:1 result:1 's:1 moves:1 its:1 lead:1 since:1 been:1 research:2 also:1 future:1 under:1 finding:1 new:1 has:1 empty:1 development:3 head:2 recently:1 may:1 company:3 restructuring:1 important:1 post:1 former:1 --:1 changes:1 joined:1 continue:1 '09:2 organization:1 efforts:1 2009:1 corporate:1
stock_BIIB r_down	sell:1 received:1 multiple:1 application:1 --:1 country:1 sclerosis:1 deficiency:1 treatment:1 letter:1 has:1 its:1
stock_BIIB r_up	development:1 biotech:1 head:1 years:1 's:1 whose:1 small:1 --:1 company:1 productivity:1 research:2 culture:1 inject:1 hopes:1 new:1 has:1 into:1 recent:1
stock_BIIB r_up	1.7:1 slipped:1 month:1 actively:1 trading:1 dropped:1 sells:1 declined:1 whose:1 21:1 shares:1 points:3 2.5:1 closed:1 6:1 boost:1 500:1 gave:1 's:2 increased:1 price:2 therapy:1 which:1 stocks:1 lower:1 last:1 wholesale:1 companies:1 drug:1 7:1 while:1 session:1 after-hours:1 popular:1 multiple-sclerosis:1
stock_BIIB r_down	sector:1 opinions:2 walking:1 restructure:1 results:1 years:1 brain:1 session:3 its:5 cardiovascular:1 blow:1 whose:3 granting:1 rose:1 recommending:1 disclosed:1 total:1 suffered:1 include:1 pill:2 earnings:1 7:3 focus:1 therapy:1 updates:1 report:1 rejection:1 month:1 bringing:1 --:5 medicines:1 56:1 companies:3 joined:1 large:1 popular:1 higher:1 week:1 drug-sector:1 force:1 another:1 laying:1 3.7:1 oncology:1 actively:3 trading:4 year:1 multiple:2 makers:1 85:1 said:3 profit:1 while:2 shares:4 research:1 looking:1 won:1 closed:1 medicine:1 new:2 boost:1 marketing:1 drug:8 regulators:3 key:1 franchise:1 approval:2 strong:1 declining:1 improve:1 gained:3 reaction:1 rare:1 would:1 launch:1 taking:1 climbed:3 36:1 against:2 infection:1 afternoon:1 usually:1 efforts:1 traded:2 comment:1 fourth-quarter:1 followed:1 into:1 number:1 spinning:1 multiple-sclerosis:3 adopted:1 lagging:1 throughout:1 market:2 8.7:1 positive:1 been:1 next:1 process:1 development:2 change:1 way:1 6:1 biggest:1 500:3 more:1 both:1 company:4 but:2 last:1 cases:2 analyst:1 insights:1 13:1 has:1 15:1 wholesale:1 work:1 aims:1 regulator:2 patients:2 growth:1 were:2 following:1 making:1 closing:1 gave:1 spotlight:2 biotech:1 medication:1 backing:1 3.1:1 dropped:2 have:3 sells:2 moves:1 increased:1 blockbuster:1 productivity:1 49:1 six:1 recommended:2 potential:1 5:1 details:1 which:2 effectiveness:1 stock:1 gaining:1 begin:1 's:9 price:2 after:1 questioning:1 driven:1 mixed:2 paving:1 significant:1 stocks:4 recent:2 off:2 sclerosis:2 biologics:1 points:9 weigh:1 came:1
stock_BIIB r_up	firm:1 biotech:1 discusses:1 plans:1 taking:1 since:1 up:1 his:1 helm:1 has:1 company:1 shaken:1
stock_BIIB r_up	1300:1 polled:1 results:3 month:1 session:2 shares:2 cuts:2 helm:1 economist:1 its:7 whose:2 21:9 rose:3 expectations:3 advanced:1 has:1 2011:3 details:2 gains:1 beat:1 bid:1 focus:2 cutting:1 background:1 sweeping:2 continued:2 string:1 --:2 companies:2 stock:3 shaking:1 looks:1 exceed:2 financial:2 growth:3 trading:2 projections:2 year:1 's:8 81:1 2.7:1 best:1 said:1 blue-chip:1 since:4 projected:1 comments:1 research:1 current:2 7:1 announced:2 recently:1 sold:2 restructuring:5 focused:2 franchise:2 100:1 manufacturing:1 beginning:1 $:3 gained:2 last:1 taking:1 climbed:3 reports:1 prior:1 economic:1 analysts:1 signature:1 streamline:1 efforts:1 traded:2 first:2 fourth-quarter:3 benefited:1 revenue:3 awaited:1 multiple-sclerosis:1 another:2 throughout:1 market:2 cost:1 industrials:1 basis:1 been:1 low:1 expected:1 percentage:1 markets:1 500:3 more:1 digits:1 ``:1 drugs:3 share:2 company:10 sales:2 than:1 13:1 1997:1 developing:2 up:4 actively:2 gave:2 1.6:1 1.1:1 1.2:1 flat:1 stronger:1 moved:2 1.9:1 '':1 single:1 drug:2 around:2 46:1 traders:1 costs:2 earnings:5 performance:1 higher:2 multiple:4 though:1 price:2 treatments:4 most:1 fell:3 stocks:2 data:2 billion:1 tracking:1 charges:3 futures:3 sclerosis:4 chief:1 points:5 biotechnology:1 profits:2
stock_BIIB r_up	roundup:1 saying:1 surprises:2 companies:1 reports:1 quarters:1 advisories:2 earnings:1 future:1 corporate:1 latest:1
stock_BIIB r_up	since:1 narrower:1 results:1 weighed:1 full-year:1 projections:1 multiple:1 narrowed:1 its:1 before:1 said:2 profit:3 rose:1 initial:1 recorded:1 2001:3 fourth:2 net:1 posted:1 2011:1 more:1 's:1 weakness:1 but:1 sales:1 driven:1 drug:1 cut:1 operating:2 disappointed:1 than:1 drugmaker:1 loss:1 revenues:1 --:2 losses:1 sclerosis:1 doubled:1 charges:1 costs:1 time:1 quarter:2 first:1
stock_BIIB r_down	8.1:3 smaller:1 --:1 company:1 stake:1 drug:1 passive:1 reported:1 making:1 holder:1 developer:1
stock_BIIB r_up	biotech:3 months:2 managers:3 another:2 deal:1 summer:1 within:1 scene:2 ended:1 been:1 least:1 questions:2 further:1 portfolio:2 throughout:1 its:1 short-term:1 announcement:1 giant:2 said:1 cycling:1 $:1 space:2 began:1 since:1 comments:1 their:2 uncertainty:1 other:1 capital:2 investors:2 out:1 officially:1 stock:1 firm:2 's:2 fundamental:1 deploy:2 drugs:2 pursuing:1 eliminates:2 consolidation:1 early:1 fund:1 anticipation:1 invested:2 pursuit:1 acquiring:1 now:2 billion:1 regarding:1 last:1 --:2 industry:1 official:1 analysts:1 have:2 options:1 acquisition:1 raises:2
stock_BIIB r_down	among:1 medication:1 number:1 brain:1 multiple:1 sells:1 total:1 bringing:1 2:1 disclosed:1 4:2 affected:1 infection:1 cases:1 95:1 10:3 rare:1 --:1 taking:1 sclerosis:1 patients:2 more:1
stock_BIIB r_up	funding:1 get:1 may:1 stent:1 into:1 supply:1 threatened:1 biologics:1 face:1 disruption:1 mental-health:1
stock_BIIB r_up	1.4:1 whose:1 lower:1 's:1 lost:1 session:1 shed:1 companies:1 1.6:2 shares:1 fell:1 trading:1 actively:1 closed:1 after-hours:1 stocks:1 500:1
stock_BIIB r_up	already:1 global:1 sales:1 multiple-sclerosis:1 our:1 market:1 $:1 menu:1 3:1 hot:1 won:1 medicine:1 net:1 pill:1 more:1 's:2 watch:1 expected:1 courtesy:1 rollout:1 approval:1 stocks:1 than:1 billion:1 annual:1 accelerating:1 morning:1 including:1
stock_BIIB r_down	updated:1 include:1 multiple:1 rare:1 sold:1 changed:1 sclerosis:1 drug:1 label:1 brain:1 infection:1 been:1 's:2 has:1
stock_BIIB r_up	among:2 biotech:1 primary:1 years:1 leads:2 trading:1 larger-cap:1 multiple:2 reducing:1 compared:1 trials:1 two:2 3:4 clinical:1 5:1 treatment:1 premarket:1 's:2 stock:1 north:2 number:1 early:2 met:1 stocks:3 endpoint:1 showed:1 success:1 movers:1 sclerosis:2 up:1 drug:3 large:1 trial:1 patients:1 gainer:1 placebo:1 oral:1 first:1
stock_BIIB r_down	gaining:2 ...:1 good:1 's:1 market:1 moves:1 drug:1 shares:1 n't:2 bad:1 daily:1 significant:1 making:1 biggest:2 news:2 stocks:2 roundup:1 declining:2 stock:1
stock_BIIB r_up	deck:2 watch:4 results:1 reports:1 also:1 report:1 quarterly:2
stock_BIIB r_down	biotech:1 shareholders:1 's:2 gear:1 deck:2 season:1 into:1 watch:4 reports:2 one:1 high:1 shifts:1 quell:1 refocus:1 growth:1 earnings:1 key:1 quarterly:1 aiming:1 company:1 dispute:1
stock_BIIB r_up	1.4:1 among:1 revenue:2 profit:2 number:2 ninth:1 '':1 brain:1 full-year:2 legacy:1 multiple-sclerosis:1 helped:2 year:2 68:4 first-quarter:2 earlier:2 its:2 6.8:2 confirmed:2 said:3 $:8 23:2 headline:1 guidance:2 1:1 investigational:1 treatment:2 products:1 net:4 has:1 more:1 ``:1 full:1 affected:1 multiple:2 sold:1 million:4 reached:1 infection:1 sales:3 reported:2 virus:1 offsetting:1 background:1 loss:3 news:1 cases:1 now:1 bringing:1 generate:2 after:2 billion:1 jump:2 rare:1 --:3 taking:1 sclerosis:2 drug:2 flagship:2 19:1 patients:2 nine:1 disregard:1 111:1 maker:2 latest:1
stock_BIIB r_up	emerging:2 since:1 increasingly:1 results:2 competitive:2 trade:1 session:4 cuts:1 portfolio:4 its:9 fifth:1 whose:4 giant:1 27:1 20:1 $:2 tablet:1 rose:12 expectations:2 should:1 better:1 treatment:4 quarterly:1 2010:1 earnings:2 closed:1 beat:2 watch:1 possibly:1 increases:2 updates:1 got:2 multiple:5 condition:1 --:6 12th:1 companies:4 53:1 morning:1 did:1 continue:1 surging:1 18:1 stock:2 better-than-expected:1 estimates:1 up:1 past:1 second:1 growth:4 trading:4 second-quarter:1 year:2 's:15 total:2 giving:2 jumped:1 multimedia:1 shares:6 current:1 boosts:2 7:1 new:6 highs:1 blowing:1 business:1 sixth:1 sold:2 after-hours:1 seventh:1 conglomerate:1 reported:1 job:1 focused:1 key:1 franchise:1 news:1 along:2 strong:5 beginning:3 gained:3 reaction:1 quarter:2 last:1 computers:2 restructuring:1 35:12 74:1 analysts:3 positive:2 traded:2 first:2 comment:1 among:1 revenue:4 period:2 marked:1 highly:1 brought:1 batch:1 improvement:1 market:2 conference:1 management:1 8.5:2 analyst:1 leading:1 call:1 9.4:1 500:3 drugs:5 company:3 but:2 expected:1 warm:1 95:1 than:1 pre-market:1 posted:1 13:1 showed:2 developing:1 rival:1 likely:1 record:1 actively:4 gave:1 detailed:1 biotech:2 investors:1 almost:1 well:3 trumped:2 sales:4 helped:1 all-time:1 drug:10 reports:1 our:1 close:1 around:1 4.7:1 5.5:1 4.2:1 perform:1 preventing:1 dependent:1 costs:3 details:1 which:3 9:1 performance:2 effectiveness:2 higher:3 added:3 first-quarter:6 price:3 after:1 friends:1 treatments:2 77:1 courtesy:1 important:3 shake-up:1 stocks:4 data:8 29:1 fiscal:1 lower:2 futures:1 sclerosis:5 disease:1 profit:1 points:9 time:2 position:3 oral:6 profits:5
stock_BIIB r_up	set:1 energy:1 results:1 report:2 shake:1 end:1 selected:1 shares:1 their:1 developments:1 markets:1 higher:1 after:1 led:1 weakness:1 rise:2 focus:2 early:1 gain:2 fall:1 front:1 rallying:1 stocks:6 lifting:1 off:3 losses:1 well:1 deals:1 record:3 slipping:1 tech:1 closing:1 stock:1
stock_BIIB r_up	help:1 energy:1 some:1 four:1 economic:1 mostly:1 special:1 6.8:1 giant:1 $:1 situations:1 shares:1 should:1 book:1 best-performing:1 500:1 's:1 generic-drug:1 far:1 showing:1 reflect:1 worst:1 stocks:2 data:1 billion:1 challenges:1 performers:1 months:1 up:1 so:1 acquisition:1
stock_BIIB r_down	among:1 sectors:1 year:1 surprise:1 stocks:1 leader:1 500:1
stock_BIIB r_up	move:1 focus:1 brain:1 including:1 its:4 25:2 group:1 $:7 under:2 troubled:1 executive:1 around:1 valued:3 effects:1 background:1 17th:1 --:3 side:1 deal:8 dealing:1 schizophrenia:1 multiple:1 11th:1 3rd:1 comments:1 medicine:1 new:1 million:5 debt:4 reaction:2 pipeline:4 last:1 annual:1 allows:3 drug:9 products:2 maker:4 comment:2 revenue:1 450:1 period:1 down:4 unit:4 initial:1 hammered:1 combined:2 sealed:4 which:1 expected:1 final:1 company:1 fund:4 hopes:1 line:1 pain:1 analyst:1 nine-year:1 has:1 960:6 were:1 10th:1 share:2 high:1 have:2 seen:1 accounting:1 blockbuster:1 technology:4 sell:4 pay:4 stake:1 details:1 holding:1 development:4 draw:1 's:1 price:1 problems:1 treatments:1 4th:1 transformational:4 allowing:1 attempt:1 sclerosis:1 latest:1 updates:1 8th:1
stock_BIIB r_up	control:1 set:1 health-care:1 number:1 hearing:1 multiple-sclerosis:1 have:1 fine:1 its:1 declined:1 shorter:1 judges:1 medications:1 overhaul:1 make:1 1:1 appellate:1 market:1 new:1 easier:1 shows:1 hit:1 slow:1 law:1 beginning:1 regimen:1 study:1 disease:1 patients:1 promise:1 works:1
stock_BIIB r_down	124:1 13:3 rare:1 brain:1 --:1 taking:1 4:1 infection:1 reported:1 patients:2 multiple-sclerosis:1 drug:1 affected:1 cases:1 bringing:1 sold:1 more:1
stock_BIIB r_up	opinions:1 all:3 over:1 move:2 trade:2 session:4 committee:1 its:1 whose:4 20:1 $:5 22:1 23:2 segments:1 same-store:1 29:1 recommending:1 treatment:1 premarket:2 under:2 has:2 therapy:1 they:1 advanced:1 name:1 lost:3 --:1 12th:1 companies:4 after-hours:1 multiple-sclerosis:1 stock:1 shed:3 human:1 deal:1 conditional:1 past:1 second:1 actively:4 trading:5 year:1 's:9 empire:1 81:1 makers:2 even:1 gross:1 said:3 profit:1 jumped:1 shares:5 pressures:1 outside:1 closed:1 marketing:2 across:1 business:1 sixth:1 seventh:1 agreement:1 news:1 beginning:2 reaction:1 granting:1 ahead:1 37:1 drug:2 prior:1 products:1 traded:2 comment:2 major:1 into:3 retailer:1 drug-sector:1 rising:1 licensing:1 approval:1 use:1 8.7:1 positive:1 due:1 adopted:1 their:1 expected:2 meeting:1 500:3 billion:1 buy:1 offer:1 drugs:1 share:1 offered:1 93:1 analyst:1 present:1 posted:1 11:1 10:1 15:1 17:1 developing:1 cash:1 regulator:1 cost:1 were:1 margin:1 spotlight:3 slid:1 adults:1 received:1 moved:1 sales:1 have:1 close:1 sells:1 respective:1 melanoma:1 media:1 1:1 recommended:1 details:1 which:1 company:1 higher:1 first-quarter:1 intended:1 though:1 price:1 4.7:1 diet:1 fell:3 stocks:3 data:1 fiscal:1 lower:5 fallen:1 medical:1 valuing:1 points:9
stock_BIIB r_down	stake:1 revenue:1 years:2 past:1 pushed:1 have:1 year:1 seen:2 reducing:1 2.6:3 member:1 additional:1 5.6:3 bottom:1 stamp:1 since:1 had:1 shares:1 its:2 late:1 strategy:1 declining:1 tactic:1 current:1 has:1 meeting:1 board:1 core:1 his:1 's:2 though:1 earnings:1 company:2 million:1 but:1 reported:1 restructuring:1 approval:1 line:1 quarters:1 investor:1 change:1 recent:2 weighed:1 charges:1 nominate:1 annual:1 sale:1 drug:2 climb:1 higher:1 maker:2
stock_BIIB r_down	results:1 trade:2 session:4 including:1 7.7:1 its:2 member:1 whose:4 $:1 rose:3 revenue:2 had:1 expectations:2 late:1 board:1 has:1 285:1 modestly:1 his:1 beat:2 watch:1 years:2 investor:1 lost:1 companies:4 morning:1 small:1 past:1 actively:4 trading:3 year:1 margins:1 2.6:1 declined:1 reducing:1 bottom:1 since:1 shares:5 increase:1 3:2 current:1 core:1 million:1 reported:2 restructuring:2 approval:1 change:1 gained:1 standalone:1 annual:1 drug:2 analysts:2 mixed:1 climb:1 traded:2 maker:3 fourth-quarter:1 slipped:1 point:1 retailer:1 total:1 additional:1 stamp:1 third-quarter:1 strategy:1 2:1 declining:1 expected:2 meeting:1 500:2 company:2 lower:1 but:1 line:1 pre-market:1 12:1 19:1 nominate:1 quarters:1 1.2:1 sales:1 weighed:1 pushed:1 dropped:1 have:1 seen:2 5.6:3 stake:1 1:1 other:1 earnings:3 tactic:1 largest:2 auto-parts:1 higher:1 's:8 though:1 helping:1 fell:1 stocks:2 recent:2 fiscal:2 booked:1 charges:2 stronger:1 sale:1 points:4 medical-device:1
stock_BIIB r_down	sector:1 among:1 led:1 components:1 health-care:1 seems:1 secret:2 fewer:1 care’s:2 patients:3 place:1 have:1 reason:1 2011:3 first:1
stock_BIIB r_down	multiple:1 which:1 investors:1 generation:1 sclerosis:1 could:1 watch:2 drug:3 its:1 makers:1 boon:1 treat:1 way:1 making:1 new:1 pills:1 market:3 like:1
stock_BIIB r_down	looking:1 after:1 says:1 $:2 may:1 many:1 drop:1 new:1 employers:1 1:2 health:1 rising:1 coverage:1 2014:1 rates:1 salmonella:1
stock_BIIB r_up	comment:1 one:1 four:2 second:1 shareholders:1 said:3 investor:1 make:1 intends:1 activist:2 candidates:2 details:1 price:1 stock:1 notice:2 's:3 plans:3 billionaire:2 company:1 affiliates:1 takeover:1 updates:1 background:1 beginning:1 analyst:1 received:2 builds:1 third:1 --:4 nominate:3 board:2 drug:1 directors:1 recommendations:1 meet:1 starting:1 maker:2
stock_BIIB r_up	breakdown:2 major:1 return:2 breaking:1 resistance:1 scene:2 back:1 down:1 start:1 benchmarks:1 retest:1 first:1
stock_BIIB r_up	slid:1 1.9:1 6.7:1 session:3 trading:3 69:1 6.9:1 whose:3 rose:3 shares:3 points:8 2.5:1 closed:1 500:3 higher:2 added:2 's:3 but:1 76:1 stocks:3 gained:2 13:1 lost:1 17:1 companies:3 actively:3 after-hours:1 mixed:1 traded:2
stock_BIIB r_up	some:1 strategic:1 session:1 trading:2 something:1 68:1 north:2 moves:1 market:1 whose:1 lead:2 rose:1 top:2 shares:1 points:3 9.9:1 has:1 500:1 higher:1 gaining:2 do:1 added:1 's:1 company:1 notable:1 filed:1 stocks:6 declining:2 gained:1 drug-stocks:1 30:1 companies:1 drug:3 actively:1 afternoon:1 were:1 making:1 stock:1 traded:1
stock_BIIB r_up	stake:1 chances:1 upgrades:1 dollar:1 treatment:1 years:2 past:2 pushed:1 3.4:3 dominating:1 year:1 seen:1 reducing:1 its:2 market:2 member:1 5.2:3 additional:1 earned:1 stamp:1 since:1 had:1 three:1 shares:1 strategy:1 late:1 declining:1 tactic:1 new:1 current:1 has:2 meeting:1 pill:1 board:1 eventually:1 attempts:1 his:1 's:4 which:1 months:1 company:3 million:1 but:1 reported:1 boost:1 got:1 approval:1 investor:1 firms:1 change:1 recent:2 rallied:1 four:1 days:1 abandoned:1 nominate:1 annual:1 sale:1 drug:1 investment:1 rival:1 multiple-sclerosis:1 stock:1 maker:1
stock_BIIB r_up	1.4:1 slid:1 stake:1 1.3:1 upgrades:1 trade:2 past:2 pushed:1 3.4:3 session:3 trading:1 year:1 years:2 seen:1 reducing:1 its:1 declined:1 member:1 24:1 whose:3 5.2:1 additional:1 earned:1 stamp:1 since:1 had:1 three:1 shares:4 strategy:1 late:1 points:1 declining:1 tactic:1 expected:2 current:1 has:2 meeting:1 500:1 board:1 his:1 's:6 which:1 months:1 company:3 million:1 but:1 reported:1 fell:1 approval:1 stocks:1 investor:1 firms:1 change:1 recent:2 rallied:1 four:1 days:1 lost:1 nominate:1 annual:1 companies:3 sale:1 drug:1 investment:1 actively:3 stock:1 maker:1
stock_BIIB r_up	among:1 like:1 wo:1 year:1 n't:1 half:1 best-performing:1 stocks:1 first:1
stock_BIIB r_down	taste:1 ranges:1 's:1
stock_BIIB r_down	move:1 sell:1 employing:1 says:1 plans:1 million:1 facility:1 960:1 suburban:1 people:1 least:1 unit:1 related:1 deal:1 close:1 its:1 104:1 $:1
stock_BIIB r_up	biotech:1 deaths:2 among:1 brain:1 multiple-sclerosis:1 drug:1 effort:1 total:3 its:1 provided:1 said:1 develop:1 bringing:3 there:1 29:2 5:1 provides:1 test:2 company:1 more:4 updated:2 145:2 affected:1 brings:1 sold:1 infection:3 diagnostic:1 reported:1 five:1 cases:2 data:2 those:1 12:4 rare:1 --:4 die:1 taking:1 reports:1 patients:4 efforts:1
stock_BIIB r_down	sector:1 help:1 sales:1 dollar:1 results:1 trends:1 another:1 should:1 full-year:1 crucial:1 next:1 outlooks:1 earnings:3 stable:1 boost:1 week:2 begin:1 's:2 price:1 includes:1 increases:1 updates:2 listening:1 report:1 during:1 along:1 strong:1 second-quarter:1 prescription:1 companies:2 batch:1 large:1 continue:1 expecting:1 biotechnology:1 overseas:1 quarter:1
stock_BIIB r_down	walking:1 followed:1 developed:1 conditional:1 year:1 sales:1 recommendation:1 positive:1 name:1 outside:1 under:1 pill:1 earlier:1 multiple:1 get:1 after:2 designed:1 approval:2 approved:2 improve:1 received:1 rejection:2 last:1 --:4 sclerosis:1 drug:1 patients:1 payments:1
stock_BIIB r_up	comment:1 biotech:1 raised:2 says:1 revenue:7 executive:1 1.8:12 while:1 sovereign:1 growth:1 per:1 year:2 multiple:2 miss:2 crisis:1 narrowly:2 strength:2 adds:1 missed:3 profit:6 guidance:2 expectations:6 comments:1 second-quarter:4 better:1 their:2 other:2 details:2 expected:2 2011:4 company:5 announced:2 stock:2 available:2 conference:2 product:2 full:2 's:7 than:4 watching:1 beat:2 earnings:3 price:2 penny:1 first:1 driven:1 severe:2 higher:1 fell:4 updates:1 closely:1 treatment:2 early:2 debt:1 beginning:3 analyst:4 acquisition-related:2 hemophilia:2 third:2 largely:1 --:8 study:2 sclerosis:2 drug:5 adjusted:2 finding:2 charges:4 estimates:1 costs:1 analysts:2 biotechnology:2 share:1 10th:1 its:2 maker:2 view:2
stock_BIIB r_down	months:1 deal:2 appeared:1 despite:1 sales:1 ninth:1 up:1 '':1 second:3 reaffirmed:1 close:1 confirms:1 technology:1 its:6 full-year:2 sell:2 said:2 remains:2 pay:1 guidance:2 three:1 same:1 current:1 saw:1 version:1 fifth:1 innovation:1 medicine:1 net:2 unit:2 correct:1 ``:1 's:2 business:1 track:2 detail:1 seventh:1 fund:1 transformational:2 latest:1 debt:1 loss:2 10th:1 --:3 6th:1 31:1 listings:1 sale:2 drug:3 remaining:1 recording:1 item:1 allow:1 follows:1 down:1 quarter:3 maker:2 narrow:1 mistake:1
stock_BIIB r_up	aided:1 major:1 setback:1 trade:2 7.2:1 session:4 businesses:1 shares:4 its:5 fifth:2 whose:4 group:1 rose:1 disability:2 expectations:1 second-quarter:1 failed:3 add:2 treatment:5 main:1 2012:1 updated:1 risk:2 early:1 loss:2 lost:2 --:8 drop:1 companies:5 benefit:1 raised:1 higher:1 better-than-expected:1 shed:2 says:1 reduce:1 actively:4 trading:2 year:1 multiple:4 fails:1 said:2 missed:1 projected:2 comments:2 increase:1 provider:1 shows:1 recently:2 marketing:1 seventh:2 reported:1 key:1 offset:1 approval:1 100:1 beginning:1 both:1 study:3 uncertainty:1 drug:6 34:1 trial:1 fell:2 placebo:2 traded:2 maker:1 experimental:1 first:1 comment:1 adjusted:2 ratios:1 primary:2 reducing:2 estimate:1 statistics:1 indicate:1 spending:1 managed-care:1 investigational:2 per-share:1 their:3 reduction:2 clinical:1 expected:2 500:2 form:2 reaction:1 company:2 analyst:3 partially:1 11:1 endpoint:2 14:1 employer:1 future:1 amid:1 meet:2 called:4 acquisition:1 sales:1 13th:1 35:1 file:1 saw:1 information:1 marking:1 compared:2 goal:1 48:1 details:3 fourth:3 effectiveness:2 stock:1 added:2 's:7 plans:1 earnings:2 membership:1 important:1 significant:2 stocks:3 data:3 lower:3 retail:1 third:2 starting:1 sclerosis:4 disease:1 points:6 oral:4
stock_BIIB r_up	major:1 increasingly:1 some:1 results:1 competitive:2 years:2 bring:1 second:2 used:1 questions:2 its:1 market:3 would:1 positive:2 away:1 seems:1 two:1 least:1 come:1 more:1 effectiveness:1 meeting:1 shows:2 full:1 multiple:2 treatments:1 but:1 bringing:1 reported:2 step:1 effects:1 data:4 than:1 fit:1 effective:1 --:4 many:1 study:2 required:1 sclerosis:2 likely:1 drug:4 side:1 n't:1 trial:1 remain:2 enter:1 latest:1 medical:1 experimental:2 first:2
stock_BIIB r_down	all:2 one:2 four:2 backed:4 another:2 said:2 managing:2 boardrooms:2 entities:2 activist:2 candidates:2 board:2 funds:2 nominees:2 advise:2 forth:2 re-election:2 firm:4 his:4 's:4 billionaire:2 slate:2 after:2 director:2 known:2 hedge:2 investor:2 day:2 change:2 well:2 up:2 directors:2 affiliate:2 put:2 push:2 efforts:2
stock_BIIB r_up	estate:1 appeared:1 well:1 energy:2 sales:1 7.6:1 pharmaceutical:1 toy:1 3rd:1 stake:3 detail:1 passive:1 also:1 other:2 exit:1 which:2 new:2 real:1 company:1 number:1 reported:3 brokerage:1 investor:2 prominent:1 --:1 positions:1 companies:1 sale:1 cigarettes:2 9th:1 owns:1 10th:1 makes:2 maker:1 stakes:1
stock_BIIB r_down	saying:1 raised:1 real:1 estate:1 rating:1 reductions:1 companies:1 into:1 near-term:1 outlook:1 one:1 second:1 cost:1 multiple-sclerosis:1 investment-grade:1 another:1 during:1 multiple:1 prominent:1 bank:1 its:1 whose:1 stocks:1 limited:1 their:1 patent:1 positive:1 saw:1 stake:1 benefit:1 including:1 touting:1 also:2 other:1 growth:1 rater:1 which:2 stable:1 performance:1 territory:1 approach:1 exposures:1 bets:1 good:1 's:5 funds:1 company:2 continues:1 expects:1 reflect:1 reported:1 opposing:1 operating:1 new:1 approval:1 strong:2 investor:1 those:1 recent:2 cigarettes:1 metrics:1 pipeline:1 owns:1 level:1 --:1 among:1 sclerosis:1 drug:2 investments:1 investment:1 credit:2 while:1 continue:1 brokerage:1 were:1 mixed:1 biotechnology:1 quarter:1 makes:1 noted:1 late-stage:1
stock_BIIB r_down	both:1 set:1 conviction:1 bullish:1 show:1 positions:1 mount:1 months:1 up:1 shares:1 traders:1 drug:1 coming:1 stock:1 makers:1 gains:1 can:1
stock_BIIB r_down	pointing:2 outstanding:2 probe:2 results:2 elected:3 6.5:2 refreshes:2 shareholders:3 said:2 federal:2 boardrooms:2 pharmaceuticals:2 activist:2 board:3 statement:2 nominees:3 company:2 stock:4 his:4 's:12 fourth:2 quote:2 slate:3 after:2 rejected:3 preliminary:2 known:2 investor:2 change:2 entire:3 shortly:2 third:2 --:6 well:2 second:2 affiliate:2 victory:4 owns:2 push:2 efforts:2 settled:2 comes:2
stock_BIIB r_up	managers:1 money:1 elected:1 say:1 experts:1 have:2 targets:2 majority:1 takeovers:1 their:1 other:1 board:2 funds:1 easier:2 big:1 but:1 driven:1 friends:1 types:1 also:1 hostile:1 companies:1 elections:2 annually:1 directors:2 pension:1 keeps:1 situation:1 efforts:1 mean:2
stock_BIIB r_down	's:2 $:2 near:1 shares:1 multi-year:1 3:2 low:1 bought:1
stock_BIIB r_up	chronic:1 's:1 appear:1 support:1 concerns:1 safety:1 treatment:1 effectiveness:1 multiple:1 earlier:1 data:1 raise:1 treating:1 did:1 sclerosis:1 disease:1 drug:1 n't:1 oral:1 called:1 experimental:1 view:1
stock_BIIB r_down	sector:1 biotech:1 companies:1 dollar:1 likely:1 any:1 market:1 again:1 third-quarter:1 looking:1 outlooks:1 earnings:1 firms:1 2011:1 2012:1 mostly:1 watching:1 weak:1 updates:2 significant:1 report:1 well:1 stronger:1 large:1 benefit:1 so:1 biotechnology:1 quarter:1
stock_BIIB r_down	help:3 less:1 broaden:1 results:2 brain:1 portfolio:1 its:3 giant:1 $:1 candidate:1 nervous:1 ease:1 had:1 should:1 treatment:1 factor:1 weeks:1 fatal:1 2010:1 gave:1 risk:1 progressive:1 --:4 prescribing:1 common:1 lasting:1 see:1 multiple:3 beyond:1 said:3 affects:1 review:1 medicine:1 shows:1 core:1 effect:1 franchise:1 strong:1 central:1 universe:1 drug:5 keep:1 trial:1 long-term:1 antibody:1 already:1 cancer:1 multiple-sclerosis:1 initial:1 system:1 form:1 infection:2 filed:1 known:1 rare:1 than:1 96:1 include:1 showed:1 solid:1 patients:2 risks:1 revenues:1 autoimmune:1 investors:1 expanding:1 evidence:1 helped:1 sells:1 check:1 information:1 1:1 application:2 potentially:1 which:2 ocrelizumab:2 status:1 extended:1 's:5 after:2 update:1 most:1 virus:1 peak:1 data:1 sclerosis:3 disease:2 fresh:1
stock_BIIB r_up	1.4:1 1.5:1 1.6:1 1.7:3 1.1:1 1.9:1 session:3 trading:3 2.3:1 recently:2 whose:3 rose:3 shares:3 closed:1 500:3 higher:3 added:3 's:9 stocks:3 gained:3 companies:3 actively:3 after-hours:1 traded:2
stock_BIIB r_up	good:1 upcoming:1 corporate:1 watch:2 reports:1 early:1 dominating:1 earnings:1 another:1 headlines:1 makes:1 acquisition:1 otherwise:1
stock_BIIB r_up	over:1 executive:2 results:4 7.2:1 session:2 shares:2 high-level:2 its:3 whose:2 zone:1 rose:3 28:1 add:1 setting:1 treatment:4 policy:2 include:1 pill:3 earnings:1 updated:1 shaky:1 handle:1 seeking:1 could:2 watch:1 closely:3 half:1 multiple:3 advanced:1 summit:1 --:3 follows:1 companies:2 morning:1 19:1 study:6 higher:1 lifted:1 says:1 leaders:1 woes:2 some:2 second:1 actively:2 trading:4 year:1 's:21 72:1 makers:2 declined:2 index:1 said:2 comments:1 research:2 version:1 safety:2 falling:1 correct:1 recently:2 filings:2 met:3 key:4 regulatory:2 approval:2 100:1 debt:3 gained:1 region:2 uncertainty:1 drug:1 speedy:2 afternoon:2 mixed:2 climb:1 traded:2 experimental:3 first:1 slipped:1 losing:1 table:1 throughout:1 open:1 crisis:1 given:1 strong:2 next:1 2:1 call:2 way:2 markets:1 500:4 more:1 disappointed:1 ``:3 efficacy:2 released:2 goals:4 sharply:1 hopes:1 analyst:1 present:1 these:2 up:2 while:3 're:2 those:1 toward:2 called:3 1.5:1 gathering:2 1.7:1 hoping:2 investors:3 1.3:1 share:1 '':3 file:1 9.75:1 watched:3 plan:1 seek:1 40:1 potential:1 speaker:1 details:1 a.m.:1 stock:2 development:2 meets:1 product:3 added:1 edged:2 plans:1 track:1 price:1 after:2 convincing:1 prepared:2 fell:1 paving:2 president:2 stocks:4 data:3 euro:1 vice:2 resolution:2 futures:2 sclerosis:3 points:9 oral:1
stock_BIIB r_up	1.4:1 gaining:2 autoimmune:1 1.1:1 session:1 up:1 certain:1 36:1 actively:1 trading:1 partner:1 made:1 stock:1 market:1 plans:1 rundown:1 25:1 moves:1 develop:1 $:5 pay:1 shares:2 points:1 various:1 treatment:1 provides:1 equity:1 9:1 12:1 closed:1 500:1 split:1 development:1 added:1 's:1 diseases:1 whose:1 million:3 agreement:2 biggest:2 75:1 part:1 upfront:1 regulatory:1 based:1 stocks:3 payment:1 declining:2 additional:1 gained:1 purchase:1 milestones:1 sizable:1 companies:1 cash:1 daily:1 costs:1 payments:1 rose:1 higher:1 oral:1 profits:1
stock_BIIB r_up	saying:2 heavily:1 scratch:1 results:3 trade:1 session:3 shares:3 7.8:1 its:6 whose:3 certainly:1 $:3 personal:1 rose:5 guidance:2 28:1 29:1 analyst:1 outlooks:1 premarket:1 under:1 has:2 details:2 digit:5 gains:2 watch:2 reversal:1 now:4 multiple:2 treating:2 lost:1 --:6 companies:3 morning:1 worries:1 multiple-sclerosis:1 raised:3 quarter:1 view:2 heavy:1 list:1 among:1 2.9:1 actively:3 trading:3 exceeded:1 2.2:1 targets:2 out:1 strategic:1 stands:1 bottom:1 jumped:1 since:1 comments:1 forecast:3 chips:1 above:1 new:1 core:2 we:1 full:2 recently:2 updated:1 announcement:1 maintains:2 hours:1 reported:1 restructuring:1 leadership:1 key:2 38:9 prior-year:1 drug:1 spending:1 range:3 notebook:1 mixed:1 climb:1 better-than-expected:1 traded:2 maker:2 fourth-quarter:1 outlook:4 revenue:8 previously:1 expectations:6 rising:2 another:1 throughout:1 pharmaceutical:1 industrials:1 8.9:1 top:2 third-quarter:5 per-share:1 their:1 2:1 too:1 way:1 expected:1 percentage:1 500:2 eurozone:1 lot:1 drugs:5 company:7 volume:1 gain:1 demand:1 line:1 highest:1 than:2 posted:2 weighed:1 12:1 single:2 while:1 growth:6 can:1 quarters:1 adjusted:1 acquisition:1 slid:2 chip:1 year:4 share:1 sales:10 helped:1 full-year:2 35:1 have:1 our:1 close:1 seen:2 moves:1 rescue:1 again:1 compared:1 weakened:1 rather:2 topped:1 also:1 earnings:12 income:1 higher:3 topping:2 experienced:1 's:13 though:2 boosted:2 felt:1 yesterday:2 includes:1 fueled:2 flurry:1 fell:2 plan:1 robust:1 stocks:2 soared:1 recent:1 lower:1 off:1 5.6:1 charges:2 sclerosis:2 drive:2 reports:1 points:6 greatest:1 biotechnology:3 once:1 latest:1
stock_BIIB r_down	distance:1 major:2 industrials:1 risen:1 lead:1 striking:1 technical:3 important:1 within:3 moving:1 average:1 continue:1 200-day:1 test:2 territory:1 has:1 markets:1 its:1 500:3 view:2
stock_BIIB r_down	comment:1 sector:1 proposed:1 health-care:1 reduce:1 expects:1 2nd:1 four:1 likely:2 including:1 committee:1 cuts:3 7th:1 throughout:1 hospitals:1 makers:1 impact:1 working:1 spending:1 government:1 negative:1 deficit:1 add:1 potential:1 4:2 insurers:1 details:1 's:3 offer:1 big:1 director:1 most:1 focused:1 key:1 budget:1 beginning:1 payment:1 those:1 areas:1 look:1 --:3 impacted:1 could:2 see:1 drug:1 benefit:1 recommendations:1
stock_BIIB r_down	pharmaceutical:2 would:2 these:2 industry:2 never:2 back:2 but:2 days:2 cutting:2 know:2 underway:2 construction:2 you:2
stock_BIIB r_up	key:1 cautions:1 now:2 high-wire:1 investors:1 expert:2 money:2 top:2 emerging:1 markets:1 5:2 expect:1 another:1 year:1 bond:1 making:2 headlines:1 moves:2 strategist:1 stock:3
stock_BIIB r_down	develop:1 said:1 's:1 $:3 joint:1 300:3 agreed:1 million:1 --:1 venture:1 have:1 based:1 establish:1
stock_BIIB r_up	sector:1 agreed:1 contribute:1 brought:1 growth:1 businesses:1 against:1 have:1 1st:1 establish:1 based:1 pharmaceutical:1 said:1 develop:2 $:5 patent:1 remainder:1 away:1 favor:1 biggest:1 new:1 electronics:1 announced:1 's:3 form:1 300:2 company:1 million:3 leukemia:1 expansion:1 conglomerate:1 joint:2 involving:1 background:1 adds:1 judgment:1 case:1 --:3 invest:1 drug:1 seeks:1 venture:2 healthcare:1 infringement:1 diversify:1 country:1 consumer:1 latest:1
stock_BIIB r_down	sector:1 course:1 huge:1 strong:1 jobless:1 bullish:1 lean:1 sports:1 rates:1 low:1 capital:1 several:1 economy:1 infrastructure:1 tops:2 plenty:1 stocks:1 he:1 cautious:1 companies:1 large:1 small:1 2012:2
stock_BIIB r_up	major:1 own:1 biosimilars:1 player:1 likely:1 not:1 become:1 its:1
stock_BIIB r_up	closely:1 dose:1 '':1 multiple-sclerosis:1 reviewing:1 have:1 given:1 said:1 monitor:1 been:1 recommended:1 ``:1 's:1 after:1 they:1 doctors:1 benefits:1 drug:3 regulator:1 patients:1 risks:1 hearts:1 first:1
stock_BIIB r_down	more:1 include:1 watch:1 morning:1
stock_BIIB r_up	fourth-quarter:1 major:1 declines:1 move:1 sales:1 competition:1 trade:1 '':1 likely:1 session:1 rising:1 years:1 still:1 25:3 generic:1 patent:1 rose:1 due:1 shares:1 indexes:1 earnings:1 largest:1 expected:1 new:1 posted:1 ``:1 reporting:1 's:4 gains:1 whose:1 drugs:2 each:1 watch:2 but:1 hurt:1 fueled:1 weighed:1 forecasts:1 data:1 cliff:1 disappointing:1 stocks:2 15:1 look:1 companies:1 profit:2 trading:1 actively:1 economic:1 handful:1 were:1 multiple-sclerosis:1 round:1
stock_BIIB r_down	has:1 says:1 growth:1
stock_BIIB r_down	acquire:1 $:1 failure:1 pay:1 agreed:1 million:1 fibrosis:1 held:1 much:1 focused:1 treatment:1 closely:1 biotechnology:1 company:1
stock_BIIB r_down	roundup:1 saying:1 surprises:2 companies:1 reports:1 quarters:1 advisories:2 earnings:1 future:1 corporate:1 latest:1
stock_BIIB r_up	biotech:1 being:1 developed:1 guided:1 executive:1 share:1 results:1 transform:1 dash:1 hopes:1 fortunes:1 bapineuzumab:2 have:1 helm:1 blockbuster:1 its:1 25:2 huge:1 '':1 occur:1 publication:1 would:1 trials:1 since:1 while:1 least:1 research:1 1:1 platform:1 3:1 asking:1 treatment:1 which:1 expected:1 stepped:1 has:3 until:2 ``:1 arrives:1 's:2 get:1 any:1 powerful:1 maritime:1 stay:2 profitability:1 said:1 therapy:1 but:1 key:1 not:1 changing:1 data:2 pilot:1 billion:1 down:1 success:2 harbor:1 should:1 could:1 drug:1 $:1 2003:1 chief:1 financially:1 either:1 very:2 become:1 agreed:1 revenues:1 experimental:1 approaching:1
stock_BIIB r_up	giant:1 's:1 results:1 drug:1 early:1 trial:1 add:1 clinical:1 appeal:1 stage:1
stock_BIIB r_up	different:1 's:3 taking:1 disease:2 find:1 patients:1 treatment:1 nonprofit:1 trying:1 route:1
stock_BIIB r_down	session:1 's:4 investors:1 watch:2 make:1 handful:1 companies:1 shares:1 trade:1 early:1 high-profile:1 actively:1 names:1 interest:1 expected:1 headlines:1
stock_BIIB r_up	heart:3 generate:1 says:1 investors:1 deaths:1 increasingly:1 certain:1 health-care:2 some:2 expects:1 years:1 '':1 stroke:3 multiple-sclerosis:2 against:1 concludes:1 cardiovascular:1 low:2 information:1 use:1 said:4 additional:1 revenue-growth:1 no:1 review:3 should:2 environment:1 senior:1 interested:1 safety:2 income:2 interest:1 between:1 dissatisfied:1 dividends:2 life-science:1 rates:1 more:2 advises:1 ``:1 used:2 's:5 initiated:1 year:1 seventh:1 company:1 stable:1 problems:2 immediate:2 credit-ratings:1 analyst:1 rated:1 link:1 value:1 background:1 previous:1 dividend:1 combined:1 than:1 types:2 recent:2 prospects:1 last:1 vice:1 --:4 amid:2 clear:1 current:1 companies:3 cash:1 drug:5 generating:1 n't:2 initiate:1 patients:3 place:1 payments:1 five:1 president:1 higher:1 starting:1 experimental:1 history:2
stock_BIIB r_up	stroke:1 used:1 says:1 heart:1 problems:1 some:1 patients:1 drug:1 should:1 n't:1 only:1 multiple-sclerosis:1 history:1 oral:1 market:1 recent:1
stock_BIIB r_up	1.5:1 based:1 list:1 estimates:1 per:1 quarters:1 current:1 companies:1 operating:1 analysts:2 3.0:1 income:1 included:1 survey:1 share:1 2.0:1 =:5 2.5:1
stock_BIIB r_down	1.5:1 based:1 list:1 estimates:1 per:1 quarters:1 current:1 companies:1 operating:1 analysts:2 3.0:1 income:1 included:1 survey:1 share:1 2.0:1 =:5 2.5:1
stock_BIIB r_up	1.5:1 based:1 list:1 estimates:1 per:1 quarters:1 current:1 companies:1 operating:1 analysts:2 3.0:1 income:1 included:1 survey:1 share:1 2.0:1 =:5 2.5:1
stock_BIIB r_down	1.5:1 based:1 list:1 estimates:1 per:1 quarters:1 current:1 companies:1 operating:1 analysts:2 3.0:1 income:1 included:1 survey:1 share:1 2.0:1 =:5 2.5:1
stock_BIIB r_up	1.5:1 based:1 list:1 estimates:1 per:1 quarters:1 current:1 companies:1 operating:1 analysts:2 3.0:1 income:1 included:1 survey:1 share:1 2.0:1 =:5 2.5:1
stock_BIIB r_up	1.5:1 based:1 list:1 estimates:1 per:1 quarters:1 current:1 companies:1 operating:1 analysts:2 3.0:1 income:1 included:1 survey:1 share:1 2.0:1 =:5 2.5:1
stock_BIIB r_up	212:1 deal:1 into:1 see:1 actively:2 trading:2 's:4 index:2 26:1 develop:1 $:1 jumped:2 shares:2 points:6 treat:1 entered:1 higher:2 added:2 recently:2 whose:2 million:1 agreement:1 73:1 stocks:2 than:1 receive:1 could:1 companies:2 disease:1 drug:1 session:2 25:1 rose:2 64:1 more:1 traded:2
stock_BIIB r_up	1.5:1 based:1 list:1 estimates:1 per:1 quarters:1 current:1 companies:1 operating:1 analysts:2 3.0:1 income:1 included:1 survey:1 share:1 2.0:1 =:5 2.5:1
stock_BIIB r_up	1.5:1 based:1 list:1 estimates:1 per:1 quarters:1 current:1 companies:1 operating:1 analysts:2 3.0:1 income:1 included:1 survey:1 share:1 2.0:1 =:5 2.5:1
stock_BIIB r_up	rated:1 managers:1 highly:1 fans:1 diverse:1 stocks:1
stock_BIIB r_up	prevent:2 consider:2 warns:2 '':2 asking:2 throughout:2 adds:2 investor:2 comments:2 fight:4 activist:2 candidates:4 board:4 between:2 letter:2 details:2 ``:2 his:4 's:2 company:2 seventh:2 possibility:2 shareholder:2 proxy:4 members:2 beginning:2 --:6 prolonged:2 directors:2 urges:2 more:2 latest:2
stock_BIIB r_up	1.5:1 based:1 list:1 estimates:1 per:1 quarters:1 current:1 companies:1 operating:1 analysts:2 3.0:1 income:1 included:1 survey:1 share:1 2.0:1 =:5 2.5:1
stock_BIIB r_up	investors:2 some:2 results:2 competition:2 bring:2 likely:4 same:2 have:4 any:2 market:4 large:2 slow:2 also:2 watching:2 been:4 their:6 concerns:2 details:2 new:2 faring:2 pipelines:2 traditional:2 manufacturers:2 drugs:2 continues:2 treatments:2 sales:2 focused:2 report:2 intensify:2 second-quarter:2 expand:2 older:2 companies:4 trends:2 drug:4 facing:2 remain:2 strategies:2 efforts:2 acquisition:2
stock_BIIB r_down	gains:1 straight:1 after:1 two:1 first:1 days:1 tense:1 place:1 still:2 eases:1 why:1 market:1 stock:1
stock_BIIB r_down	1.5:1 based:1 list:1 estimates:1 per:1 quarters:1 current:1 companies:1 operating:1 analysts:2 3.0:1 income:1 included:1 survey:1 share:1 2.0:1 =:5 2.5:1
stock_BIIB r_up	help:2 results:3 trade:2 session:2 shares:2 headlines:1 its:9 rundown:1 cut:1 $:1 22:1 rose:3 guidance:4 analyst:1 only:1 treatment:4 2012:4 details:1 modestly:1 which:1 weakness:1 rise:1 watch:2 early:1 increases:1 gloomy:1 continued:5 runs:1 --:3 companies:2 surging:1 activity:1 worries:1 raised:2 quarter:1 heavy:1 actively:2 pricing:1 slumped:1 said:4 pressured:1 comments:1 forecast:1 for-profit:1 reading:1 weak:1 hours:1 operating:1 key:2 estimate:2 strong:3 pipeline:1 launch:1 losses:1 drug:3 34:11 a.m.:2 late-stage:1 outlook:1 revenue:6 multiple-sclerosis:3 another:1 throughout:1 pharmaceutical:2 manufacturing:1 interest:1 expected:2 upbeat:1 markets:1 ``:2 company:6 peers:1 biggest:2 somewhat:1 second-quarter:3 tide:1 enrollment:1 flagship:1 readies:1 growth:2 dispute:1 investors:1 sales:4 '':2 pushed:1 spends:1 weaken:1 hampered:1 also:1 stemming:1 earnings:4 fourth:1 stock:1 product:2 's:8 plans:1 after:1 workforce:1 student:1 weigh:1 grow:2 fiscal:1 lower:1 tracking:1 downbeat:1 amid:2 futures:1 costs:1 biotechnology:1 corporate:1 affirmed:2
stock_BIIB r_down	1.5:1 based:1 list:1 estimates:1 per:1 quarters:1 current:1 companies:1 operating:1 analysts:2 3.0:1 income:1 included:1 survey:1 share:1 2.0:1 =:5 2.5:1
stock_BIIB r_down	now:1 management:1 financial:1 just:1 skills:1 but:1 cash:1 controls:1 chief:1 're:1 officer:1 accounting:1 counts:1 still:1 beginning:1 you:1 those:1 if:1
stock_BIIB r_up	1.5:1 based:1 list:1 estimates:1 per:1 quarters:1 current:1 companies:1 operating:1 analysts:2 3.0:1 income:1 included:1 survey:1 share:1 2.0:1 =:5 2.5:1
stock_BIIB r_down	partners:1 deal:1 n't:3 see:1 does:1 between:1
stock_BIIB r_down	1.5:1 based:1 list:1 estimates:1 per:1 quarters:1 current:1 companies:1 operating:1 analysts:2 3.0:1 income:1 included:1 survey:1 share:1 2.0:1 =:5 2.5:1
stock_BIIB r_down	1.5:1 based:1 list:1 estimates:1 per:1 quarters:1 current:1 companies:1 operating:1 analysts:2 3.0:1 income:1 included:1 survey:1 share:1 2.0:1 =:5 2.5:1
stock_BIIB r_up	1.5:1 based:1 list:1 estimates:1 per:1 quarters:1 current:1 companies:1 operating:1 analysts:2 3.0:1 income:1 included:1 survey:1 share:1 2.0:1 =:5 2.5:1
stock_BIIB r_up	1.5:1 based:1 list:1 estimates:1 per:1 quarters:1 current:1 companies:1 operating:1 analysts:2 3.0:1 income:1 included:1 survey:1 share:1 2.0:1 =:5 2.5:1
stock_BIIB r_down	1.5:1 certain:2 agreed:2 estimates:1 quarters:1 accelerate:2 3.0:1 2.0:1 its:2 2.5:1 sell:2 management:2 based:1 $:4 per:1 investment:2 current:1 companies:1 other:2 income:1 has:2 =:5 payments:2 firm:4 share:1 royalty:2 operating:1 allowing:2 included:1 lupus:2 rights:2 list:1 drug:2 survey:1 analysts:2 18.3:4
stock_BIIB r_up	available:1 multiple:1 sclerosis:1 disease:1 pill:1 second:1 therapy:1 treat:1 making:1 oral:1 approved:1 market:1
stock_BIIB r_up	1.5:1 based:1 list:1 estimates:1 per:1 quarters:1 current:1 companies:1 operating:1 analysts:2 3.0:1 income:1 included:1 survey:1 share:1 2.0:1 =:5 2.5:1
stock_BIIB r_down	gaining:2 thought:1 used:1 eye:1 pharmaceutical:1 drugs:3 series:1 caught:1 sclerosis:2 disease:1 traction:3 treat:1 gain:1 seen:2 labs:1 once:1
stock_BIIB r_down	1.5:1 based:1 list:1 estimates:1 per:1 quarters:1 current:1 companies:1 operating:1 analysts:2 3.0:1 income:1 included:1 survey:1 share:1 2.0:1 =:5 2.5:1
stock_BIIB r_down	fourth-quarter:1 increasingly:2 results:3 trade:2 session:3 comments:1 still:1 its:2 previous:2 20:1 $:1 application:1 28:1 expectations:1 contractor:1 treatment:5 premarket:1 inherited:2 earnings:1 updated:1 half:1 replace:1 intensify:2 bigger:1 amid:2 --:11 companies:2 anxious:2 slide:2 worries:2 stock:3 disorder:3 shed:1 says:1 bleeding:1 euro-zone:2 actively:3 trading:2 year:2 led:2 margins:1 points:7 index:1 said:4 since:2 shares:3 forecast:1 electronics:1 increasing:2 recently:1 met:1 key:2 offset:1 debt:2 gained:1 rare:3 ahead:2 reported:1 study:5 losses:2 slightly:1 experimental:1 late-stage:1 among:1 protests:2 slipped:3 revenue:1 one:2 down:1 open:2 market:1 decline:4 101:2 positive:3 two:1 next:1 clinical:2 overhead:1 way:1 expected:3 today:1 form:1 three:2 biggest:2 goals:1 90:2 analyst:1 13:1 14:2 showed:2 below:1 growth:1 500:1 were:2 growing:2 situation:2 drops:2 minutes:2 0.8:2 weaker:1 tap:2 investors:2 0.1:2 sales:2 home:2 sharp:4 5.1:1 also:1 potential:2 details:2 which:1 higher:1 's:9 plans:1 4.4:1 price:1 after:2 treatments:1 extending:2 modest:1 fell:5 blood:2 phase:2 stocks:2 data:2 fiscal:1 lower:1 hemophilia:6 studies:1 futures:6 costs:1 first:1
stock_BIIB r_down	application:1 says:1 background:1 bleeding:1 treatment:2 one:3 way:1 experience:1 have:2 year:3 still:1 their:1 market:1 fill:1 paving:1 throughout:1 details:1 candidate:1 no:1 chosen:1 positive:1 two:1 been:1 next:1 also:1 outside:1 willing:2 choose:1 which:1 expected:1 new:1 firms:1 more:1 's:2 plans:1 form:1 though:1 overall:1 treatments:1 met:1 job:1 said:1 goals:1 key:2 half:1 potential:2 bigger:1 rare:1 look:1 hemophilia:4 --:3 disorder:1 industry:1 fewer:1 prior:1 while:1 late-stage:1 studies:1 study:3 experimental:1 first:1
stock_BIIB r_up	1.5:1 based:1 list:1 estimates:1 per:1 quarters:1 current:1 companies:1 operating:1 analysts:2 3.0:1 income:1 included:1 survey:1 share:1 2.0:1 =:5 2.5:1
stock_BIIB r_down	information:1 expects:1 more:1
stock_BIIB r_up	point:1 sclerosis:2 one:1 actively:2 trading:4 dropped:1 further:2 its:4 index:2 said:2 rose:1 people:2 shares:2 41:1 safety:2 new:2 effectiveness:2 supports:2 pill:2 higher:1 added:1 's:2 multiple:2 were:2 fell:2 five:3 stocks:2 data:2 lower:1 15:1 companies:2 points:5 evaluating:2 jumped:1 multiple-sclerosis:2 studies:2 experimental:2
stock_BIIB r_down	says:1 background:1 share:1 updated:1 multiple-sclerosis:4 its:4 regulator:1 said:3 additional:4 analyst:1 rather:1 review:4 three:3 comments:1 approved:1 3:4 extends:1 treatment:1 has:6 company:1 product:1 extended:3 's:1 may:1 timeline:1 price:1 but:3 early:2 key:1 ask:1 now:1 than:1 pipeline:1 --:3 months:3 drug:1 pill:2 n't:4 did:1 studies:4 asked:3 experimental:3
stock_BIIB r_up	fix:2 can:1 taxes:1 ca:2 tax:2 ``:2 '':2 n't:2 say:1 growth:2 multiple-sclerosis:2 together:1 have:1 battle:1 80:1 saw:2 its:2 out:1 party:1 different:1 cut:2 banding:1 plan:1 ways:1 rose:2 avoid:2 political:1 third-quarter:2 been:1 should:1 deficit:2 raising:1 other:1 earnings:2 which:1 biggest:2 2012:4 you:2 cliff:1 boost:2 treatment:2 do:1 inevitable:1 's:2 way:2 enough:1 big:1 company:2 million:1 possible:1 tied:2 increases:1 reports:1 gain:2 groups:1 new:1 bit:1 come:1 than:1 but:1 executives:1 fiscal:1 received:2 13:6 your:1 signed:1 getting:1 no:2 companies:1 up:1 drug:2 specific:1 matter:1 manifesto:1 comes:1 said:1 done:1 problem:2 more:2 top:1 urging:1 gridlock:1
stock_BIIB r_down	biotech:2 investors:2 revenue:2 increasingly:2 over:2 updated:2 past:2 earnings:2 shares:2 have:2 year:2 's:2 throughout:2 spends:2 even:2 adding:2 anticipation:4 $:2 spending:2 rose:2 third-quarter:2 comments:2 next:2 potential:2 details:2 8:2 several:2 price:2 2013:2 stock:2 core:2 product:6 million:2 multiple:6 business:2 big:2 company:6 continues:2 sums:2 pipeline:2 drug:2 than:2 new:2 franchise:2 continued:4 grow:4 additional:2 value:2 13:4 last:2 --:6 launches:4 months:2 sclerosis:4 up:4 doubled:2 excited:2 large:2 became:2 18:2 more:2 its:4 late-stage:2
stock_BIIB r_down	opens:1 says:1 slip:1 people:2 bleeding:2 burden:2 comments:1 questions:1 year:1 throughout:1 its:2 said:2 raise:1 shares:1 next:1 application:1 potentially:2 treatment:3 2013:1 common:2 meets:1 door:2 plans:1 form:2 opening:1 could:2 company:1 most:2 first-half:1 goals:3 key:1 regulatory:1 analyst:1 hemophilia:3 met:2 --:3 study:3 lessen:2 drug:3 while:1 analysts:1 comparisons:1 disorder:2 filing:1 experimental:3
stock_BIIB r_down	trounced:1 's:3 scenario:1 factor:1
stock_BIIB r_up	generation:1 treatments:1 years:1 patients:1 caution:1 have:1 doctors:1 pill:1 urging:1 first:1
stock_BIIB r_down	provided:1 outlook:1 partly:1 revenue:1 drop:1 weak:1 due:1 competition:1 next:1 drug:1 likely:1 levels:1 multiple-sclerosis:1 earnings:1 year:1 expected:1 new:1 2012:1 its:1 2013:2 anticipating:1
stock_BIIB r_up	development:1 because:1 most:1 track:1 industry:1 30:1 drugs:2 eight:1 speeding:1 new:1 approve:1 than:1 experimental:1 more:1
stock_BIIB r_up	1.4:1 index:1 seven:1 added:1 recently:1 session:1 rose:1 points:3 up:1 shares:1 trade:1 companies:2 27:1 trading:2 actively:2 were:1 expected:1 's:2 stocks:1 higher:1
stock_BIIB r_up	actively:1 index:1 added:1 15:1 8.9:1 rose:1 after:1 companies:1 up:1 hours:1 points:2 trading:1 closed:1 's:1 stocks:1 higher:1
stock_BIIB r_up	billion:1 pipelines:1 $:1 up:1 our:1 promising:1 list:1 treatments:1 drug:1 sales:1 1:1 most:1 potential:1 5:2 here:1 have:1 year:1 's:1 makers:1 2013:2
stock_BIIB r_down	among:1 move:1 results:1 trade:2 session:2 its:8 issues:1 $:1 cliff:1 had:1 than:1 failed:3 add:1 other:2 treatment:4 earnings:1 survival:1 discontinue:2 liability:1 historic:1 disappointed:1 day:1 look:1 treating:1 --:3 companies:2 doubled:1 did:2 reduced:1 gaining:2 says:2 deal:1 testing:1 some:1 related:1 actively:2 projections:1 year:1 said:2 shares:2 3:2 stock-index:1 new:1 patient:1 avert:1 notable:1 hours:1 sift:1 succeed:1 groups:1 others:1 declining:2 improve:1 pipeline:1 ahead:1 study:1 fourth-quarter:1 drug:4 trial:3 inspired:1 traded:1 experimental:1 late-stage:2 comment:1 nerve:1 revenue:1 clues:1 primary:2 throughout:1 quality:1 unit:1 additional:1 charge:1 next:1 clinical:2 biggest:2 manufacturer:1 more:2 firm:2 flat:1 life:1 drugs:1 company:2 hoped:1 data-storage:1 expected:2 goals:2 sharply:1 demand:1 second-quarter:1 made:1 14:1 n't:2 patients:1 meet:2 could:1 acquisition:1 ringing:1 investors:2 cited:1 sales:1 have:1 rally:1 moves:1 tumbled:1 weakened:1 causing:2 details:1 largest:1 reversed:1 development:4 's:8 after:3 prepared:1 halted:1 stocks:3 recent:1 fiscal:2 lower:1 slightly:1 futures:1 disease:5 relief:1
stock_BIIB r_down	development:1 life:1 's:1 study:1 after:1 disease:1 halted:1 failed:1 treatment:1 survival:1 improve:1 quality:1 its:1 experimental:1 late-stage:1
stock_BIIB r_down	said:1 pill:1 launch:1 --:1 after:1 prepared:1 solid:1 relying:1 maintain:1 multiple-sclerosis:1 treatment:1 strong:1 oral:1 its:1 momentum:1 2012:1
stock_BIIB r_down	blockbuster:1 have:1 drugs:1 been:1 drug:1 any:1 their:1 outside:1 safety:1 multiple-sclerosis:1 until:1 which:1 advisers:1 not:1 new:1 sells:1 has:1 approve:1 asked:1 risks:1
stock_BIIB r_down	ratings:1 upgrade:3 hit:3 soars:1 companies:1 three:2 one:3 while:1 health:3 helps:2 cuts:1 firms:2 gets:1
stock_BIIB r_up	pessimistic:1 fourth-quarter:1 his:1 futures:3 investors:1 bell:1 results:2 trade:1 see:1 growth:2 including:1 rally:1 2.7:1 its:3 market:1 before:1 whose:1 bullish:1 profit:1 durable:2 revenue:1 shares:2 much:1 don’t:1 biotechnology:1 top-line:1 net:1 hope:2 earnings:5 product:1 buy:2 's:4 wavering:1 views:1 company:1 after:1 bear:1 hurt:1 bulk:1 expected:2 rise:2 fell:1 gain:1 key:1 others:1 active:1 than:1 pipeline:1 goods:2 reported:1 amid:1 later:1 companies:2 up:1 n't:1 continue:1 2013:1 position:1 efforts:1 stock:2 noted:1
stock_BIIB r_up	fourth-quarter:1 adjusted:1 strengthening:1 revenue:3 share:2 disease:1 growth:2 multiple-sclerosis:1 expect:1 blockbuster:1 2.7:3 its:3 drugs:1 said:1 $:4 forecast:1 also:1 version:1 earnings:2 stable:1 9:1 new:1 2013:1 product:1 's:3 successful:1 company:3 rise:1 bulk:1 fell:1 nerve:1 billion:1 10:1 pipeline:1 up:1 drug:1 trial:1 biotechnology:1 efforts:1 late-stage:1
stock_BIIB r_up	's:3 file:1 would:1 into:1 board:1 fame:1 fund:1 five:1 plan:1 members:1 enter:1 hedge:1 halls:1 proxy:2
stock_BIIB r_up	over:4 manager:2 session:1 6.3:1 appetite:1 renewed:3 rose:2 send:2 economy:2 going:2 helps:2 policy:2 momentum:1 build:1 his:2 risk:1 big:2 rise:2 early:2 five:1 half:1 report:2 day:2 room:1 lost:2 companies:1 worried:2 bad:2 continue:1 stock:4 shed:1 financial:3 deal:3 some:2 second:2 actively:1 trading:2 election:2 year:1 close:2 calendar:1 investment:2 best:2 out:1 index:5 said:2 sentiment:3 profit:1 jumped:1 since:2 chaos:3 shares:1 routing:1 strategist:2 across:3 after:6 recently:1 dividends:1 monetary:2 100:5 earlier:1 hampers:1 ahead:2 country:3 taking:1 30:1 37:1 drug:1 turn:2 stoked:2 first:1 question:1 multiple-sclerosis:1 market:1 takes:1 would:2 leading:2 political:2 pretax:1 9.1:1 empty:1 ``:2 selling:1 punish:3 benchmark:2 hurt:2 lift:2 former:3 raising:1 11:1 14:1 whether:1 markets:5 straight:2 were:1 situation:2 leaves:1 control:1 futures:3 600:2 investors:1 cents:1 0.2:1 0.4:1 0.6:1 '':2 player:2 dropped:1 rally:4 clearly:2 5.1:1 equities:1 fears:5 stayed:2 also:2 concerns:2 earnings:2 which:1 meeting:2 performance:2 sidelines:2 higher:4 week:1 's:5 applaud:2 reporting:1 fell:1 stoke:1 stocks:3 data:1 inspiration:1 rallied:1 lower:5 popularity:3 daily:2 points:3 putting:2 reward:1
stock_BIIB r_down	control:1 fourth-quarter:1 investors:1 revenue:1 agreed:1 weighed:1 against:1 full:1 multiple-sclerosis:1 reports:1 7.5:1 partner:1 blockbuster:1 its:2 out:1 decline:1 said:1 generic-drug:1 profit:1 contributed:1 3.25:1 earnings:1 interest:1 markets:1 core:1 buy:1 's:1 business:1 weakness:2 overall:1 small:1 fell:1 gain:1 day:1 $:1 billion:1 37:3 drug:1 giving:1 squeezed:1 round:1 latest:1
stock_BIIB r_up	company’s:1 rush:3 slow:2 investors:1 tumble:1 downgrades:1 earlier:1 shares:3 deter:1 see:1 wake:1 don’t:3 opportunity:1 day:1 buying:1
stock_BIIB r_down	notes:1 's:1 broker:1 today:1 pick:1
stock_BIIB r_down	has:1 ride:1 while:1 expansion:1 any:1 manager:1 economic:1 economy:1 market:1 stocks:1 grow:1 decade:1 can:1
stock_BIIB r_up	billion:2 acquisitions:1 shareholders:1 said:1 return:1 $:2 would:1 refinance:1 after:1 sclerosis:1 sale:1 drug:2 its:1 1:1 3.25:1 stake:1 multiple:1 debt:1 maker:1 make:1
stock_BIIB r_up	plummet:1 caused:1 sale:2 multiple-sclerosis:1 investment:2 before:2 said:2 $:3 stake:2 two:2 fatalities:1 its:4 85:2 company:1 week:1 multiple:1 plans:2 offer:2 outlined:2 after:3 several:1 takeover:2 investor:2 anemia:3 billion:1 made:2 last:1 recall:2 sclerosis:1 days:2 drug:7 recalls:1 plunges:2 maker:2
stock_BIIB r_up	sector:1 biotech:1 averaged:1 lagging:1 show:1 tells:1 tepid:1 over:1 microscope:1 tax:2 we:1 month:3 '':1 likely:1 itself:1 higher:1 another:1 existence:1 go:1 further:1 targets:1 previous:1 impact:2 provided:1 shareholders:1 said:1 would:1 space:1 spending:1 translate:1 plethora:1 had:1 detail:1 incentive:1 its:1 add:1 doubt:1 growth:1 way:1 under:1 expected:1 so:1 holiday:1 approach:1 headwinds:1 economy:1 ``:1 casting:1 behind:1 company:2 payroll:1 little:2 but:1 delayed:1 increases:1 takeover:1 invested:1 report:1 payrolls:1 declining:1 look:1 fades:1 nonfarm:1 retail:3 jobs:2 hostile:1 refunds:1 sweeten:1 changed:1 gasoline:1 's:1 defends:1 into:1 remain:1 future:1 expecting:1 have:1 headcount:1 2012:1 consumer:1 notes:1 acquisition:1 expect:1
stock_BIIB r_up	said:1 type:1 candidate:1 multiple:1 positive:1 study:1 sclerosis:1 results:1 late-stage:1 investigational:1 year:1 seen:1 has:1 two-year:1 its:1 first:1
stock_BIIB r_up	pill:1 multiple:1 form:1 third:1 company:1 sclerosis:1 drug:1 its:1 treatment:1 new:1 first:1 's:2 approved:2 treat:1
stock_BIIB r_down	behavior:1 executive:2 including:1 have:1 cancel:1 recover:3 violates:2 pharma:1 would:1 also:1 make:2 able:1 bad:1 next:1 makers:1 their:2 biggest:1 firms:1 easier:2 's:1 buckling:1 payouts:3 rules:2 big:1 pressure:1 pay-for-performance:1 report:1 ethics:2 investor:1 level:1 --:1 should:1 taking:1 companies:2 drug:1 compensation:2 future:1 stopped:1 payments:1 policies:2 revising:2 executives:1 otherwise:2
stock_BIIB r_up	billion:1 buy:1 $:1 might:1 company:1 sweetened:1 back:1 drug:1 makers:1 1:1 takeover:1 plan:1 speculation:1 approach:1 approved:1 stock:1
stock_BIIB r_down	raised:1 just:1 people:2 easy:1 share:1 deep:1 7.3:1 done:1 year:1 its:1 pharmaceutical:1 rely:2 said:1 $:3 investment:1 find:1 way:1 offered:1 firm:1 around:1 power:2 offer:1 than:1 company:1 earlier:1 cities:2 grow:1 pool:1 billion:2 12:1 talent:1 up:2 drug:1 valuing:1 city:1 maker:1
stock_BIIB r_up	costly:1 direction:1 's:4 last:1 treatments:1 deepens:1 taking:1 move:1 find:1 disease:1 drug:1 research:1 maker:1 tests:1 setback:1 despite:1 year:1 new:1 efforts:1 disorder:1 its:1
stock_BIIB r_down	sticking:1 faith:1 shareholders:1 's:1 whether:1 clear:1 potential:1 higher:1 have:1 not:1 out:1 price:1 more:1
stock_BIIB r_down	three-day:1 streak:1 ahead:3 movers:2 second-quarter:1 release:1 earnings:3 rallies:2 losing:1 rebounds:1 its:1
stock_BIIB r_up	again:1 cooling:1 his:1 off:1 movers:2 tweet:2 after:1 year:1 took:1 shares:1 pops:2 start:1 finally:1 followers:1 blazing:1 defensive:1 news:1 rally:1 stocks:1 pending:1
stock_BIIB r_down	sector:1 biotech:1 right:1 have:2 bubble:2 companies:1 year:1 some:2 rally:2 projected:1 regulatory:1 say:2 trading:1 been:1 reaching:1 seen:1 1990s:1 cold:1 blockbuster:1 bolstered:1 market:1 even:1 large:1 execution:2 now:1 indexes:1 names:1 no:1 since:1 question:1 due:1 hepatitis:1 next:1 late:2 everything:1 clinical:1 exuberance:2 earnings:1 new:2 's:1 it’s:1 go-go:1 run:1 string:1 index:1 drugs:1 big:1 highs:2 but:2 quite:1 whether:1 they:1 bull:1 not:1 stocks:2 multiple:1 all-time:2 healthy:1 industry:1 could:1 30:1 sclerosis:1 days:1 begun:1 times:1 herald:1 successes:1 analysts:2 tear:1 think:1 latest:2
stock_BIIB r_down	sector:1 biotech:1 join:1 energy:1 stampede:1 finally:1 bull:1 market-beating:1 stocks:1 bubble:1
stock_BIIB r_down	control:1 give:1 money:1 cost:1 alternative:1 your:1 sell:1 writes:1 there:1 orders:2 volatile:1 you:2 markets:1 big:1 stop:3 using:2 loss:2 losses:1 up:1 stopped:2 can:1 problem:1 order:1
stock_BIIB r_up	billion:1 night:1 buy:1 's:4 $:1 proposed:1 offer:1 --:2 billionaire:1 company:1 stockholders:1 deal:1 holders:1 24.4:1 largest:1 last:1 alternative:1 stock:1 investor:1 public:1 out:1
stock_BIIB r_up	billion:1 four:1 said:1 off:1 $:3 deal:1 programs:1 share:1 company:1 had:1 drug:1 1:3 approaches:1 royalty:1 fends:1 reached:1 stream:1 investor:1 pharmaceutical:1
stock_BIIB r_up	delivered:1 now:1 blistering:1 's:1 gains:1 stocks:1 manager:1 has:1 buying:1 he:1
stock_BIIB r_down	rebuild:1 raised:1 secure:1 business:1 bid:1 drug:1 maker:1 pressure:1 takeover:1 multibillion-dollar:1 increasing:1 investor:1 its:3 independence:1
stock_BIIB r_down	over:2 move:1 nominated:1 6.4:1 seats:1 threshold:2 its:5 based:1 $:1 situations:1 3:2 candidates:1 board:2 has:1 tactic:1 bid:1 royalty:1 during:1 hedge:1 one:1 investor:2 drugmaker:1 --:1 50:1 activity:1 90:1 often:1 trading:1 said:1 encourage:1 tends:1 increasing:1 approach:3 earlier:1 recently:1 expansion:1 takeover:1 struggle:2 launch:1 drug:3 weight-loss:1 streams:1 holders:1 maker:1 block:1 acceptance:2 strategic:1 size:1 pharmaceutical:3 shareholders:1 initial:1 three:1 9.9:1 more:2 firm:1 lowering:1 selling:1 offer:1 drugs:1 funds:1 company:1 rejected:1 bidding:1 longer-term:1 appointed:1 buying:1 made:1 cash:1 nine:1 following:1 investors:1 outstanding:1 share:1 twist:2 have:1 around:1 heft:1 holds:1 started:1 which:3 plus:1 stock:2 's:2 after:1 director:1 most:1 shareholder:2 such:1 approved:1 recent:1 billion:1 directors:1 invests:1 latest:2
stock_BIIB r_down	biotech:3 play:2 join:1 risk:1 protection:1 offer:1 ways:2 funds:1 writes:1 these:1 3:2 levels:1 boom:3 want:1 varying:1 you:1
stock_BIIB r_down	actively:1 index:1 stocks:1 's:1 increased:1 rose:1 after:1 companies:1 shares:1 points:3 trading:1 9.7:1 closed:1 close:1 9.5:1 138:1 added:1 higher:1
stock_BIIB r_up	1.4:2 index:1 lower:1 's:2 lost:1 1.3:1 after:1 companies:1 shed:1 shares:1 fell:1 trading:1 actively:1 closed:1 close:1 stocks:1
stock_BIIB r_up	raised:1 stream:1 revenue:1 increasingly:1 over:1 its:2 pharmaceutical:1 $:1 no:1 8:1 bitter:1 royalties:1 buy:1 offer:1 company:1 complicated:1 struggle:1 investor:1 billion:1 attempt:1 longer:1 third:1 drug:2 owns:1
stock_BIIB r_down	talked:1 37:1 down:2 actively:2 trading:4 dropped:2 climbed:1 recently:2 index:3 4.1:1 touts:2 rose:1 shares:3 turnaround:3 closed:1 higher:1 company’s:1 added:1 's:5 gains:1 after:2 hours:1 fell:2 moving:1 127:1 stocks:3 effort:1 session:2 four:1 lower:2 38:1 14:1 40:1 movers:2 16:1 companies:3 up:3 points:9 were:3 five:1
stock_BIIB r_up	billion:1 case:1 outlook:1 settle:1 's:3 $:1 generic-drug:1 pay:1 agreed:1 after:1 patent-infringement:1 negative:1 lowered:1 stable:1 has:1 its:1 1.6:1 manufacturer:1
stock_BIIB r_up	ago:1 guide:1 's:4 launch:1 becoming:1 successfully:1 three:1 quadruple:1 years:1 helped:1 pressure:1 drug:1 value:1 under:1 has:1 its:1 company:1 market:1 he:1
stock_BIIB r_down	billion:1 's:2 $:1 formally:1 review:1 request:1 up:1 biotechnology:1 worth:1 takeover:1 pursuit:1 foiled:1 following:1 8:1 bid:1 ending:1 company:1 its:3 laws:1
